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Abstract of the Dissertation

The System I and System III Holocytochrome c Synthases
in Cytochrome c Biogenesis
by
Brian San Francisco
Doctor of Philosophy in Plant and Microbial Biosciences
Washington University in St. Louis, 2013
Professor Robert G. Kranz, Chair

Cytochromes c are proteins that are involved in important redox reactions in organisms
from every kingdom of life. C-type cytochromes, uniquely, possess a covalently bound heme.
Since cytochromes c are assembled at their site(s) of function (outside of the cytoplasmic
membrane in bacteria, in the chloroplast lumen, or in the mitochrondrial intermembrane space),
their assembly poses unique challenges to heme trafficking and post translational modification.
Three major systems exist in nature for cytochrome c assembly, termed systems I, II, and III.
Using recombinant Escherichia coli, aspects of systems I and III were analyzed, with an
emphasis on the synthase protein(s) and protein complexes that carry out the covalent attachment
of heme to apocytochrome. Studies on system I focused on the integral membrane protein
CcmF, the putative cytochrome c synthetase, which was shown to contain a stable and
stoichiometric heme b. The ligands to the b-heme were identified (TM-His1 and TM-His2), and
the midpoint potential of the heme b was determined and found to be consistent with its
involvement in a critical redox reaction underlying the synthetase reaction. Additionally, a longx

suspected interaction between CcmF and the periplasmic heme chaperone, holoCcmE, was
characterized, with the discovery that heme from holoCcmE is coordinated by two conserved
periplasmic histidines in CcmF (P-His1 and P-His2) that flank the conserved WWD domain. It
was also shown that CcmF, in complex with CcmH, is the holocytochrome c synthase for system
I, able to synthesize cytochromes c in the absence of other Ccm components. Studies on system
III, the human HCCS, constituted the first purification and biochemical characterization of an
HCCS protein. It was discovered that HCCS purifies with a heme b and forms a stable complex
with the human cytochrome c. Using a combination of mutagenesis (of both the apocytochrome
and HCCS), functional analysis, and biochemical characterization (of HCCS, alone and in
complex with cytochrome c), these studies facilitated an elaboration of the molecular
mechanisms for holocytochrome c formation by HCCS.

xi

Chapter 1: Introduction, Significance, Summary, and Scope of Thesis
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Introduction
Heme type and structure, and cytochrome classifications
Cytochromes are an important class of heme proteins that facilitate electron transfer
reactions in a wide range of biologically critical reactions. Cytochromes are broadly classified
according to the type of heme they possess. Hemes (b, o, a, and c) are distinguished from one
another by the type of covalent modification(s) to the heme. In heme biosynthesis, reduced iron
(Fe2+) is inserted into a porphyrin ring (known as protoporphyrin IX) by the ferrochelatase
enzyme [1]. Within the heme macrocyle, each of the four pyrrole ring nitrogens supplies a
planar ligand to the iron atom. Extending out from the heme macrocycle are vinyl groups at the
2- and 4-positions, and propionate groups at positions 6 and 7. Heme, thus synthesized, is
known as heme b (or protoheme) and is incorporated (non-covalently) into many proteins,
including cytochromes b (hence their nomenclature) and the globins (e.g., myoglobin).
Typically, the side chains of certain amino acids (usually histidine, methionine, cysteine, or
tyrosine) provide the 5th and 6th axial (i.e., non-planar) ligands to the heme iron. Alternatively,
heme b may undergo subsequent covalent modification to form hemes a, o, or c (see Fig 1)
[1,2,3]. The synthesis of heme a and heme o is carried out by single dedicated integral
membrane proteins, respectively, and involves the addition of a 17-carbon hydroxyethylfarnesyl
group to the heme 2-vinyl [3]. Heme a has an additional formyl group at the 8-position.
Although both hemes a and o undergo covalent modifications to the porphyrin structure, these
hemes are associated with their respective proteins non-covalently. Heme c (Fig 1) is unique in
this regard; the vinyls of heme are covalently attached (via thioether linkages) to the target
protein (usually, at the thiols of two cysteines in a conserved Cys-Xxx-Xxx-Cys-His motif)
2

[2,4,5]. Thus, synthesis of heme c is fundamentally the same as cytochrome c assembly, with
protein folding occurring after covalent attachment.
The unique covalent attachment of heme in the c-type cytochromes is thought to confer
additional stability to the holo-protein (i.e., to prevent heme loss) [6]. This theory is consistent
with the fact that cytochromes c function outside of the cytoplasmic membrane. In fact, in some
prokaryotes, cytochromes c operate at a great distance from the cytoplasmic membrane [7] (for
example, in the reduction of insoluble metal oxides in the environment by the multiheme
cytochromes c that comprise the Shewanella nanowire [8,9]). There are a few examples of other
proteins that contain covalent heme. For example, the heme chaperone protein of system I,
holoCcmE (discussed below), binds heme covalently through a histidine residue [10,11,12,13].
However, since this particular protein is not a cytochrome, per se (i.e., its primary function is not
electron transfer), synthesis of holoCcmE is not formally considered cytochrome c biogenesis. A
globin from cyanobacteria also has a covalent link to a histidine side chain [14,15,16].
The various heme types discussed above can be distinguished from one another by
spectrophotometric techniques. Hemes, and heme proteins, exhibit three characteristic
absorption maxima (“peaks”) in the visible range, termed the α (550-560 nm), β (520-530 nm),
and Soret (400-430 nm) [17]. Changes in the positions of these peaks are reflective of changes
in the heme binding environment within a protein. A particularly sensitive method using UVVis absorption spectroscopy, known as the pyridine hemochrome, can further distinguish
between hemes with zero, one, or two covalent modifications to the vinyls [18]. In this assay,
the heme protein is denatured by sodium hydroxide and the native axial ligands are replaced by
pyridine. Chemical reduction (typically, with the strong reducing agent sodium dithionite) of the
pyridine hemochrome yields characteristic α maxima that can be used to discern the number of
3

covalent attachments to the heme vinyls: a 550 nm α absorption indicates covalent modification
at both the 2- and 4-vinyls of heme, 553 nm is indicative of a single covalent modification, and
556 indicates no covalent attachments.
General requirements for formation of cytochrome c
Cytochromes c are assembled at their site of function. In prokaryotes, this is outside of
the cytoplasmic membrane (i.e., in the periplasm of gram negative bacteria, and extra-cellularly
in the gram positives). In eukaryotes, cytochromes c are matured in the intermembrane space of
mitochondria or in the lumen of chloroplasts. In all cases, the site of cytochrome c assembly is
separated from biosynthesis of heme and translation of the apoprotein by a lipid bilayer, thus
posing unique challenges to heme trafficking, apocytochrome secretion, and the covalent
attachment reaction. Cytochrome c synthesis, therefore, requires dedicated mechanisms to
traffick heme and apocytochrome to the site of thioether formation [2,4,5]. Prokaryotic
apocytochromes contain signal sequences that direct the unfolded polypeptide from the site of
translation across a lipid bilayer (via the general Sec pathway) to the site of cytochrome c
assembly [19,20]. In mitochondria, this is accomplished by components of the TOM complex
[21].
Apocytochromes are defined by the conserved Cys-Xxx-Xxx-Cys-His motif. In
holocytochrome formation, the thiol groups of the N- and C-terminal cysteines attack the 2- and
4- heme vinyls, respectively, to form thioether linkages, and the imidazole group of the histidine
serves as an axial ligand to the iron of heme [22,23]. Thioether formation is a spontaneous
(energy-independent) Markovnikov addition, where each of the reduced thiols attacks the more
substituted α carbon of the heme vinyl, with addition of hydrogen to the less substituted β carbon
(Fig 1). Rare, variant cytochrome c attachment motifs (including Cys-Xxx-Xxx-Cys-Lys, Cys4

Xxx15-Cys-His, and even Ala-Xxx-Xxx-Cys-His, with a single covalent link to heme) have been
identified [24,25], but the requirements for cytochrome c assembly are the same. For covalent
attachment to occur, the heme of iron must be in the reduced (Fe2+) state, and the thiols of the
cysteines must be reduced [22,26]. Unlike other cytochromes, the c-type cytochromes fold into
their functional conformations only after covalent attachment of heme [27]; in the absence of
heme, the unfolded polypeptide is often rapidly degraded.
Systems for cytochrome c formation in nature
Three major systems have evolved for cytochrome c biosynthesis, termed systems I, II
and III (Fig 2) [2,4,5]. System III is found in the mitochondria of animals and some protozoa;
system II is found in most gram positive bacteria, the cyanobacteria and the chloroplasts of
plants and algae; system I is found in most gram negative bacteria, the archaea, and the
mitochondria of plants and certain protozoa. Although the three systems differ in terms of
complexity, mechanism, and phylogenetic distribution, each accomplishes covalent ligation of
heme to the apocytochrome (usually, at Cys-Xxx-Xxx-Cys-His).
System I
Genetic analyses in Rhodobacter capsulatus [28,29,30,31] (and, subsequently,
Paracoccus denitrificans [32,33,34], Bradyrhizobium japonicum [35,36], and E. coli [37]) in the
late 1980s and early 1990s revealed a pathway for bacterial cytochrome c assembly. Called
system I, this pathway consists of between 8 or 9 dedicated proteins (CcmABCDEFGH, in E.
coli), most of which are integral membrane proteins (Fig 2). In some organisms, such as R.
capsulatus, ccmH is split into two ORFs, encoded by ccmH and ccmI [28]. In bacteria, the ccm
genes are usually found as an intact operon, but, sometimes, are split into several gene clusters
[38]. In plants, some of the ccm genes are present in the mitochondrial genome and others are
5

nuclear-encoded [39,40]. The general Sec and Dsb pathways are required for apocytochrome
secretion and (indirectly) reduction of the apocytochrome thiols, respectively [20,41]. The
import of the nuclear-encoded apocytochrome into plant mitochondria is less well-understood.
However, unlike apocytochrome secretion, heme translocation for cytochrome c maturation
occurs exclusively as a function of the system I proteins [42].
Heme trafficking in system I proceeds in two steps (Fig 2): (i) formation and release of
the heme chaperone protein, called holo (+ heme) CcmE, (from CcmABCD) and (ii) heme
transfer from holoCcmE to the apocytochrome (putatively, via the CcmFH complex) to yield a
holocytochrome c. Formation of holoCcmE occurs in the CcmCDE complex [43,44], where a
unique covalent attachment is formed between the β carbon of the heme 2-vinyl and a conserved
histidine residue (His130) in CcmE [10,11,12,13,45]. CcmC is a member of a heme-handling
protein (HHP) superfamily [46] that also includes CcmF and the system II cytochrome c
synthetase, CcsBA. The defining feature of these proteins is the conserved WWD domain [29], a
hydrophobic, extra-cytoplasmic feature (for interaction with heme) that is flanked by two
conserved histidines that serve as heme axial ligands. In the absence of CcmAB, CcmCDE form
a stable holo (+ heme) complex, where heme, covalently attached to His130 of CcmE, is bound
in the CcmC WWD domain with axial ligands from CcmC His60 and His184 [43].
Expression of CcmAB leads to formation of an ABC transporter complex (CcmABCD)
that uses ATP hydrolysis to release covalent holoCcmE [47,48,49]. These studies were initially
carried out in R. capsulatus, where the CcmABCD complex was first identified [49]. CcmA,
CcmB, and CcmC each have homology to individual subunits of components of ABC-transporter
complexes, with the classic Walker domain found in CcmA [50]. Hydrolysis of ATP by
CcmABCD leads to the release of oxidized (Fe3+) holoCcmE, which is proposed to chaperone its
6

heme to the site of cytochrome c formation, CcmFH, (see below) [44,51,52]. It has been
established that formation of covalent holoCcmE occurs independent of ATP-hydrolysis (and in
the absence of CcmAB altogether); thus, CcmABCD functions a holoCcmE release complex
[48].
CcmG and CcmH are thioredox-active proteins that maintain the apocytochrome thiols
(in the Cys-Xxx-Xxx-Cys-His motif) in the reduced state [28,39,53,54]. CcmG and CcmH each
contain a conserved pair of cysteine residues (in the classical thioredoxin Cys-Xxx-Xxx-Cys
motif) that are involved in reduction of the disulfide bond between the two cysteines in the
apoctychrome (at Cys-Xxx-Xxx-Cys-His). The three-dimensional structures of the soluble
domains of both CcmG [55,56] and CcmH [57,58] have been determined. There is significant
evidence that CcmH interacts directly with the apocytochrome [39,57,59,60] and with CcmF
[44,52,61,62]. CcmH is proposed to orient the thiols of the apocytochrome for thioether
formation with the heme bound in the CcmF WWD domain. CcmG does not associate directly
with the CcmFH complex (see below). Rather, the cysteines in CcmG are reduced by DsdD
[63]; reduced CcmG, in turn, likely reduces the cysteines in CcmH, which is then thought to
reduce the disulfide bond in the apocytochrome [54,64] (initially formed by the action of DsbA
[65], or an environmental oxidant).
CcmF is a 13-transmembrane domain (TMD) integral membrane protein that contains
four conserved histidines: two in transmembrane domains (TM-His1 and TM-His2) and two in
periplasmic loops (P-His1 and P-His2) that flank the conserved WWD domain [44]. In the
absence of other Ccm proteins, purified CcmF contains a stoichiometric and stable non-covalent
heme b [44,66], which we have hypothesized plays a role in reducing the incoming heme from
holoCcmE [42,66] (see Fig 2). Reduced heme (Fe2+) is required for thioether formation [22,26],
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and reduction would also favor the release of heme from CcmE His130 [42,43,66]. CcmF forms
an integral membrane complex with CcmH, which has been purified [44] or coimmunoprecipitated [52,61,62]. CcmF (in complex with CcmH) is believed to be the site of
thioether formation between the heme vinyls and the apocytochrome; thus, it has been termed the
“cytochrome c heme lyase” or “cytochrome c synthetase” [42,67,68,69,70].
System II
Genetic analyses in Chlamydomonas [71,72,73,74] and some bacterial species (including
Bacillus [75,76,77] and Bordetella [78,79,80]) in the mid-1990s revealed the presence of a
pathway for cytochrome c assembly distinct from system I (Fig 2). These studies defined four
proteins required for this pathway, termed system II: CcsA, CcsB, DsbD (or a related protein,
CcdA, in some species), and CcsX (a thioredoxin involved in reduction of the apocytochrome
Cys-Xxx-Xxx-Cys-His motif). The activities of DsbD and CcsX can be complemented by
addition of thiol-reducing agents (e.g., dithiothreitol); therefore, DsbD and CcsX are thiolreducing components of the system II pathway.
CcsA and CcsB consist of six and four TMDs, respectively. CcsA, a member of the
heme handling protein (HHP) family, contains the conserved WWD domain flanked by two
conserved histidines, and an additional conserved histidine in a transmembrane domain [50,81].
CcsB also contains a conserved transmembrane histidine and a large (up to 500 residues) poorlyconserved extra-cytoplasmic domain that is thought to be involved in apocytochrome handling
[78]. Studies in Bordetella [79], and subsequent studies in heterologous E. coli [82], showed that
CcsA and CcsB form a complex for cytochrome c assembly. The CcsBA protein complex,
together, thus contains four conserved histidines (TM-His1 and 2, and P-His1 and 2) and the
WWD domain, in a remarkably similar orientation to that of CcmF. In some species (such as
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Helicobacter and Wolinella) system II is encoded as a single fused ORF, called ccsBA.
Expression of CcsBA (from Wolinella [83] or Helicobacter [51]) heterologously in E. coli is
sufficient to facilitate robust cytochrome c assembly; thus, CcsBA is the system II cytochrome c
synthetase. The CcsBA complex is proposed to carry out the processes of heme translocation,
apocytochrome binding, and thioether formation [42,82,84].
The CcsBA complex from Helicobacter hepaticus (expressed in E. coli as an N-terminal
fusion to glutathione S-transferase) has been purified and characterized. Similar to CcmF,
CcsBA purifies with a bound heme b. Mutation of either TM-His1 or TM-His2 abolishes or
significantly impairs heme binding, while mutation of either P-His1 or P-His2 does not affect
levels of the bound heme b. Each of the four histidines is required for cytochrome c assembly:
substitution with alanine or glycine abolishes holocytochrome formation. Substitutions can be
complemented chemically by adding imidazole directly to culture, thus confirming a heme
ligand-type function for each His residue. Interestingly, imidazole complements only weakly
under aerobic conditions, while anaerobically, imidazole restores function to near-WT levels.
This suggests that the His residues in CcsBA may function to protect heme from oxidation as it
is being channeled from its transmembrane binding site to the external WWD.
System III
The gene product responsible for cytochrome c formation in Saccharomyces cerevisiae
was identified in 1987 by Dumont and colleagues [85]. Termed the holocytochrome c synthase
(HCCS) or cytochrome c heme lyase (CCHL), this enzyme, when expressed in the E. coli
cytoplasm (along with its cognate apocytochrome), is sufficient for holoctyochrome c formation
(Fig 2) [86]. HCCS, which comprises system III, functions in the intermembrane space of the
mitochondria of most eukaryotes (including humans). In some species, there is a dedicated heme
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lyase (CC1HL) for covalent heme attachment to cytochrome c1 [85,87], while in others a single
HCCS is active towards both cytochrome c and cytochrome c1 [67,88]. CC1HL is highly related
to CCHL.
HCCS is required for the import of the nuclear-encoded apocytochrome into
mitochondria [89,90]. Mitochondrial import of the unfolded apocytochrome is initially mediated
by components of the TOM complex [21], and, subsequently, depends on recognition of the
incoming N-terminus of the apocytochrome by HCCS. Covalent heme attachment by HCCS
(and subsequent folding of the holocytochrome c) prevents the holocytochrome from re-exiting
the intermembrane space [89,90,91,92]. Import of the membrane-bound cytochrome c1 occurs
via a separate mechanism [93] that does not involve a cytochrome c heme lyase. A number of
studies (all using the HCCS from S. cerevisiae) in yeast and E. coli have identified residues in
the apocytochrome N-terminus (including the Cys-Xxx-Xxx-Cys-His motif) that are required for
mitochondrial import and/or covalent heme attachment [86,94,95,96,97,98]. Cyc2p, a FADbinding protein, is an accessory protein that is important, but not required, for maturation
[99,100,101]. This protein is present only in S. cerevisiae and may play a role in reducing heme,
but more work is needed to determine its precise function. An earlier report suggested that CysPro-Xxx motifs in HCCS might be heme-binding sites [102] (Fig 2), but since these motifs are
absent in some HCCSs [67], this is unlikely.
Other systems for cytochrome c assembly
Greater than 99 % of organisms rely on systems I, II, or III for cytochrome c biogenesis.
However, some rare, alternative pathways exist for holocytochrome c formation. System IV,
also called the ccb pathway, is a dedicated pathway for covalent heme attachment to a single
cysteine in cytochrome b6 of the cytochrome b6f complex [103,104], present in the chloroplasts
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of the oxygenic phototrophs [105]. Some archaea and a very few bacteria contain an abbreviated
ccm pathway (which some have termed system I’) that lacks a clear homolog of CcmH, and in
which the covalent heme-binding histidine of CcmE has been replaced with a cysteine [106].
Finally, certain protozoa, which produce a unique cytochrome c with covalent attachment to a
single Cys (i.e., Ala-Xxx-Xxx-Cys-His), do not appear to encode the genes for system I, II, or III
[107,108,109]. The cytochrome c assembly pathway present in these organisms has been
designated System V, although this nomenclature may be premature since the genes that
comprise this apparent system have yet to be identified.
Evolutionary history of the three systems
Why are there three separate systems for cytochrome c assembly, and what, if any, are
the advantages conferred? All mitochondria contain either system I or system III. Since the
ancestor of the modern mitochondrion (an alpha-proteobacterium) contains system I, it is clear
that system III evolved in mitochondria after the mitochondrial endosymbiosis [110,111,112].
We hypothesize that at some point after endosymbiosis, the complicated, ATP-dependent system
I may have become “obsolete” and was replaced by the simpler system III. The protozoa are
especially useful to consider in this regard, since some protozoal mitochondria contain system I
and some contain system III. The protozoa that contain system I may be evolutionary
“holdovers” stuck in the transition from system I to system III, and future studies may reveal
some species that contain both systems. We speculate that the mitochondria of plants (all of
which contain system I) and those protozoa that contain system I, may face more challenging
environments for cytochrome c synthesis (possibly iron- or heme-poor, and certainly highly
oxidizing) such that the advantages of the system I pathway are required (see below). Note that
system I, as well as system II, has evolved to maintain heme in (or reduce heme to) the Fe2+
11

state; thus, plants may have retained system I (in mitochondria) and system II (in chloroplasts) to
protect heme from oxidation.
Dissecting the evolutionary history of systems I and II is complicated by the significant
lateral gene transfer that has occurred with these two systems [38]. One would expect that
system II (with its lower energetic requirement) should predominate unless system I confers
some selection advantage. We showed previously that system I can synthesize cytochromes at 5fold lower heme levels than can system II [113], and that holoCcmE of system I can function as
a heme reservoir [51]. Thus, we speculate that the holoCcmE heme reservoir and high heme
affinity of system I may have evolved (and was retained) to meet the challenges of synthesizing
cytochromes in iron- or heme-poor environments. Attempts to correlate the occurrence of a
given system (I or II) with a specific bacterial microhabitat (e.g., iron-poor or iron-rich) have
been difficult, owing primarily to the lack of information about the microhabitats of
microorganisms. Interestingly, some species (e.g., Bordetella parapertussis) encode the genes
for both systems I and II. Whether both systems are actively expressed, or expressed
differentially as a function of environmental conditions, has not been examined, but organisms
such as these may offer clues as to the evolutionary advantages of a system I versus a system II
cytochrome c assembly pathway.
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Significance, Summary, and Scope of the Thesis
Early studies in the field of cytochrome c assembly were directed at identifying the gene
products required for assembly. Reconstitution of each of the three major pathways
heterologously in E. coli (∆ccm, deleted for the endogeneous cytochrome c maturation genes)
was a major advance in this regard. More recent approaches have been designed to elucidate the
molecular mechanisms underlying cytochrome c assembly, including heme trafficking, control of
redox state, and protein-protein interactions. Of particular interest to this thesis are the structural
and mechanistic aspects of the synthase proteins and protein complexes of systems I (CcmFH)
and III (HCCS), and the molecular details of their function (Fig 2).
At the beginning of this research, some limited biochemical progress had been made with
several system I proteins: high-resolution three-dimensional structures had become available for
the soluble domains of apoCcmE [114], CcmG [56] and CcmH [57]. Excitingly, the first
biochemical and spectroscopic characterization of the putative system I synthetase, CcmF (from
E. coli), had just been reported from the Kranz lab, with the discovery that CcmF (purified in the
absence of other Ccm proteins) contained a stable and stoichiometric heme b [44]. A possible
heme ligand (TM-His1) to the heme b had been identified, and, crucially, a revised topology for
CcmF had been reported. The updated topology revealed that CcmF contained two additional
TMDs, which repositioned the WWD domain adjacent to the outer leaflet of the cytoplasmic
membrane, where it is flanked by two conserved His residues (P-His1 and P-His2). Importantly,
the new topology illustrated the marked structural similarities between CcmF and the other
WWD-domain containing proteins, CcsBA (the cytochrome c synthetase of system II) and
CcmC.
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Building off of these findings, the first aim of this research was to define and
spectroscopically characterize the b-heme binding site within CcmF, with the ultimate goal of
understanding the role of this heme in cytochrome c biogenesis. This research, discussed in
chapter 2, identified the second axial ligand to the b-heme (TM-His2), and piloted the used of
exogeneous imidazole to chemically complement the cytochrome c assembly defects of
substitutions at either TM-His1 or TM-His2 in CcmF, thus solidifying the heme-binding function
of these residues. The role of these histidines as axial ligands to the heme b was confirmed by
resonance Raman spectroscopy, in collaboration with Dr. Kenton Rodgers (NDSU). A reliable
and tractable assay for the determination of redox potentials was adapted (from the laboratory of
Dr. Emma Raven, Leicester University) for use with membrane proteins, and was employed to
determine the midpoint potential of the heme b in CcmF. This constituted the first functionallyrelevant data pertaining to the heme b: since the midpoint potential was below (more negative
than) that of the heme in holoCcmE, our hypothesis that the heme b may be involved in
reduction of the incoming heme from holoCcmE (thus preparing it for attachment to the
apocytochrome) is indeed feasible.
Another significant thrust of this research was devoted to understanding interactions
between CcmF and other Ccm proteins. Formation of a complex between CcmF and CcmH had
been well-documented [44,52,61,62], although the specific sites of interaction in each protein
were (and are) still unknown. Less-well understood, however, was the interaction of CcmF with
the periplasmic heme chaperone protein, holoCcmE. Although nearly every review on
cytochrome c biosynthesis in the last decade had proposed formation of a holoCcmE-CcmF
complex as an intermediate required for holocytochrome formation [42,67,68,69,70], data
directly demonstrating this interaction had not been reported. Another similarly conspicuous gap
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in our understanding of system I was the absence of direct experimental evidence that CcmF (in
complex with CcmH) is the synthetase for system I. Unlike systems II and system III (which are
single proteins or protein complexes whose expression in E. coli ∆ccm is sufficient for robust
holocytochrome c formation), CcmF had never been shown to be capable of synthesizing
cytochrome c in the absence of other Ccm proteins. The assignment of the synthetase activity
was largely circumstantial in that it was based primarily on interactions with other Ccm proteins,
some of which were experimentally-supported (e.g., with CcmH, which has a demonstrated
apocytochrome binding function) and others that were more hypothetical (i.e., with holoCcmE).
Research in this thesis showed, directly, that CcmFH (along with CcmG) is the
cytochrome c synthetase of system I: expression of CcmFGH (in the absence of other Ccm
components) in E. coli ∆ccm is sufficient for robust covalent heme attachment to bacterial
cytochromes c2 and c4. The synthetase activity required three conserved histidines in CcmF
(TM-His1 and 2, and P-His1) as well as the conserved cysteine pairs in the thioredoxins CcmG
and CcmH, and led to production of holocytochrome c with biochemical and spectroscopic
properties indistinguishable from that produced by the full system I. These studies are discussed
in chapter 4. Chapter 3 of this thesis discusses characterization of the CcmF-holoCcmE
complex, trapped only in the absence of CcmH, with the discovery that complex formation
depends on all four conserved His residues in CcmF. HoloCcmE must be released from complex
with CcmABCD in order to interact with CcmF, and heme in holoCcmE was required for
complex formation with CcmF: apoCcmE interacted at 20-fold lower levels than holoCcmE.
Together, these results address two important remaining questions in cytochrome c biogenesis,
and fill some of the larger gaps in the field.
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For system III, progress in understanding the mechanisms underlying HCCS function had
been severely impeded by difficulties in expression and purification [24]. In fact, despite the
identification of HCCS as the gene product responsible for heme attachment to cytochrome c in
Saccharomyces cerevisiae over twenty-five years ago [85], the enzyme had never been purified
or characterized, and the mechanism by which HCCS mediates covalent heme attachment to the
apocytochrome was poorly understood. Every review on mitochondrial cytochrome c assembly
states this deficiency (e.g., [24,42,67,68]). Chapter 5 of this work discusses successful
purification and characterization of the human HCCS from recombinant E. coli. The human
HCCS was found to be membrane-associated (despite the absence of predicted TMDs) and was
purified with endogenous heme coordinated by a conserved histidine (His154). The amino acids
in the human apocytochrome required for covalent attachment were identified, and the nonsubstrate cytochrome c2 from the alpha-proteobacterium Rhodobacter capsulatus was converted
into a robust substrate for the human HCCS by engineering three sequence alterations. Trapped,
intermediate complexes between HCCS, heme, and cytochrome c, with a conserved histidine in
each protein serving as a heme axial ligand, were purified and characterized. These findings
suggest mechanisms for heme binding, interaction with apocytochrome c, thioether formation,
and release of mature holocytochrome c from HCCS.
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Figures
Figure 1. Structure of heme c and genes required for heme c formation.
Porphyrin ring carbon atoms are numbered according to the Fischer system. Diagram is
modified from [42].
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Figure 2. Systems I, II, and III for cytochrome c biogenesis.
Models depict subpathways for trafficking of heme and apocytochrome during holocytochrome c
formation. Representative organisms possessing each system are listed. Diagram is modified
from [42].
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Abstract
Cytochrome c maturation in many bacteria, archaea, and plant mitochondria involves the
integral membrane protein CcmF, which is thought to function as a cytochrome c synthetase by
facilitating the final covalent attachment of heme to the apocytochrome c. We previously
reported that the E. coli CcmF protein contains a b-type heme that is stably and
stoichiometrically associated with the protein and is not the heme attached to apocytochrome c.
Here, we show that mutation of either of two conserved transmembrane histidines (His261 or
His491) impairs stoichiometric b-heme binding in CcmF and results in spectral perturbations in
the remaining heme. Exogeneous imidazole is able to correct cytochrome c maturation for
His261 and His491 substitutions with small side chains (Ala or Gly), suggesting that a “cavity”
is formed in these CcmF mutants in which imidazole binds and acts as a functional ligand to the
b-heme. The results of resonance Raman spectroscopy on wild-type CcmF are consistent with a
hexacoordinate low spin b-heme with at least one endogeneous axial His ligand. Analysis of
purified recombinant CcmF proteins from diverse prokaryotes reveals that the b-heme in CcmF
is widely conserved. We have also determined the reduction potential of the CcmF b-heme (Em,7
= -147 mV). We discuss these results in the context of CcmF structure and functions as a heme
reductase and cytochrome c synthetase.
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Introduction
The c-type cytochromes are heme proteins present in nearly all organisms that participate
in electron transfer, typically for the generation of an electrochemical proton gradient. C-type
cytochromes function outside of the cytoplasmic membrane in prokaryotes, in the intermembrane
space of the mitochondrion, and in the lumen of the chloroplast. Cytochromes c are commonly
distinguished by covalent attachment of the two vinyl groups (α-carbons) of heme to the thiols of
a conserved Cys-Xxx-Xxx-Cys-His motif in the apocytochrome. For thioether formation
between heme and apocytochrome, the heme iron and the cysteine thiols must be in the reduced
state (1, 2). In many prokaryotes, nearly all plant mitochondria and some protozoan
mitochondria, cytochromes c are assembled by the cytochrome c maturation (ccm) pathway
called system I (Figure 1A), which typically comprises eight or nine integral membrane proteins
(In E. coli, CcmABCDEFGH) (3-6).
In system I, heme is initially bound at a site in CcmC (Figure 1A) (7-9). Here, a unique
covalent attachment is formed between His130 of CcmE and the β-carbon of the 2-vinyl of heme
(10-12). CcmE with covalent heme is released from CcmC by the action of CcmAB (an ABC
transporter) (13-15). CcmE is believed to traffic heme to the site of cytochrome c assembly,
putatively the CcmF/H synthetase complex, where the heme from holoCcmE is attached to
apocytochrome c (8, 16, 17). Although studies have shown that CcmF and CcmH form an
integral membrane complex (8, 16, 18), the function of this complex, including its role as a
synthetase, is poorly understood.
We have proposed that formation of the covalent bond between CcmE and heme (within
the holoCcmCDE complex) is favored by heme oxidation (to Fe3+) (5, 7, 8). Consistent with
this, the purified holoCcmCDE complex (7, 8) and purified holoCcmE (8, 11, 12) contain
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covalent heme in the oxidized (Fe3+) state. However, heme attachment to the apocytochrome
requires that the heme from holoCcmE is reduced (Fe2+) prior to ligation (1, 2, 5). A possible
mechanism for reducing heme in holoCcmE before heme attachment to apocytochrome c has
recently emerged: we discovered that CcmF contains a b-type heme, independent of all other
Ccm proteins, that exists in 1:1 stoichiometry with the protein (8). We proposed that reduction
of the heme in holoCcmE by the CcmF b-heme would facilitate release of the CcmE His130
covalent bond and prepare the heme for attachment to the apocytochrome (5, 7).
It is important to establish the spectral and redox properties of the b-heme in CcmF to
understand the function(s) of CcmF in the maturation of cytochromes c. Topological studies
have revealed that CcmF contains 13 transmembrane domains (TMDs; Figure 1B) (8, 19). There
are four completely conserved histidines that might serve as axial ligands to the b-heme: two are
predicted to be in periplasmic loops (His173 and His303 in CcmF from E. coli) and two are
predicted to reside in TMDs (His261 and His491) (see stars in Figure 1B). Alanine substitutions
at each of these histidines show severe defects in cytochrome c assembly (16). To identify the
axial ligands to the b-heme in CcmF, we use spectroscopic and site-directed mutagenesis
approaches as well as chemical complementation with exogeneous imidazole. We show that the
b-heme is present in recombinant CcmF proteins from diverse organisms and determine the
reduction potential of the CcmF b-heme. Our findings address the location of the b-heme in
CcmF and allow us to propose redox control mechanisms in the CcmF synthetase reactions.
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Experimental Procedures
Bacterial Growth Conditions. Escherichia coli strains (Table S1) were grown at 37oC by
shaking at 240 rpm in Luria-Bertani broth (LB; Difco) supplemented with the appropriate
antibiotics (Sigma-Aldrich) and other media additives at the following concentrations, unless
otherwise noted: carbenicillin, 50 µg ml-1; chloramphenicol, 20 µg ml-1; gentamicin, 10 µg ml-1;
kanamycin, 100 µg ml-1; isopropyl-β-D-thiogalactopyranoside (IPTG, Gold Biotechnology), 1
mM; arabinose (Gold Biotechnology), 0.1 % (wt/vol).
Protein Expression and Purification. For expression, E. coli strains RK103 (17) or
RK113 (this work, see Table S1) were used. Starter cultures were initiated from a single colony
and grown overnight at 37oC in 10 mL of LB with the appropriate antibiotics. 1 L of LB was
inoculated to 1 % and was grown to an OD600 of 1.8, at which point the culture was induced with
1 mM IPTG for pGEX-based expression or 0.1 % arabinose (wt/vol) for pBAD-based expression
for 14-16 hr. Cells were harvested at 5,000 x g for 12 min and frozen at -80oC. Cell pellets were
thawed and resuspended in 10 mL/gram wet wt of a modified 1 x TALON (Clontech) buffer (20
mM Tris-HCl, pH 8; 100 mM NaCl) and treated with 4-(2-aminoethyl) bezenesulfonyl fluoride
hydrochloride (AEBSF, Gold Biotechnology; 1 mM) and egg white lysozyme (Sigma-Aldrich;
100 µg ml-1) for 30 min while shaking on ice. Cells were disrupted by repeated sonication for 30
sec bursts on a Branson 250 sonicator (50 % duty, 60 % output) until clearing of the suspension
was observed. Crude sonicate was centrifuged at 24,000 x g for 12 min to remove unbroken
cells and cell debris, and membranes were isolated by centrifugation at 100,000 x g for 45 min.
Membrane pellets were solubilized in 1 x modified TALON buffer with 1 % (wt/vol) Anatrace
n-Dodecyl-β-D-Maltopyranoside (DDM, Affymetrix). Solubilized membranes (called “L” or
load in Figures) were passed over TALON resin per the manufacturer’s recommendations and
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bound protein was washed in 1 x modified TALON buffer with 0.1 % DDM with increasing
concentrations of imidazole (in Figures, denoted as wash 1 “W1”, 0 mM imidazole; wash 2
“W2”, 2 mM imidazole; or wash 3 “W3”, 5 mM imidazole). Bound hexahistidine-tagged protein
was eluted in 1 x modified TALON buffer containing 0.1 % DDM and 75 mM imidazole (called
“E” or elution in Figures). The purified protein was concentrated and subjected to buffer
exchange in an Amicon Ultra Centrifugal Filter 30,000 MWCO (Millipore) after purification
(called “EC” or concentrated elution in Figures) to reduce imidazole to less than 100 µM, unless
otherwise noted. To address the accumulation of DDM, purification of CcmF was alternately
carried out using 0.02 % DDM instead of 0.1 %. For these purifications, imidazole was removed
by successive dialysis using Pierce SnakeSkin Pleated Dialysis Tubing 7,000 MWCO (Thermo
Scientific) against 20 mM Tris, pH 8, 100 mM NaCl, 0.02 % DDM, and the protein was
concentrated in an Amicon Ultra Centrifugal Filter 100,000 MWCO (Millipore). Using this
method, the concentration of DDM was maintained at 0.02 % throughout purification and
concentration.
Resonance Raman spectroscopy. Resonance Raman (rR) spectra were obtained using 30
to 40 µM CcmF protein from E. coli, purified with the endogeneous b-heme. Sample solutions
contained 20 mM Tris, pH 8.0, 100 mM NaCl, and dodecyl maltoside at 0.02 %, 0.48 %, or 3.2
%. Heme carbonyl complexes of CcmF were prepared in 5 mm NMR tubes by exhaustive
equilibration of the CcmF solution with water-saturated N2 followed by titration of the sample
with sodium dithionite to reduce the heme. The inert atmosphere in the tube was then displaced
with either natural isotopic abundance CO or 13CO (95 atom % 13C). Raman scattering was
excited using 413.1 nm emission from a Kr+ laser. Sample tubes were spun at ~20 Hz and
spectra were recorded at ambient temperature. Scattered light was collected in the 135o
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backscattering geometry, passed through a holographic notch filter to remove Rayleigh scattered
light and depolarized. The Raman spectrum was recorded using a 0.6 m spectrograph equipped
with a 2400 g/mm holographic grating and a LN2 cooled CCD detector. Spectra were calibrated
versus toluene, DMSO d6, and dibromomethane. Vibrational frequencies reported here are
reproducible to ±1 cm−1.
Heme stains and other methods. Heme stains and immunoblots were performed as
described in (17, 20). Proteins were separated by 12.5 % SDS-PAGE and transferred to Hybond
C nitrocellulose membranes (GE Healthcare). Anti-His antibodies (Santa Cruz technologies)
were used at a dilution of 1:5000. Protein A peroxidase (Sigma-Aldrich) was used as the
secondary label. The chemiluminescent signal for heme stains and anti-His westerns was
developed using the Pierce SuperSignal Femto kit (Thermo Scientific), and detected with an
LAS-1000 Plus detection system (Fujifilm-GE Healthcare). Protein concentrations were
determined using the Pierce BCA Protein Assay Kit (Thermo Scientific) using BSA as a
standard. The concentration of heme in the CcmF protein preparations was determined by UVvisible absorption spectroscopy, pyridine extraction as described in (21) or heme stain as
described in (22). Protein purity was assessed by Coomassie Blue staining of SDS-PAGE.
UV/Vis absorption spectroscopy. UV-visible absorption spectra were recorded with a
Shimadzu UV-2101 PC UV-Vis scanning spectrophotometer at room temperature as described in
(23). Chemically reduced spectra were generated by addition of sodium dithionite (sodium
hydrosulfite) to the purified sample. Unless otherwise indicated, all spectra were recorded in 20
mM Tris-HCl (pH 8), 100 mM NaCl, 0.1 % DDM. To analyze the effect of imidazole on the
electronic spectrum, small quantities of a concentrated imidazole solution (1 M, pH 7) were
added to purified protein and spectra were recorded.
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Cytochrome Reporter and Imidazole Complementation Assays. Cytochrome c4:His6
production was assayed by the following methods using two different strains. (Method 1) Strain
RK111 (∆ccm carrying the arabinose-inducible chromosomal integrate of the cyt c4:His6 gene)
harboring pRGK406 (pGEX ∆ccmF) and one of the following pBAD ccmF plasmids (pRGK408,
409, 410, 411, 412, 413, 414, 415, 416, 417, or 418; see Table S1 in Supporting Information)
was grown aerobically in 5 mLs of LB with appropriate antibiotics for 3 hr and induced for an
additional 3 hr with 0.8 % arabinose (wt/vol). (Method 2) Strain RK103 ((17); ∆ccm) harboring
pRGK332 ((17); carrying the arabinose-inducible cyt c4:His6 gene) and one of the following
pGEX system I-based plasmids (pRGK386 (17), pRGK403, pRGK404, pRGK405, or pRGK407;
see Table S1 in Supporting Information) was grown aerobically in 5 mL LB with appropriate
antibiotics for 3 hr and induced for an additional 3 hr with 0.2 % arabinose (wt/vol) and 1 mM
IPTG. For both methods, cells were harvested by centrifugation at 10,000 x g for 5 min and the
cell pellet was resuspended in 200 µL of Bacterial Protein Extraction Reagent (BPER, Thermo
Scientific) to lyse cells and extract protein. Total protein concentration was determined using the
Nanodrop 1000 spectrophotometer (Thermo Scientific) and 100 µg was analyzed by SDS-PAGE
followed by heme stain. Imidazole complementation assays were performed in the same way
with 10 mM imidazole (pH 7) added to the media prior to inoculation.
Determination of the Reduction Potential of CcmF. The reduction potential for the bheme in CcmF was determined by reduction of a dye of known potential (24), using a
modification of the Massey method (25). The assay contained 20 mM Tris-HCl, pH 7, 100 mM
NaCl, DDM at 0.02 % or 1.2 %, 500 µM xanthine (Sigma-Aldrich), 20 µM CcmF and one of the
following redox dyes: nile blue chloride (Em = -116 mV) (26), resorufin (Em = -50 mV) (26), or
safranin O (Em = -280 mV) (26). 50 to 100 nM of xanthine oxidase enzyme (Sigma-Aldrich)
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was added to initiate the reaction. The reaction was performed at 25oC in a Coy Anaerobic
Airlock Chamber after all solutions were allowed to equilibrate with N2 overnight. Visible
spectra were recorded every 2 min using a Shimadzu UV-1800 spectrophotometer until reduction
was complete (typically between 1 and 2 hrs). The absorbance change for the b-heme peak was
measured at 426 nm, where the change in absorbance of the dye is negligible, and the absorbance
change for the dye was measured at 632 nm, where there is little contribution from heme
absorbance. The changes in absorbance were analyzed by the Nernst equation terms: [25 mV ln
(b-hemered/b-hemeox)] for the one-electron reduction of heme and [12.5 mV ln (dyered/dyeox)] for
the two-electron reduction of dye, where b-hemered/b-hemeox and dyered/dyeox represent ratios of
the molar concentrations of the reduced and oxidized forms of the b-heme and the dye,
respectively. Values corresponding to the Nernst equation terms for the b-heme and the dye at
each time point during the titration were plotted against each other on the x- and y-axes,
respectively, yielding a straight line with a slope of 1. The y-intercept of this line represents the
difference in potential between the b-heme and the known potential of the reference dye. Using
this method, the reduction potential for the b-heme was calculated to within ± 2 mV based on
four independent titrations. To establish the accuracy of this method, two heme proteins of
known potential (cytochrome c and myoglobin) were titrated using the above method and their
respective reduction potentials were found to be within 2 mV of published values. Potentials are
given versus the standard hydrogen electrode.
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Results
Resonance Raman Spectroscopy
Resonance Raman (rR) spectroscopy of heme proteins can yield considerable insight into
structural, conformational and electronic properties of the heme cofactor. Specifically, it is
possible to determine coordination number, oxidation number, and spin state of the iron, as well
as heme conformation, axial ligand identity, the nature of axial ligand bonding, and nonbonded
interactions with the protein (27-30). To gain some of this insight into the heme b that purifies
with CcmF, we recorded Soret-excited rR spectra of ferric and ferrous WT CcmF. We also
recorded spectra of the CcmF-CO complex to further probe the heme pocket.
Figure 2 shows the high- and low-frequency Soret excited rR spectra of ferric (top, red)
and ferrous (bottom, violet) CcmF in 0.02 % DDM. The bands in the high frequency regions of
these spectra report oxidation and spin states of the heme iron as well as the coordination number
(29, 30). The v3 regions of the these spectra exhibit two bands (1491 and 1504 cm-1 for ferric
CcmF; 1469 and 1491 cm-1 for ferrous CcmF) typical of pentacoordinate high-spin (5cHS) and
hexacoordinate low-spin (6cLS) heme complexes in both oxidation states. Thus, the heme b in
ferric and ferrous CcmF exists as an equilibrium mixture of 5cHS and 6cLS states. Note that for
ferrous CcmF, the 1469 cm−1 v3 band corresponding to the 5cHS fraction (Figure 2, bottom) is
considerably more intense than its 6cLS counterpart. However, this intensity ratio does not
reflect the relative populations of the two states of the ferrous heme because the relative rR
scattering cross sections are not the same. In an effort to estimate the population ratio, the UVvisible spectrum was fit so that the Soret band intensities from the HS and LS populations could
be compared (Figure S1). Based on this analysis, ferrous CcmF contains approximately 20 %
5cHS heme.
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To assess whether the heme heterogeneity is intrinsic to CcmF or induced by solubilizing
the protein in detergent, Soret-excited rR spectra of ferric and ferrous CcmF were recorded from
solutions containing 0.02 % (Figure 2), 0.48 %, and 3.2 % DDM. The high-frequency spectra of
ferric CcmF are compared in Figure 2 (partial traces, red). The rR spectra clearly show that
higher DDM concentrations correspond to greater HS heme populations. Thus, although
heterogeneity was apparent in all of the preparations, low DDM concentrations clearly favor the
6cLS heme population of ferric CcmF. Two possible explanations for this detergent dependence
are envisioned at this time. First, the two states of the heme could be reporting conformational
states of the protein that are accessed as part of its native function. For example, these could be
states whose populations are modulated by in vivo interaction with CcmH, holoCcmE, or
apocytochrome c. Alternatively, the population of two ferric heme states may arise from a nonphysiological CcmF conformer whose formation is induced by solubilizing the protein in DDM
detergent. It is important to note that the relative populations of 5cHS and 6cLS ferrous CcmF
were only slightly sensitive to detergent concentration (data not shown).
Raman scattering by νFe-His modes of 5cHS ferrous hemes is typically well enhanced with
blue excitation and usually occurs within the range of 200 to 245 cm-1 (32). Thus, if the axial
ligand is an imidazole side chain of a histidine residue, we would expect to see a strong band in
that frequency range. The second spectrum from the bottom (blue) in the low frequency range of
Figure 2 shows the 441.6-nm excited rR spectrum of ferrous CcmF(WT). This spectrum exhibits
an intense band at 210 cm−1, within the frequency range of Fe-His stretching modes. Such bands
are typical for a Fe−His unit wherein the proximal histidine ligand is the donor to a weak H-bond
within the proximal heme pocket (28, 31, 32). Such H-bonds can involve water in a H-bond
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network or O atoms from backbone carbonyl groups. Thus, in the 5cHS ferrous form, the
proximal ligand is almost certainly the imidazole side chain of a histidine residue.
Vibrational frequencies of the FeCO group in heme—CO complexes are useful probes of
the distal heme pocket. To further investigate the proximal ligand properties of CcmF with
respect to the heme b, we recorded spectra of the CcmF—CO complex. By virtue of the π
backbonding that typifies FeCO moieties, there is an inverse relationship between the sensitivity
of the Fe—C and C—O bond strengths to the bonded and nonbonded interactions of the FeCO
unit (34-36). This inverse relationship is clearly revealed on a heme FeCO backbonding
correlation plot by the negative slope of the Fe—C stretching frequency versus the C—O
stretching frequency for a large number of iron porphyrinates, including carbonyl complexes of
heme proteins. Because the donor strength of the proximal ligand modulates the vertical position
of a heme carbonyl complex on the correlation plot, the nature of the proximal ligand can be
discerned from the position of the heme carbonyl complex relative to the positions of other heme
carbonyls with known proximal ligands.
In order to place a particular complex on the correlation plot, the frequencies must be
identified in the rR spectrum by isotope editing of the vibrational frequencies with 13CO. By this
method, the frequencies of modes involving distortions of the FeCO unit can be unambiguously
identified. Figure 3A shows the regions of the rR spectrum of the CcmF—CO (green) and
CcmF—13CO (blue) complexes where bands arising from FeCO vibrations occur (33). Bands
were assigned based on their 13C sensitivity, which is apparent from the difference spectra shown
in red. The bands at 494 and 572 cm-1 are assigned to the vFe—C and the δFeCO modes,
respectively. The band at 1962 cm-1 was assigned to the vC—O mode. Interestingly, the low
frequency region of the CcmF—CO spectrum recorded in 3.2 % DDM (bottom, violet) reveals
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two Fe—C stretching bands: one at 495 cm−1 (the same Raman shift observed at low DDM
concentrations) and the other at 525 cm−1. Thus, high DDM concentrations induce formation of
a second CcmF—CO complex.
Figure 3B shows the FeCO backbonding correlation plot described above, with three
inverse correlations between vFe−C and vC−O frequencies for a wide selection of heme carbonyl
complexes. The bottom (green) line in Figure 3B correlates Fe—C and C—O bond strengths for
proximal ligands having anionic character, such as the strongly H-bond donating proximal
imidazoles of the heme peroxidases and the proximal thiolates of the cytochromes P450. The
middle (black) line correlates the analogous bond strengths in proteins that have charge neutral
proximal ligands that are bound to the heme iron through an N atom. Nearly all of these
complexes have proximal imidazole ligands from histidine residues. The top (blue) line
correlates heme—CO complexes that are either pentacoordinate or have proximal O-atom donor
ligands. The position of CcmF—CO in 0.48 % DDM is indicated by the half-filled red diamond
in Figure 3B. This point falls on the proximal histidine correlation line, consistent with at least
one endogenous axial histidine ligand for the heme b of CcmF. Note that this analysis does not
facilitate identification of the specific coordinating histidine residue. The heme carbonyl that
was only observed in 3.2 % DDM falls on the top line in Figure 3B, as shown by the half-filled
red triangle. This position constitutes compelling evidence that the heme—CO complex in high
DDM is either pentacoordinate or has a sixth axial ligand coordinated to iron through an oxygen
atom. This result shows that in high DDM solutions, the second protein-based axial ligand that
gives rise to 6cLS heme is unavailable to the heme in a significant fraction of these ferrous
heme—CO complexes. This behavior is consistent with the correlation between the HS ferric
heme population and DDM concentration illustrated in Figure 2.
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Heme content of Ala substitutions
To identify the ligands to b-heme iron in CcmF, we focused on the four conserved
histidines (His173 and His303 in periplasmic loops, and His261 and His491 in TMDs).
Previously, we showed that purified CcmF with a His173Ala substitution contained wild-type
(WT) levels of b-heme, while CcmF with a His261Ala substitution had approximately four-fold
less heme (8). Here, we analyze heme levels in purified CcmF with alanine substitutions at
His303 or His491. Figure 4A shows that CcmF His303Ala and CcmF His491Ala were each
purified as full-length proteins with minimal degradation. Comparison of the Soret maxima in
the electronic spectra indicates that CcmF His303Ala purified with heme levels similar to WT
CcmF while CcmF His491Ala purified with less than 20 % of WT levels (note the differences in
absorbance in Figures 4B, 4C, and 4D). This was confirmed by semi-quantitative heme stain to
detect the b-heme, which runs at the dye front during SDS-PAGE (Figures 4E, 4F, and 4G). The
purified concentrated preparations (lane 8 of Figures 4E, 4F, and 4G) show much less heme for
CcmF His491Ala. The same concentration of purified CcmF was analyzed for each of the
proteins; thus, the fractional heme loading in each protein can be directly compared. These data
and previous findings in ref. (8), suggest that periplasmic His173 and His303 are not b-heme
ligands, while transmembrane His261 and His491 are good candidates for ligands to the b-heme.
In agreement with this, CcmF with glycine substitutions at His261 and His491 also contained
approximately 20 % heme content relative to WT CcmF (data not shown).
Spectral perturbations in His261Cys
In making substitutions to His261 and His491, we observed that a His261Cys substitution
in CcmF retained a high level of function relative to WT (see below) and that purified CcmF
His261Cys (Figure 5A) contained approximately 50 % of the b-heme as WT (Figure 5B).
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Cysteine has been shown to function as a ligand in place of the natural histidine ligand in many
heme proteins, including myoglobin (37-39), cytochrome b5 (40), and flavocytochrome b2 (41).
The UV/Vis absorption spectrum of CcmF His261Cys has several distinct features in comparison
to the spectrum of WT CcmF (compare Figures 5C and 5D). Oxidized (“as purified”) WT CcmF
exhibits a sharp Soret maximum at 412 nm, whereas the Soret band for CcmF His261Cys is
broad with a maximum at 406 nm. Additionally, the α and β absorptions in the visible region are
much less pronounced for CcmF His261Cys than for WT CcmF. The position of the Soret at
406 nm is indicative of high-spin heme (40), but the breadth of the Soret band and the α and β
absorptions suggest that ferric CcmF His261Cys may also contain a population of 6cLS heme
(42, 43). Thus, while the UV/Vis absorption spectrum of ferric WT CcmF is dominated by
features characteristic of 6cLS heme (40), the spectrum of ferric CcmF His261Cys is consistent
with a mixture of 5cHS and 6cLS heme. The dithionite-reduced spectrum for CcmF His261Cys
shows a Soret of 423 nm and exhibits clear α and β absorptions, although the α:β peak ratio is
different than for WT CcmF. Based on the position of the Soret band and the clearly resolvable
α and β maxima, ferrous CcmF His261Cys appears to contain predominantly low-spin heme
(40). The presence of 6cLS heme in CcmF His261Cys suggests possible coordination by His491
and Cys261. While low-spin hemes with cysteine ligands typically exhibit Soret bands near 450
nm (44), Soret absorptions near 425 nm have been observed when the sulfur-iron bond is
weakened or displaced (39, 42, 43, 45). These spectral perturbations observed in ferric and
ferrous CcmF His261Cys (relative to the spectrum of WT CcmF) suggest that in the WT protein,
His261 is an axial ligand to the b-heme.
Imidazole, the side chain of histidine, has been used as a surrogate proximal ligand to
probe heme binding sites in proteins in vitro (e.g., 40, 42, 46). To investigate the effect of
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imidazole on heme in the His261Cys CcmF protein, UV/Vis spectra of purified CcmF
His261Cys were recorded in the presence of imidazole. At a concentration of 30 mM imidazole,
the spectrum of the oxidized His261Cys mutant shifts to resemble that of WT CcmF (compare
solid lines in Figures 5C and 5E). The Soret band occurs at 414 nm (compared to 406 nm in the
absence of imidazole) and pronounced α and β absorptions similar to WT CcmF can be
observed. Upon reduction with sodium dithionite, the His261Cys (+ 30 mM imidazole) exhibits
a Soret band at 423 nm and an α to β peak ratio similar to that of reduced WT CcmF. Addition
of 30 mM imidazole to WT CcmF preparations did not change the UV/Vis spectrum (not
shown). These data suggest that in the presence of imidazole, heme in His261Cys is
predominantly 6cLS in both the oxidized and reduced states. The similarities in the spectra of
CcmF His261Cys in the presence of imidazole and WT CcmF suggest that, in the WT protein,
the b-heme may be liganded by the imidazole side chains of two His residues.
Functional restoration of CcmF His261 and His491 mutants by imidazole
Alanine substitutions at each of the four conserved histidine residues (His173, His261,
His303, and His491) abolished in vivo function (cytochrome c assembly) in E. coli under aerobic
conditions (Figure S2). Initially, we analyzed whether these alanine substitutions could be
corrected for in vivo function by adding imidazole to E. coli cultures (Figure S1). In vivo
chemical complementation by exogeneous imidazole is conceptually similar to the correction of
heme binding by imidazole in the recombinant myoglobin His93Gly “cavity” mutant, for which
10 mM imidazole was optimal (47). This approach has also been used to correct the function of
histidine mutants in the hydrogenase cytochrome b of Azotobacter vinelandii (48) and the
CcsBA system II cytochrome c synthetases from Helicobacter hepaticus (23) and Wolinella
succinogenes (49). The His491Ala mutant of CcmF was corrected for cytochrome c4 assembly
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at 10 mM imidazole (Figure S2, lane 12). To determine if glycine substitutions in CcmF could
be corrected for function, we replaced transmembrane His491 or His261 with glycine and
assayed for cytochrome c4 assembly in the absence and presence of imidazole. Substitution of
either His261 or His491 with glycine abolished or severely impaired cytochrome c4 assembly in
vivo (quantified in Figure 6A and 6B; representative heme stains for cytochrome c4 are in Figure
S3). Addition of 10 mM imidazole restored function to CcmF His261Gly and to His491Gly
(Figure 6A and 6B). We propose that the CcmF His261Gly and His491Ala/Gly proteins form
“cavities” in which imidazole can bind and serve as a ligand to the b-heme in CcmF. Based on
these results, we predicted that amino acids with bulkier side chains (that are unable to function
as b-heme ligands) would not accommodate imidazole binding in the “cavity”, and thus would
not permit functional correction. We tested this by engineering additional substitutions at
His261 and His491. As mentioned above, His261Cys was roughly 70 % functional relative to
wild-type in the absence of imidazole (Figure 6A). However, neither His261Tyr nor His261Met
were functional above background levels, nor were these substitutions corrected substantially by
imidazole (Figure 6A). The same was true for Cys and Tyr substitutions at His491 (Figure 6B).
His491Arg showed a low level of function relative to WT (approximately 18 %), but imidazole
did not improve the function of this mutant (Figure 6B). These results are consistent with
His261 and His491 acting as heme ligands, such that when these His residues are substituted
with amino acids containing small side chains (Gly or Ala), a cavity is formed in which
imidazole can bind and serve as a surrogate heme axial ligand. The inability of imidazole to
correct the cytochrome c assembly defect of CcmF His261Ala could be the result of the methyl
group of Ala occluding the “cavity” such that imidazole is unable to bind. We have not
investigated this further.
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Conservation of the b-heme in CcmF
To determine if the b-heme in CcmF is conserved, we engineered CcmF proteins from a
phylogenetically diverse group of prokaryotes (Figure 7A; gamma proteobacteria- Escherichia
coli and Shewanella oneidensis; delta proteobacteria-Desulfovibrio vulgaris, alpha
proteobacteria-Roseobacter denitrificans; deinococci-Thermus thermophilus). CcmF proteins
from E. coli (NrfE, here called CcmF2) and Shewanella (here called CcmF3) that recognize and
mature cytochromes c with alternate heme binding sites (Cys-Xxx-Xxx-Cys-Lys in E. coli; and,
putatively, Cys-Xxx15-Cys-His in Shewanella) were also engineered with hexahistidine tags and
purified (Figure S4). Each of these CcmF homologs possesses the four conserved histidine
residues studied above in the E. coli CcmF. Heme analysis by UV/Vis absorption spectroscopy
(Figure 7B) and heme stain (Figure S4) revealed that each purified CcmF protein contained bheme in approximately equimolar stoichiometry.
Reduction potential of the b-heme in CcmF
We determined the reduction potential for the CcmF b-heme using the purified CcmF
from E. coli (Figure 8). Using a modification of the method of Massey (with xanthine/xanthine
oxidase to generate reductant) (25), values for the midpoint potential of the CcmF b-heme
(Fe3+/Fe2+) were determined against nile blue chloride (Em= -116 mV) at pH 7 (26). The spectral
results obtained from a typical reduction run with CcmF and nile blue chloride are shown in
Figure 8A. The decreases in absorbance at 412 nm and 480 nm and the increase in absorbance at
426 nm are indicative of reduction of the CcmF b-heme. The decrease in absorbance at 632 nm
is due to reduction of nile blue chloride. The linear Nernst plot for reduction of the b-heme and
nile blue chloride produced the expected slope of 1 (Figure 8B), indicating that the reduced and
oxidized forms of the dye and the heme were at their equilibrium concentrations at the time each
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spectrum was recorded. This behavior ensures that there is no overpotential contribution to the
midpoint potentials determined from these measurements. The reduction potential of the b-heme
in CcmF was found to be -147 ± 2 mV. This value was confirmed using resorufin (Em = -50
mV) (26) or safranin O (Em = -280 mV) (26) as alternate redox dyes (Figure S5). It has been
observed previously that the type of detergent (50, 51) and detergent concentration (50) can alter
reduction potentials of b-type hemes in membrane proteins. To assess the effects of DDM, we
determined the reduction potential of the CcmF b-heme in solutions containing 0.02 % (Figure 8)
or 1.2 % DDM. The reduction potential in 1.2 % DDM was found to be substantially more
positive (Em = -110 ± 4 mV) than in 0.02 % DDM (Figure S6). This is likely attributable to the
same DDM-dependent speciation of the ferric heme-b between HS and LS states that was
revealed by the rR spectra (vide supra).
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Discusssion
Here, we present several lines of evidence that TMD His261 and His491 are the ligands
to the CcmF b-heme: (i) Gly or Ala substitutions at either His result in approximately 80 % less
heme as compared to WT CcmF (Figure 4), (ii) substitution of His261 with Cys, a known heme
ligand, yields a functional CcmF that shows improved heme binding relative to substitutions with
non-ligand residues (Ala or Gly) and shows a perturbed UV/Vis spectrum (Figure 5), and (iii)
exogeneous imidazole chemically corrects the in vivo cytochrome c synthetase function of small
residue substitutions at CcmF His261 and His491, but not substitutions with bulkier residues
(Figure 6). The results of rR spectroscopy confirm the presence of hexacoordinate, low-spin bheme (Figure 2), and rR analysis of the heme-carbonyl complex suggests axial His coordination
of the b-heme (Figure 3). Additionally, we show that the CcmF b-heme is widely conserved by
analyzing recombinant CcmF proteins from diverse bacteria (Figure 7).
Implications of His261 and His491 as the b-heme axial ligands in CcmF
His261 in CcmF is located in TMD5, and His491 is located near the C-terminus in
TMD12 (see Figure 1B). In order for these residues to coordinate the iron of the b-heme, we
propose that TMD5 and TMD12 are positioned close to each other in the three-dimensional
structure of CcmF. These findings suggest that the most likely position for the b-heme is directly
below the periplasmic WWD domain in CcmF (refer to Figure 1B). The WWD domain is a
highly conserved tryptophan-rich motif that is located at the outer leaflet of the inner membrane
and has been shown to interact directly with heme in the WWD family member CcmC (7). In
CcmC, heme axial ligands are provided by two His residues located in periplasmic loops that
flank the WWD domain (7, 8). Similar to CcmC, we predict that the WWD domain of CcmF
forms a heme binding site for heme from holoCcmE, with periplasmic His173 and His303 of
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CcmF serving as heme axial ligands (Figure 1B). Thus, the positioning of the b-heme directly
below the CcmF WWD domain is consistent with our hypothesized role for CcmF in reducing
heme from holoCcmE prior to attachment to the apocytochrome (see below).
The function of CcmF b-heme as a holoCcmE reductase
Reduction of the heme in holoCcmE is required for covalent attachment of this heme to
the apocytochrome c. We have previously discussed that reduction of the holoCcmE heme could
also favor ejection of the CcmE His130 covalent linkage (5). To address our hypothesis that the
b-heme in CcmF may be involved in electron transfer to holoCcmE (5, 8), we determined the
reduction potential of the CcmF b-heme. We report here that the CcmF b-heme has a midpoint
potential of -147 mV at pH 7 (Figure 8). Harvat et al. have reported a redox potential of -121
mV at pH 7.3 for holoCcmE´, a soluble version of CcmE without the single TMD (52). Despite
the differences in the buffer conditions used in determining the reduction potentials for
holoCcmE´ and here for CcmF (e.g., the presence of DDM), it is certainly feasible that CcmF
functions as a holoCcmE reductase. However, the reduction potential of isolated, purified
holoCcmE´ may not reflect the physiological potential of this heme prior to attachment to the
apocytochrome c. Recall that, en route to attachment to apocytochrome c, the holoCcmE heme
likely enters the WWD domain of CcmF, where heme axial ligands are provided by His173 and
His303 of CcmF (see Figure 1B). In purified holoCcmE, Tyr134 of CcmE has been shown to
serve as an axial ligand to the heme (12, 53). It is well-established that heme reduction potential
is sensitive to changes in axial ligation (38, 41, 54), and tyrosine axial ligation is typically
associated with a lowering of the reduction potential (i.e., more negative) relative to ligation by
histidine (38, 55, 56). Thus, the heme ligand “switch” from CcmE Tyr134 to CcmF
His173/His303 upon binding of holoCcmE in the CcmF WWD domain could result in an
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increase in the reduction potential (i.e., more positive) of the heme in holoCcmE. Although the
identity of the physiological electron donor to the CcmF b-heme is unknown, we previously
showed that CcmF could be reduced by select quinone species in vitro in the presence of
dithiothreitol (8). Further studies are needed to investigate these features of cytochrome c
assembly.
Interaction between CcmF and holoCcmE
Although it is widely believed that the heme from holoCcmE moves onto the
apocytochrome c via CcmF, to our knowledge, an interaction between CcmF and holoCcmE has
never been detected. Thony-Meyer and colleagues have suggested that apoCcmE and CcmF
interact (16). However, in that study, because the genes encoding CcmABCD were absent, all of
the CcmE was in the apo- form, so the physiological relevance of this finding is unclear.
Furthermore, while Ren et al. (16) showed that antisera to CcmF co-immunoprecipitated
apoCcmE, the reverse co-immunoprecipitation with anti-sera to CcmE yielded “non-specific
signals” (16). In our hands, the only protein that co-purifies with CcmF is CcmH (for example,
see Figure 4 in ref. (8)). We have been unable to detect apo- or holoCcmE above background
levels in purifications of hexahistidine-tagged CcmF. We suggest that holoCcmE may not copurify with CcmF (or the CcmF/H complex) unless the apocytochrome c acceptor (Cys-XxxXxx-Cys-His) is bound. This proposal is in part based on our recent findings on the “acceptordependent” nature of the CcmC-heme-CcmE complex of system I (7). CcmC does not bind
detectable levels of heme in its WWD domain in the absence of CcmE (Figure 1A), indicating
that heme binding in CcmC requires the presence of the heme acceptor, CcmE. By analogy,
heme in holoCcmE may not enter the WWD domain of CcmF unless the heme acceptor protein,
apocytochrome c, is present. Future work will be dedicated to better understanding the
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interaction of holoCcmE with CcmF; specifically, investigating if the docking of holoCcmE in
the CcmF WWD domain requires the presence of the apocytochrome c acceptor, and, if the
holoCcmE/CcmF/CcmH complex can be “trapped,” determining the reduction potential of the
heme in holoCcmE when (and if) it is bound in the CcmF WWD domain.
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Figures
Figure 1. Model for stystem I and membrane topology of CcmF
Adapted from reference (5). (A) Current working model of the system I cytochrome c
biogenesis pathway. Model includes trafficking and oxidation states of heme as well as the
subpathways for apocytochrome translocation and reduction. (B) Topology of the CcmF integral
membrane protein from E. coli. Possible histidine axial ligands to heme are starred. The highly
conserved WWD domain is shaded as are the hydrophobic patches. Completely conserved
amino acids (red) were identified by individual protein alignments using CcmF ORFs from the
following organisms: the alpha proteobacteria, Agrobacterium tumefaciens C58, R. capsulatus,
Caulobacter crescentus CB15, and Bradyrhizobium japonicum; the beta proteobacteria,
Nitrospira mutliformis ATCC 25196 and Nitrosomonas europaea ATCC 19718; the gamma
proteobacteria, E. coli K-12 MG1655, Pseudomonas fluorescens Pf01, Shewanella oneidensis
MR-1 and Vibrio parahaemolyticus RIMD 2210633; the delta proteobacteria, Myxococcus
xanthus and Desulfovibrio desulfuricans; and the deinococci, Deinococcus geothermalis and
Thermus thermophilus.
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Figure 2. Resonance Raman spectral analysis of the CcmF b-heme
Soret-excited resonance Raman spectra of the heme b in ferric (red) and ferrous (violet, blue)
CcmF. Sample solutions were 88 µM in holoCcmF, 20 mM in Tris, pH 8, 100mM in NaCl, 0.02
% in dodecyl maltoside, ~2 nm in imidazole. HoloCcmF concentrations in the 3.2 % and 0.48 %
DDM samples were 23 and 25 µM, respectively. The red and violet spectra were recorded using
10 mW of laser light at 413.1 nm (line focus of emission from Kr+ laser). The low-frequency
blue spectrum was recorded with 2 mW of 441.6-nm emission from a HeCd laser to identify the
Fe−His stretching band.

57

58

Figure 3. Resonance Raman spectral analysis of CcmF-CO complexes
(A) Soret(413.1 nm)-excited rR spectra of natural abundance CcmF−CO (green) and
CcmF−13CO (blue) in the vFe-C and vC-O frequency regions. The red traces are the difference
spectra, whose amplitudes have been multiplied by a factor of two for ease of viewing. The
difference features reveal the bands whose frequencies are 13C dependent, thereby facilitating
their assignments to FeCO modes, which are indicated in the labels above the bands. The violet
trace shows the spectrum of natural abundance CcmF−CO in 3.2 % DDM. Note that this
spectrum exhibits two Fe−C stretching bands. This heterogeneity is attributed to protein
conformational changes driven by the high detergent concentration. (B) Heme FeCO
backbonding correlation plot showing the positions of the two CcmF−CO conformers. The
CcmF−CO complex that falls on the middle line (0.48 % DDM) most likely contains a proximal
imidazole ligand from a His residue. Its position low and to the right on the imidazole line
shows that the CO ligand interacts only weakly with the heme pocket. The CcmF−CO complex
that falls on the top line (3.2 % DDM) is either pentacoordinate or has a proximal ligand that is
bound through an oxygen atom.
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Figure 4. Heme levels in CcmF (WT), His303Ala, and His491Ala proteins.
Coomassie stain (A) of CcmF(WT), CcmF(H303A), and CcmF(H491A) showing purified fulllength 54 kDa proteins (indicated by arrow). UV/Vis absorption spectra of CcmF(WT) (B),
CcmF(H303A) (C), and CcmF(H491A) (D) as purified (oxidized; solid lines) and dithionitereduced (dotted lines). Absorption maxima are indicated with arrows. Heme stains of
CcmF(WT) (E), CcmF(H303A) (F), and CcmF(H491A) (G); free heme is indicated with arrows;
M, molecular weight standards; L, load; FT, flow-through; W1-W3, washes 1-3; E, elution; EC,
concentrated elution, as described in Experimental Procedures. 20 µM purified CcmF protein
was analyzed by UV/Vis absorption spectroscopy (B, C, D) and 30 µg was analyzed by heme
stain or Coomassie stain (A; E, F, G, lane 8).
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Figure 5. Spectral analysis of CcmF His261Cys and wild-type CcmF (WT) proteins.
Coomassie stain (A) and heme stain (B) of CcmF(WT) and CcmF(H261C) proteins. UV/Vis
absorption spectra of CcmF(WT) (C), CcmF(H261C) (D), and CcmF(H261C) in the presence of
30 mM imidazole (E), oxidized (solid lines) and dithionite-reduced (dotted lines). Absorption
maxima are indicated with arrows. Absorbance values between 500 nm and 700 nm have been
multiplied by a factor of 3. 30 µg of purified protein was analyzed by Coomassie and heme stain
(A, B). For UV/Vis absorption spectra approximately 20 µM purified protein was analyzed for
wild-type, and approximately 40 µM purified protein was analyzed for His261Cys in the
presence and absence of 30 mM imidazole.
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Figure 6. Imidazole correction of CcmF His261 and His491 mutants.
The function of each of the indicated substitutions at CcmF His261 (A) or His491 (B) is reported
as a percentage of wild-type CcmF (WT) function. Holocytochrome c4 was quantified by
measuring the chemiluminescent heme stain signal of 100 µg of BPER-isolated proteins from
three independent experiments. Representative heme stains are provided in Supporting
Information (Figure S3). Error bars denote standard deviation. “C” denotes control, which
represents chemiluminescent signal in the absence of CcmF (any signal lower than the control is
considered background).
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Figure 7. Phylogenetic distribution and spectral analysis of diverse CcmF proteins.
(A) Adapted from reference (23). Representative distribution of systems I, II and III among the
bacteria and archaea. The system number is noted in parentheses after each group name, and
stars indicate groups containing organisms from which recombinant hexahistidine-tagged CcmF
was analyzed in the present study. (B) Reduced UV/Vis absorption spectra of CcmF from E. coli
(Ec), Thermus thermophilus (Tt; Deinococcus group), Desulfovibrio vulgaris (Dv), Roseobacter
denitrificans (Rd), and Shewanella oneidensis (So); Shewanella oneidensis CcmF-3 (So-F3), and
E. coli CcmF-2 (Ec-F2). Absorption maxima are indicated with arrows. Spectra have been
offset for clarity. Approximately 20 µM of each purified CcmF protein was analyzed for which
Coomassie and heme stains are provided in Supporting Information (Figure S4).
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Figure 8. Redox titration of the CcmF b-heme.
Spectra collected during a typical reductive titration of CcmF b-heme with nile blue chloride (A)
and the corresponding linear Nernst plot (B). Arrows in (A) indicate the direction of changes in
absorption during the course of the titration. In (B), [25 mV ln (b-hemered/b-hemeox)] was used
for the one-electron reduction of heme and [12.5 mV ln (dyered/dyeox)] was used for the twoelectron reduction of dye, where b-hemered/b-hemeox and dyered/dyeox represent ratios of the
molar concentrations of the reduced and oxidized forms of the b-heme and the dye, respectively.
Conditions: 20 mM Tris-HCl, pH 7, 100 mM NaCl, 0.02 % DDM.
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Supporting Information
Construction of strains and plasmids. All oligonucleotide primer sequences, plasmids, and
strains are given in Table S1. To create RK113, we deleted the endogeneous ccm operon in E.
coli BW25113 by P1 transduction. Briefly, P1 phage were grown first in LB media containing 5
mM CaCl2 and 0.2 % glucose (wt/vol) with the donor strain (RK103 (1)). Donor cells were
killed by addition of chloroform and phage were isolated. Dilutions of isolated phage (100 µL)
were incubated with 100 µL of the recipient strain (BW25113) in LB containing 5 mM CaCl2
and 100 mM MgSO4 at 37oC for 30 min. Physical interaction between the phage and cells was
disrupted by addition of 66.7 mM sodium citrate (Fisher), pH 5.5, and the culture was added to 1
mL LB broth and incubated for one hour at 37oC while shaking at 300 rpm. Transductants were
selected by growth on LB + Kan, and cells were purified from P1 phage by repeated streaking on
LB + Kan plates containing sodium citrate. Deletion of the ccm operon in RK113 was confirmed
by genomic PCR. To create RK111, we used the pKNOCK system (2). Briefly, the cyt c4:His6
gene along with the araC gene were cloned from pRGK332 (1) into pKNOCK-Gm (2). The
araC gene was included to serve as the site for homologous recombination with the
chromosome. Cloning was done in E. coli S17-1/λpir, and the plasmid was conjugally
transferred to E. coli RK103 (1). Putative exconjugants were selected for resistance to 10 ug ml-1
gentamicin, and correct integration of cyt c4:His was verified by genomic PCR.
E. coli strains TB1 and HB101 were used as host strains for cloning. pRGK333 (1)
containing the full system I operon (ccmABCDEFGH) was the template for all PCR
amplifications unless otherwise indicated. A plasmid containing ccmABCDE (∆ccmFGH) was
constructed by PCR amplification of ccmABCDE with Ccm_N-term and Del_CcmF_Left, the
product of which was digested, and ligated into BamHI and EcoRI digested pGEX-4T-1 (GE
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Healthcare) to make pRGK402. To generate the His173Ala, His261Ala, and His303Ala
mutants, short PCR products were amplified using Del_CcmE_Right and
CcmF_His173Ala_Rev, CcmF_His261Ala_Rev, or CcmF_His303Ala_Rev. These products
were gel purified and used in a second amplification with CcmH_XhoI_Rev using pRGK386 (3)
as template to generate ccmF(His173Ala):His6GH, ccmF(His261Ala):His6GH, and
ccmF(His303Ala):His6GH (His6 refers to a hexahistidine tag at the carboxy terminus of CcmF).
The final, full-length products were ligated into NdeI and XhoI digested pRGK402 to generate
pRGK403, pRGK404, and pRGK405, respectively. A plasmid containing ccmABCDEGH
(∆ccmF) was constructed by PCR amplification of ccmGH with Del_CcmF_Right and Ccm_Cterm primers, the product of which was digested and ligated into EcoRI and NdeI digested
pRGK402 to make pRGK406. For the His491Ala mutant, a short PCR product was generated by
amplifying with CcmF_His491Ala_Fwd and CcmF_ 6xHis_NdeI_Rev. This product was gel
purified and then used in a second amplification with Del_CcmE_Right to generate ccmF
(His491Ala):His6. The final, full-length product was ligated into the single NdeI site of
pRGK406 to generate pRGK407.
To insert ccmF:His6, ccmF(His261Ala):His6, or ccmF(His491Ala):His6 into pRGK330
(1) for arabinose-inducible expression in the absence of other ccm genes, the corresponding
ccmF gene was amplified from pRGK386, pRGK404, or pRGK407, respectively, with
CcmF_NcoI_Fwd and CcmF_6xHis_PstI_Rev, digested, and ligated into NcoI and PstI digested
pRGK330 to make pRGK408, pRGK409, and pRGK410. His261Gly, Cys, Tyr, and Met were
generated by amplifying with the appropriate reverse mismatch primer and CcmF_NcoI_Fwd to
generate short PCR products. These products were gel purified and used in a second
amplification with CcmF_6xHis_PstI_Rev. His491Gly, Cys, Tyr and Arg were generated by
72

amplifying with the appropriate forward mismatch primer and CcmF_6xHis_PstI_Rev to
generate short PCR products. These products were gel purified and used in a second
amplification with CcmF_NcoI_Fwd. The final, full-length products for all site-directed mutants
at His261 and His491 described above were digested with NcoI and PstI and inserted into
pRGK330 to generate pRGK411-418. Each of the final constructs was sequenced to confirm the
mutation.
The ccmF-3 gene from Shewanella oneidensis (SO_0478) was PCR amplified from
genomic DNA, digested, and ligated into the NcoI and PstI sites in pRGK330 to generate
pRGK420. The ccmF gene from Roseobacter denitrificans (RD1_3223) was amplified from
genomic DNA, digested, and ligated into the EcoRI and KpnI sites of pRGK330 to make
pRGK424. Roseobacter denitrificans genomic DNA was provided generously by the
Blankenship lab. The ccmF-2 gene from E. coli (b4074) was amplified from genomic DNA,
digested, and ligated into the NcoI and XbaI sites of pRGK330 to make pRGK421. The ccmF
genes from Shewanella oneidensis (SO-0266), Desulfovibrio vulgaris (DVU_1050), and
Thermus thermophilus (TTHA1404) were each amplified from genomic DNA with the
appropriate primers and cloned into pCR-Blunt II-TOPO (Invitrogen). From pCR-Blunt IITOPO, the ccmF gene from Shewanella oneidensis was ligated into the NheI and XhoI sites of
pRGK330 to make pRGK419, the ccmF gene from Desulfovibrio vulgaris was ligated into the
NcoI and XbaI sites to make pRGK423, and the ccmF gene from Thermus thermophilus was
ligated into the KpnI and NheI sites to make pRGK422. Desulfovibrio vulgaris subsp. vulgaris
ATCC 29579 and Thermus thermophilus ATCC 27634 strains were obtained from ATCC and
cultured according to ATCC recommendations, and genomic DNA was prepared using the
Puregene System Cell and Tissue DNA Isolation Kit (Gentra Systems).
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Figure S1. Peak fitting of the ferrous CcmF UV-visible absorbance spectrum.
The fit peaks reveal speciation between 6cLS (red) and 5cHS (blue) hemes with a significant
fraction being 5cHS. Assuming that the extinction coefficients at the HS and LS Soret maxima
are roughly equal, the samples of ferrous CcmF(WT) used in this study comprise approximately
20 % 5cHS heme. Based on similarities among the UV-visible spectra and insensitivity of the 3
ratios to [DDM] between 0.48 % and 0.02 %, this speciation is essentially independent of DDM
concentration.
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Figure S2. Cytochrome c4:His6 assembly in the presence or absence of 10 mM imidazole.
Arrow indicates 24 kDa holocytochrome c4:His6 matured by a functional system I. “pSysI∆F”
denotes a system I deleted for ccmF; “c4:His only” denotes an absence of all ccm genes; “M”
denotes molecular weight standards (shown is the 28 kDa standard). 100 µg of BPER-isolated
proteins was loaded into each lane for SDS-PAGE prior to heme staining.
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Figure S3. Cytochrome c assembly in the presence or absence of imidazole.
Representative heme stains showing cytochrome c4:His6 assembly of mutants at His261 (A) and
His491 (B) in the presence or absence of 10 mM imidazole (as described in Figure S1). Arrow
indicates 24 kDa holocytochrome c4:His6 matured by a functional system I. Substitutions: A,
Ala; G, Gly; C, Cys; Y, Tyr; M, Met; R, Arg. The dash denotes the negative control condition
(absence of CcmF) and “wt” denotes wild-type CcmF. “M” denotes molecular weight standards
(shown is the 28 kDa standard). 100 µg of BPER-isolated proteins was loaded into each lane for
SDS-PAGE prior to heme staining.
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Figure S4. Purification of CcmF proteins from diverse bacteria.
Coomassie stain (A) and corresponding heme stain (B) after SDS-PAGE of CcmF:His6 from E.
coli (Ec), Thermus thermophilus (Tt; Deinococcus group), Desulfovibrio vulgaris (Dv),
Roseobacter denitrificans (Rd), Shewanella oneidensis (So), Shewanella oneidensis CcmF-3 (SoF3), and E. coli CcmF-2 (Ec-F2). Arrows indicate full-length 54 kDa CcmF:His6 and free heme
at the SDS-PAGE dye front. Note that some of the So-CcmF3 and Ec-CcmF2 aggregate at
approximately 117 kDa, possibly a dimeric form, under the conditions of SDS-PAGE used.
Additionally, note that for Dv, So-CcmF3 and Ec-F2, some heme is retained in the full length
protein and/or in the higher molecular weight forms. For each of the proteins analyzed, heme
was found to be non-covalent as determined by pyridine hemachromagen (data not shown).
Thus, Dv, So-CcmF3 and Ec-F2 may bind heme in a partially SDS-resistant, although noncovalent, manner. 30 µg of purified hexahistidine-tagged protein was analyzed for each.
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Figure S5. Redox titration of the CcmF b-heme with alternate redox dyes.
Spectra collected during reduction of CcmF b-heme with resorufin (A) or safranin O (B).
Arrows indicate the direction of changes in absorption during the course of the titration. The
decreases in absorbance at 534 nm and 572 nm in (A) are due to reduction of resorufin. In (B),
the decrease in absorbance at 412 nm and the increase in absorbance at 426 nm are indicative of
reduction of the CcmF b-heme, and the decrease in absorbance at 532 nm is due to reduction of
safranin O. Note that the dye resorufin (Em = -50 mV) (4) is completely reduced before
reduction of the CcmF b-heme, while the CcmF b-heme is completely reduced before reduction
of safranin O (Em = -280 mV) (4). This indicates that the relative midpoint potential of the
CcmF b-heme is in between that of resorufin and safranin O. Conditions: 20 mM Tris-HCl, pH
7, 100 mM NaCl, 0.02 % DDM.
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Figure S6. Redox titration of the CcmF b-heme in high DDM (1.2 %).
Spectra collected during a reductive titration of CcmF b-heme with nile blue chloride (Em = -116
mV) (4) (A) and the corresponding linear Nernst plot (B). Arrows in (A) indicate the direction
of changes in absorption during the course of the titration. In (B), [25 mV ln (b-hemered/bhemeox)] was used for the one-electron reduction of heme and [12.5 mV ln (dyered/dyeox)] was
used for the two-electron reduction of dye, where b-hemered/b-hemeox and dyered/dyeox represent
ratios of the molar concentrations of the reduced and oxidized forms of the b-heme and the dye,
respectively. The reduction potential in 1.2 % DDM was substantially more positive (Em = -110
± 4 mV) than in 0.02 % DDM. Conditions: 20 mM Tris-HCl, pH 7, 100 mM NaCl, 1.2 % DDM.
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Abstract
The periplasmic heme chaperone holoCcmE is essential for heme trafficking in the cytochrome c
biosynthetic pathway in many bacteria, archaea, and plant mitochondria. This pathway, called
system I, involves two steps: i) formation and release of holoCcmE (by CcmABCD), and ii)
delivery of the heme in holoCcmE to the putative cytochrome c heme lyase complex, CcmFH.
CcmFH is believed to facilitate the final covalent attachment of heme (from holoCcmE) to the
apocytochrome c. Although all models for system I propose that holoCcmE delivers heme
directly to CcmF, no interaction between holoCcmE and CcmF has been demonstrated. Here, a
complex between holoCcmE and CcmF is “trapped”, purified, and characterized. HoloCcmE
must be released from the ABC-transporter complex CcmABCD to interact with CcmF, and the
holo-form of CcmE interacts with CcmF at levels at least 20-fold higher than apoCcmE. Two
conserved histidines (here termed P-His1 and P-His2) in separate periplasmic loops in CcmF are
required for interaction with holoCcmE, and evidence is presented that P-His1 and P-His2
function as heme-binding ligands. These results show that heme in holoCcmE is essential for
complex formation with CcmF, and that the heme of holoCcmE is coordinated by P-His1 and PHis2 within the WWD domain of CcmF. These features are strikingly similar to formation of the
CcmC:heme:CcmE ternary complex (Richard-Fogal and Kranz, JMB 2010), and suggest
common mechanistic and structural aspects.
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CcmF forms a complex with holoCcmE
HoloCcmE must be released from CcmABCD to interact with CcmF
Heme binding by holoCcmE is essential for complex formation with CcmF
CcmF P-His1 and P-His2 are required for binding holoCcmE
CcmH controls formation of the CcmF—holoCcmE complex
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Introduction
C-type cytochromes are heme proteins involved in vital electron transfer reactions in the
cell. These cytochromes function outside of the cytoplasmic membrane in prokaryotes, in the
lumen of chloroplasts, and in the intermembrane space of mitochondria. Cytochromes c are
unique among heme proteins in that the heme is covalently attached to the protein (via thioether
linkages between the 2- and 4-vinyls of heme and two thiols of a conserved Cys-Xxx-Xxx-CysHis motif in the apoprotein). For covalent attachment to occur, both the apocytochrome thiols
and the iron of heme must be reduced 1; 2. In many bacteria, plant and protozoal mitochondria,
and archaea, holocytochrome c formation requires the cytochrome c maturation (ccm) pathway,
called system I (see Fig 1), which comprises eight dedicated membrane proteins (in E. coli,
CcmABCDEFGH) 3; 4; 5; 6; 7.
System I can be conceptually described as two steps (see Fig 1): (i) formation and release
of the heme chaperone protein, called holo (+ heme) CcmE, (from CcmABCD) and (ii) heme
transfer from holoCcmE to the apocytochrome (putatively, via CcmFH) to yield a
holocytochrome c. Formation of holoCcmE occurs in the CcmCDE complex 8; 9, where a unique
covalent attachment is formed between the β carbon of the heme 2-vinyl and a conserved
histidine residue (His130) in CcmE 10; 11; 12. Expression of CcmAB leads to formation of an
ABC transporter complex (CcmABCD) that uses ATP hydrolysis to release covalent holoCcmE
13; 14; 15

. Released, oxidized (Fe3+) holoCcmE is proposed to chaperone its heme to the site of

cytochrome c formation, CcmFH, but this has not been proven (see below) 9; 16; 17. CcmF, which
forms an integral membrane complex with CcmH, is believed to be the site of thioether
formation between the heme vinyls and the apocytochrome; thus, it has been termed the
“cytochrome c heme lyase”. The CcmFH integral membrane complex has been purified 9 or co88

immunoprecipitated 17; 18; 19. CcmF contains a separate and stable non-covalent heme b 9; 20,
which we have hypothesized plays a role in reducing the incoming heme from holoCcmE 4; 20.
Reduction of heme (to Fe2+) is a requirement for thioether formation 1; 2; 4, and would also favor
the release of heme from CcmE His130 4; 8; 20. CcmG 21; 22; 23 and CcmH 24; 25 are thioredox
proteins that maintain the apocytochrome thiols (in the Cys-Xxx-Xxx-Cys-His motif) in the
reduced state 26; 27; 28. In some species, such as Rhodobacter capsulatus, ccmH is split into two
open reading frames (called ccmH and ccmI). While there is significant evidence that the
apocytochrome interacts with the CcmFH cytochrome c heme lyase complex (via CcmH) 24; 26; 29;
30

, there has been no data demonstrating that holoCcmE interacts with CcmF (see Discussion for

details). Nonetheless, formation of a complex between holoCcmE and CcmF has been proposed
in nearly every review on cytochrome c biogenesis during the last decade (e.g., 3; 4; 5; 6; 7). Thus,
the proposal that holoCcmE trafficks heme directly to CcmF (see Fig 1) for holocytochrome c
formation remains unproven.
Here, we describe purification and characterization of an intermediate complex between
holoCcmE and CcmF, achieved by purifying CcmF from detergent-solubilized membranes
lacking CcmG and CcmH. We show that holoCcmE must be released from CcmCD in order to
interact with CcmF, and that holoCcmE forms a complex with CcmF at levels at least 20-fold
higher than apoCcmE. We demonstrate that two periplasmic histidines (His173 and His303,
here called P-His1 and P-His2, respectively) in separate periplasmic loops in CcmF are required
for interaction with holoCcmE, with evidence that these residues function as heme-binding
ligands. We propose that heme in holoCcmE is a critical component for interaction with CcmF
and we discuss how these results mirror formation of the CcmC:heme:CcmE ternary complex 8
(see Fig 1).
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Results
The holoCcmE-CcmF complex
Although all current in vivo models for the system I pathway presume a holoCcmE—
CcmF intermediate during holocytochrome c biosynthesis, we have been unable to co-purify
holoCcmE at detectable levels in our preparations of CcmFH 9. Our purifications of CcmF (and
CcmFH complex) are typically from DDM-solubilized membranes that contain all Ccm proteins
(CcmABCDEFGH). The inability to identify a complex between holoCcmE and CcmF could be
due to a transient, short-lived interaction or current models for system I may be incorrect. In an
attempt to detect an interaction between holoCcmE and CcmF, we expressed CcmF along with
the minimal set of CCM components required for formation and release of holoCcmE from the
CcmABCD complex (i.e., CcmABCDEF, or pGEX ∆CcmGH; Fig 2 A-D). Note that the
proteins CcmG and CcmH are absent in these cells. Full-length hexahistidine-tagged CcmF (54kDa) was TALON-purified as a single polypeptide to greater than 90% purity (Fig 2A, lane 8)
that reacted with CcmF antisera (Fig 2B, lane 8). Heme staining revealed that, in addition to the
CcmF b-type heme (which dissociates from the protein and migrates as free heme during
denaturing SDS-PAGE) preparations of CcmF from membranes lacking CcmG and CcmH
contained 20-kDa holoCcmE (Fig 2C, lane 8). Immunodetection with CcmE antisera confirmed
that the 20-kDa covalent heme species was holoCcmE (Fig 2D, lane 8).
UV-Vis absorption spectra of the oxidized (as purified) CcmF-holoCcmE preparation
showed a Soret maximum at 412 nm and broad α and β absorptions between 500 and 600 nm
(Fig 2E). Chemical reduction with sodium dithionite yielded a Soret maximum at 426 nm and
sharp α and β absorptions at 559 and 530, respectively. These spectral features, in addition to the
556 nm absorption in the reduced pyridine hemochrome (Fig 2E, inset) are characteristic of non90

covalent, b-type hemes 32, and are indistinguishable from those of the CcmF b-heme 9; 20.
Because the holoCcmE polypeptide is not readily detectable by Coomassie staining (Fig 2A, lane
8), it is likely that holoCcmE is less than stoichiometric with CcmF in the CcmF-holoCcmE
complex. This result, together with only slight differences in the electronic absorptions of
holoCcmE and CcmF, make it difficult to discern the spectral contributions of the heme from
holoCcmE. We next wanted to analyze the role of other Ccm proteins as well as specific
residues in CcmF in formation of the holoCcmE-CcmF complex.
HoloCcmE co-purifies with CcmF in the absence of CcmG and CcmH
As mentioned above, purifications of CcmF from membranes containing all Ccm proteins
(CcmABCDEFGH) typically do not yield detectable holoCcmE. Therefore, we directly
compared levels of holoCcmE that co-purified with CcmF in the presence of all Ccm proteins
(expressed from pSysI) to those that co-purified with CcmF in the absence of CcmG and CcmH
(expressed from pSysI ∆GH). As controls, we included in this analysis constructs lacking ccmF
(pSysI ∆FGH, or pGEX ccmABCDE) and ccmE (pSysI ∆EGH, pGEX ccmABCDF:His6). With
the exception of ∆FGH, CcmF was purified as a single full-length polypeptide (54-kDa; Fig 3A,
lanes 2-4) that reacted with CcmF antisera (Fig 3B, lanes 2-4). Immunoblotting with CcmH
antisera showed that co-purified 34-kDa CcmH was present only in CcmF purifications from the
pSysI background, as expected (Fig 3C, lane 4). Heme staining and anti-CcmE immunoblotting
of TALON-purified fractions revealed that, in the absence of CcmG and CcmH, CcmF copurified with approximately 10-fold more holoCcmE than when CcmG and CcmH were present
(Fig 3D and E, compare lanes 3 and 4; quantified in Fig 3H). In the absence of CcmF (pSysI
∆FGH), no holoCcmE was detected by heme stain or anti-CcmE immunoblot (Fig 3D and E,
lane 1), showing that there was no detectable retention of holoCcmE on the TALON resin.
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Similarly, in the absence of CcmE (pSysI ∆EGH), no 20-kDa covalent heme species or reactivity
with CcmE antisera were observed (Fig 3D and E, lane 2). Analysis of DDM-solubilized
membrane fractions by heme staining and immunoblotting with CcmE antisera showed that all
membranes (with the exception of those from pSysI ∆EGH) contained holoCcmE at levels at
least as high as that of pSysI ∆GH (Fig 3F and G; quantified in Fig 3I). Therefore, the 10-fold
higher levels of holoCcmE that co-purified with CcmF from pSysI ∆GH are not due to increased
expression of holoCcmE from this construct. We conclude that CcmH prevents (controls)
trapping of the holoCcmE/CcmF complex (see Discussion).
HoloCcmE must be released from CcmCD to interact with CcmF
The first step in heme translocation in the system I (CCM) pathway involves formation of
covalent (holo) CcmE, which occurs via complex formation with CcmC and CcmD 8; 9; 35.
Subsequently, CcmA and CcmB form an ABC transporter “release complex” with CcmC and
CcmD, which uses ATP hydrolysis to release holoCcmE for heme trafficking to (putatively)
CcmFH 13; 14; 15. In the absence of CcmAB, holoCcmE becomes “trapped” with CcmCD in a
very stable intermediate complex 8, and holocytochrome c formation is blocked at this step. We
examined whether interaction between CcmF and holoCcmE is dependent on release of
holoCcmE from CcmABCD. We engineered an in-frame deletion of ccmAB in pSysI ∆GH to
yield pSysI ∆GH delAB (pGEX ccmCDEF:His6), with a GST translational fusion to CcmC
rather than CcmA.
CcmF was expressed from pSysI ∆GH delAB and purified as a single full-length
polypeptide (54-kDa; Fig 4A, lane 3) that reacted with CcmF antisera (Fig 4B, lane 3). Heme
staining and anti-CcmE immunoblotting revealed that the absence of CcmAB resulted in at least
a 10-fold decrease in the amount of holoCcmE that co-purified with CcmF (Fig 4C and D,
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compare lanes 2 and 3; quantified in Fig 4G). Analysis of DDM-solubilized membrane fractions
by heme staining and immunoblotting with CcmE antisera showed that membranes from pSysI
∆GH delAB contained holoCcmE at levels at least as high as that of pSysI ∆GH (Fig 4E and F;
quantified in Fig 4H). To confirm that release of holoCcmE from CcmCD was blocked by
deletion of ccmAB, we purified GST:CcmC from the flow-through fraction of the TALON
column (Fig 4 I-L). Purified full-length GST:CcmC (48-kDa) and free GST each reacted with
GST antisera (Fig 4K, lane 1). Heme staining (Fig 4J, lane 6) and immunodetection with CcmE
antisera (Fig 4L, lane 1) revealed that purified GST:CcmC contained high levels of trapped
(unreleased) holoCcmE. Thus, in the absence of CcmAB, holoCcmE is trapped on CcmC, which
effectively abolishes formation of the CcmF-holoCcmE complex. Only released holoCcmE
interacts with CcmF, as previous models have hypothesized. This strongly suggests that the
interaction we detect between holoCcmE and CcmF is a true intermediate during
holocytochrome c formation.
ApoCcmE does not interact with CcmF
CcmE binds heme through a unique covalent bond between conserved His130 and the 2vinyl of the heme 10; 11; 12. Previous work has shown that mutation of His130 to alanine abolishes
covalent bond formation between heme and CcmE 36, although CcmE(His130Ala) still forms a
complex with CcmCD and is likely released upon ATP hydrolysis by CcmAB 8. Since released
CcmE(His130Ala) is completely apo- (lacking heme), holocytochrome c formation is blocked at
this step (i.e., the covalent bond to heme in holoCcmE is necessary for CcmE to chaperone heme
to, putatively, CcmFH). To test whether apo-CcmE could interact with CcmF, we engineered the
His130Ala substitution in ccmE in pSysI ∆GH to yield pSysI ∆GH mutE (pGEX
ccmABCDE(His130Ala)F:His6). CcmF was expressed from pSysI ∆GH mutE and purified as a
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single full-length polypeptide (54-kDa; Fig 5A, lane 3) that reacted with CcmF antisera (Fig 5B,
lane 3). As expected, heme staining showed no evidence of holoCcmE in purified CcmF
fractions (Fig 5C, lane 3; quantified in Fig 5G), since mutation of His130 results in only the apoform of CcmE (Fig 5E, lane 3; quantified in Fig 5H). Immunoblotting with CcmE antisera
revealed approximately a 20-fold decrease in the amount of apoCcmE that co-purified with
CcmF (Fig 5D, compare lanes 2 and 3; quantified in Fig 5G), even though DDM-solubilized
membranes from pSysI ∆GH mutE contained apoCcmE at levels at least as high as those of
pSysI ∆GH (Fig 5F, compare lanes 2 and 3; quantified in Fig 5H). Thus, apoCcmE is not
capable of interaction with CcmF, which suggests that holoCcmE—CcmF complex formation is
heme-dependent (see Discussion).
CcmF P-His1 and P-His2 exhibit heme ligand activity
CcmF contains four conserved His residues (see Fig 6): His261 in TMD5 and His491 in
TMD12 (here called TM-His1 and TM-His2, respectively); and His173 and His303 in
periplasmic loops flanking the conserved WWD domain (here called P-His1 and P-His2,
respectively). Alanine substitutions at any of the His residues in CcmF abolishes
holocytochrome c formation 9; 17; 20. TM-His1 and TM-His2 are ligands to the b-heme in CcmF:
mutation of either of these transmembrane His residues results in a loss of nearly all b-heme in
the purified protein 9; 20. However, the roles of P-His1 and P-His2 are unknown. Based on their
position flanking the WWD domain (which, in CcmC, has been shown to be the site of
interaction with the holoCcmE heme 8), we hypothesize that P-His1 and P-His2 in CcmF may be
ligands to the incoming heme from holoCcmE (see Fig 6 and Discussion).
Previously, we showed that the cytochrome c assembly defects of glycine substitutions at
TM-His1 and TM-His2 could be corrected in vivo by addition of 10 mM imidazole directly to
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culture 20. Conceptually, this is similar to the correction of heme binding in the myoglobin
His93Gly “cavity” mutant by imidazole 37. Thus, functional correction of a histidine mutant by
imidazole can be suggestive of a heme ligand function. To test whether P-His1 or P-His2 might
exhibit a ligand function, we engineered alanine, glycine, cysteine, tyrosine, or methionine
substitutions at each His residue and assayed for holocytochrome c4 formation in the absence
and presence of imidazole. Heme staining of BPER fractions revealed that in the absence of
imidazole, none of the engineered substitutions at P-His1 or P-His2 supported holocytochrome c
formation (Fig 7A and B, lanes 1-7; quantified in Fig 7C and D). However, 10 mM imidazole
corrected the holocytochrome c assembly defects of glycine substitutions at P-His1 and P-His2
to approximately 50% levels of WT (Fig 7A and B, lane 10; quantified in Fig 7C and D).
Substitution of P-His1 with bulkier amino acids did not result in detectable holocytochrome c4
formation in the presence of imidazole (Fig 7A, lanes 9-15; quantified in Fig 7C). The tyrosine
and methionine substitutions at P-His2 were corrected to approximately 10% and 5% levels of
WT, respectively, suggesting that the P-His2 position may be more flexible than the P-His1 (i.e.,
for imidazole). We conclude that the glycine substitutions at P-His1 and P-His2 result in the
formation of a cavity in which imidazole can bind and serve as a ligand to support
holocytochrome c formation. However, bulkier amino acids (including perhaps the methyl side
group of alanine) may present a steric hindrance to imidazole correction. Since we have
previously shown that neither P-His1 nor P-His2 were ligands to the CcmF b-heme, we theorize
that the apparent ligand function of these residues is related to the incoming heme from
holoCcmE.
CcmF P-His1 and P-His2 are required for interaction with holoCcmE
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To directly test if P-His1 and P-His2 are required for interaction with holoCcmE, we
engineered alanine substitutions at each residue, as well as a double alanine substitution, in the
pSysI ∆GH background and assayed for holoCcmE in preparations of CcmF. CcmF was
expressed from pSysI ∆GH(P-His1Ala), pSysI ∆GH(P-His2Ala), or pSysI ∆GH(P-His1Ala/PHis2Ala) and purified as a single full-length polypeptide (54-kDa; Fig 8A, lanes 3-5) that reacted
with CcmF antisera (Fig 8B, lanes 3-5). Heme staining and immunoblotting with CcmE antisera
showed approximately a 5-fold decrease in the amount of holoCcmE that co-purified with CcmF
for each of the single substitutions (Fig 8C and D, compare lane 2 to 3 and 4; quantified in Fig
8G), and approximately a 10-fold decrease for the double mutant (Fig 8C and D, compare lanes 2
and 5; quantified in Fig 8G). DDM-solubilized membranes from all backgrounds contained
similar levels of holoCcmE (Fig 8E and F; quantified in Fig 8H). Thus, P-His1 and P-His2 in
CcmF are essential for interaction with holoCcmE, and are likely the ligands to the heme from
holoCcmE.
The CcmF b-heme is required for interaction with holoCcmE
CcmF contains two conserved histidines in transmembrane domains (TM-His1 and TMHis2) that are ligands to the CcmF b-heme. Substitution of either histidine residue with alanine
abolishes b-heme binding in CcmF to undetectable levels 20. To test if the CcmF b-heme is
required for interaction with holoCcmE, we engineered alanine substitutions at TM-His1 and
TM-His2 in the pSysI ∆GH background and assayed for holoCcmE in preparations of CcmF.
CcmF was expressed from pSysI ∆GH(TM-His1Ala) or pSysI ∆GH(TM-His2Ala) and purified
as a full-length polypeptide (54-kDa; Fig 9A, lanes 3-4) that reacted with CcmF antisera (Fig 9B,
lanes 3-4). Heme staining and immunoblotting with CcmE antisera showed approximately an 8fold decrease in the amount of holoCcmE that co-purified with CcmF for each substitution (Fig
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9C and D, compare lane 2 to 3 and 4; quantified in Fig 9G). DDM-solubilized membranes from
all backgrounds contained similar levels of holoCcmE (Fig 9E and F; quantified in Fig 9H).
Note that purified CcmF (TM-His1Ala) and CcmF (TM-His2Ala) do not contain the b-heme (see
“free heme” in Fig 9C, compare lane 2 to 3 and 4). This is in stark contrast to the P-His1 and PHis2 substitutions, which showed b-heme levels identical to WT CcmF (see “free heme” in Fig
8C). Thus, the b-heme in CcmF (with ligands from TM-His1 and TM-His2) is essential for
interaction with holoCcmE.
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Discussion
Requirements for formation of the holoCcmE—CcmF complex
Here, we report isolation of an integral membrane protein complex between the system I
heme chaperone, holoCcmE, and the putative cytochrome c synthetase, CcmF. Interaction
between these two essential CCM proteins has long been suspected, but never shown directly.
Ren and colleagues (2002) previously reported that CcmE could be immunoprecipitated from
cell extracts using CcmF antisera (see Fig 4 of 17). However, since only the apo-form of CcmE
was analyzed in that study (the strain utilized lacked the genes for ccmABCD altogether), the
relevance of that finding to holocytochrome c formation is unclear. Despite the fact that only
apoCcmE was analyzed, many CCM models have cited the findings of Ren and colleagues as
evidence of interaction between holoCcmE and CcmF. In our study, using a strain expressing
CcmABCDE and CcmF, we showed that covalent, released holoCcmE interacts with CcmF at
levels at least 20-fold higher than the apo-form of CcmE (see Fig 5). Given that the predicted
function of CcmF is to facilitate heme transfer from holoCcmE to the apocytochrome, it is not
surprising that the holo-form of CcmE preferentially binds. Ren and colleagues also reported
that point mutants in CcmF (including alanine substitutions at P-His1 and P-His2) showed
unaltered interactions with (apo) CcmE, relative to WT CcmF. In contrast, we found that
substitution of either P-His1 or P-His2 caused a 5-fold decrease in the levels of holoCcmE that
co-purified with CcmF (relative to WT CcmF), and that the double mutant showed a 10-fold
decrease (see Fig 8). The critical roles of P-His1 and P-His2 (which are in periplasmic loops
adjacent to the CcmF WWD domain; see Fig 6) in binding holoCcmE had been proposed
previously, and is further elaborated upon below. We suggest that the apoCcmE detected in
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preparations of CcmF represents a low background level (likely non-physiological), and that the
holoCcmE “trapped” in complex with CcmF is the true physiological intermediate in system I.
Implications of P-His1 and P-His2 binding heme from holoCcmE
CcmF is a member of the heme-handling superfamily of proteins 38, which also includes
CcmC and the system II cytochrome c synthetase, CcsBA. The hallmark of the heme-handling
proteins is the “WWD domain” 39; 40; 41; 42, a conserved tryptophan-rich periplasmic loop that is
flanked by two conserved histidine residues in adjacent periplasmic loops. CcmC, which is
sometimes referred to as the holoCcmE synthase (due to its well-described role in formation of
holoCcmE) 14; 35 forms a stable intermediate complex with holoCcmE (in the absence of
CcmAB) 8. In the “trapped” holoCcmCDE complex, heme from holoCcmE is bound in the
WWD domain of CcmC, and the two flanking histidines (CcmC His60 and His184) supply the
5th and 6th axial ligands to heme. Richard-Fogal and Kranz (2010) showed that substitution of
either histidine, as well as certain tryptophans in the WWD domain of CcmC, caused
perturbations in the absorption spectrum of the CcmCDE complex 8. In the absence of heme,
there was no detectable interaction between (apo) CcmE and CcmC, indicating that the WWD
domain of CcmC is a platform for interaction with heme rather than for the CcmE polypeptide.
Thus, we proposed that heme, CcmC, and CcmE are each essential to form the stable “ternary”
complex 8.
By analogy to the CcmCDE complex, we have hypothesized that the WWD domain of
CcmF is the site of interaction for heme from holoCcmE, after it is released from CcmCD.
Several of our findings here are in agreement with this hypothesis: i) CcmF P-His1 and P-His2
(which flank the WWD domain) exhibited ligand-type activity (Gly substitutions at these
residues were functionally restored by adding exogeneous imidazole), ii) P-His1 and P-His2
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were required for interaction with holoCcmE, iii) only the holo-form of CcmE (i.e., with heme),
and not apoCcmE, interacted with CcmF, and iv) only holoCcmE released from CcmCD
interacted with CcmF. The requirement for both heme (i.e., “holo” CcmE) and the WWD
domain-flanking histidines for formation of the holoCcmE—CcmF complex is remarkably
similar to formation of the holoCcmCDE complex.
Identifying the CcmF WWD domain as the binding site for holoCcmE also has
implications for understanding the cytochrome c heme lyase function of CcmF. Experimentally
established models for the membrane topology of CcmF 9 suggest that the b-heme (with ligands
from TM-His1 and TM-His2) is positioned spatially below the WWD domain (see Fig 6). Given
this transmembrane “architecture,” a mechanism for reduction of the incoming heme from
holoCcmE (in the WWD domain) by electron transfer directly from the b-heme can be readily
envisioned. Further studies will be needed to test this. In particular, since the holoCcmE that copurifies with CcmF is sub-stoichiometric, it will be necessary to further enrich for holoCcmE in
the complex to begin these and other spectroscopic studies.
Absence of CcmGH is critical to formation of the holoCcmE—CcmF complex
Surprisingly, we found that levels of the “trapped” holoCcmE—CcmF complex increased
10-fold when CcmGH were absent (see Fig 3). In fact, purification of CcmF from this particular
background (pSysI ∆GH) initially enabled us to detect the holoCcmE—CcmF complex. CcmG is
a periplasmic thioredoxin that has been shown to reduce the cysteines of CcmH (in vitro) (e.g.,
28

), but it does not co-purify with the CcmFH complex 9; 19. By contrast, interaction between

CcmF and CcmH is well established 9; 17; 18; 19. CcmH is a polytopic membrane protein with two
transmembrane α helices and a large C-terminal periplasmic domain (see Fig 6). Apart from the
two conserved cysteine residues in the N-terminal periplasmic domain, which have been shown
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to reduce the apocytochrome thiols (in the Cys-Xxx-Xxx-Cys-His motif) 24; 28; 43, discrete
functional domains within CcmH have not been well defined. Recently, Verissimo and
colleagues (2011) and Di Silvio and colleagues (2013) have shown that CcmI, which is
analogous to the C-terminus of E. coli CcmH, interacts with the C-terminus of apocytochrome c
(not at Cys-Xxx-Xxx-Cys-His), but not holocytochrome c 29; 30. Given our results here, it is
likely that CcmH may also modulate the interaction between CcmF and holoCcmE. For
example, in the absence of apocytochrome, CcmH may occlude the CcmF WWD domain from
interaction with holoCcmE, thus only “permitting” holoCcmE reduction (to Fe2+) when the
apocytochrome c “acceptor” is present. Alternatively, but not mutually exclusively, CcmH may
facilitate the rapid release of CcmE from the CcmF WWD domain. We have proposed that
reduction of heme in holoCcmE accomplishes two reactions (see Fig 10). First, reduction of
heme (to Fe2+) would favor the ejection of His130 imidazole from the β carbon of the heme 2vinyl (see Fig 10A, reverse blue arrow). Second, reduced heme is required for the 2- and 4vinyls of heme to form thioether linkages with the apocytochrome c thiols (at Cys-Xxx-XxxCys-His; see Fig 10B). It makes ‘sense’ to only allow the first reaction to occur (ejection of
CcmE His130) when the acceptor is properly positioned (by CcmH) for the second reaction.
Thus, the synthetase reactions are elegantly orchestrated by the holoCcmE:CcmF:CcmH
complex.
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Materials and Methods
Bacterial Growth Conditions. Escherichia coli strains (Supplemental Table 1) were grown at
37oC by shaking at 230 rpm in Luria-Bertani broth (LB; Difco) supplemented with the
appropriate antibiotics (Sigma-Aldrich) and other media additives at the following
concentrations, unless otherwise noted: carbenicillin, 50 ug ml-1; chloramphenicol, 20 ug ml-1;
gentamicin, 10 ug ml-1; IPTG (Gold Biotechnology), 1 mM; arabinose (Gold Biotechnology), 0.2
% (wt/vol).
Protein Expression and Purification. E. coli ∆ccm strain RK103 (Table S1) 16 was used for
expression. Starter cultures were initiated from a single colony and grown overnight in 10 mL of
LB with the appropriate antibiotics. 1 L of LB and was inoculated with the 10 mL starter culture
and grown to an OD600 of 1.8, then induced with 1 mM IPTG for 14-16 hr. Cells were harvested
at 5,000 x g and frozen at -80oC. Cell pellets were thawed and resuspended in PBS (100 mM
NaCl, 7.5 mM Na2HPO4, 2 mM NaH2PO4) and treated with 1 mM PMSF (Sigma-Aldrich) and
100 µg ml-1 egg white lysozyme (Sigma-Aldrich) for 30 min while shaking on ice. Cells were
disrupted by repeated sonication for 30 sec bursts on a Branson 250 sonicator (50% duty, 8
output) until clearing of the suspension was observed. Crude sonicate was centrifuged at 24,000
x g for 20 min to clear cell debris, and membranes were isolated by centrifugation at 100,000 x g
for 45 min. Membrane pellets were solubilized in a modified 1x TALON (Clontech) buffer (50
mM Tris-HCL, pH 7; 300 mM NaCl) with 1 % (wt/vol) dodecyl maltoside (DDM, Anatrace) on
ice for 1 hr. DDM-solubilized membranes were centrifuged at 24,000 x g for 20 min to remove
unsolubilized material. Solubilized membranes (L; load) were passed over TALON resin per the
manufacturer’s recommendations and washed in 1 x modified TALON buffer with 0.02 % DDM
with increasing concentrations of imidazole (wash 1 (W1), 0 mM imidazole; wash 2 (W2), 2 mM
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imidazole; wash 3 (W3), 5 mM imidazole). Bound hexahistidine-tagged protein was eluted in 1
x modified TALON buffer containing 0.02 % dodecyl maltoside and 150 mM imidazole (E;
elution). Total protein concentration was determined using the Nanodrop 1000
spectrophotometer (Thermo Scientific).
Cytochrome Reporter and Imidazole Complementation Assays. Cytochrome c4:His6 production
was assayed in RK111 (∆ccm carrying the arabinose-inducible chromosomal integrate of the cyt
c4:His6 gene 20) harboring pRGK402 (pGEX ABCDE 20) and one of the following pBAD
ccmF:His6GH plasmids (pRGK434, 435, 436, 437, 438, 439, 440, 441, 442, or 443; see
Supplemental Table 1). Starter cultures were initiated from a single colony and grown overnight
in LB with the appropriate antibiotics. 5 mL of LB was inoculated using 800 mL of starter
culture and grown for 3 hr, then induced for 3 hr with 0.8 % (wt/vol) arabinose. Cells were
harvested by centrifugation at 10,000 x g and the cell pellet was resuspended in 200 µL of BPER
(Thermo Scientific) to lyse cells and extract protein. Total protein concentration was determined
using the Nanodrop 1000 spectrophotometer (Thermo Scientific) and 100 µg was analyzed by
SDS-PAGE followed by heme stain. Imidazole complementation assays were performed in the
same way, with 10 mM imidazole (pH 7) added to the media prior to inoculation.
Production of antibodies to CcmF. E. coli CcmF was engineered with a hexahistidine tag as
described in 9, and was expressed from pRGK386 in E. coli strain RK103 16. Cell growth,
protein expression, and purification were carried out as described above. Eluted hexahistidinetagged CcmF was analyzed by 12.5 % SDS-PAGE and electroeluted from gel fragments over 4-5
hr at 25 mV into 1x SDS-PAGE buffer (3.5 mM SDS, 50 mM Tris, 384 mM glycine). Purity of
the preparations (assessed by Coomassie Blue staining) was greater than 95 %. Antiserum was
generated in rabbits at a commercial facility (Cocalico Biologicals). Antibodies were purified
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from serum by ammonium sulfate precipitation and adsorbed against crude E. coli extract
containing all other Ccm proteins.
Heme stains and other methods. Heme stains and immunoblots were performed as described
previously 16; 31. Proteins were separated by 12.5 % SDS-PAGE and transferred to Hybond C
nitrocellulose membranes (GE Healthcare). Anti-CcmF antibodies were used at a dilution of
1:10000, anti-CcmE antibodies at 1:10000, anti-GST antibodies at 1:10000, and anti-CcmH
antibodies at 1:5000. Protein A peroxidase (Sigma-Aldrich) was used as the secondary label.
The chemiluminescent signal for heme stains was developed using the SuperSignal Femto kit
(Thermo Scientific) or, for immunoblots, the Immobilon Western kit (Millipore), and detected
with an LAS-1000 Plus detection system (Fujifilm-GE Healthcare). The abundance of
holoCcmE was determined by densitometry analysis of the chemiluminescent signal from heme
stains and anti-CcmE immunoblots using the Science Lab 99-Image Gauge version 3.4 software
(Fujifilm-GE Healthcare). Heme concentration in protein preparations was determined by
pyridine extraction as described in 32 or heme staining as described in 33. Protein purity was
assessed by Coomassie Blue staining of SDS-PAGE.
UV/Vis absorption spectroscopy. UV-visible absorption spectra were recorded with a Shimadzu
UV-2101 PC UV-Vis scanning spectrophotometer at room temperature as described previously
34

. All spectra were recorded in the same buffer (modified 1x TALON buffer) in which the

proteins were purified. Chemically reduced spectra were generated by addition of sodium
dithionite (sodium hydrosulfite).
Construction of plasmids. All oligonucleotide primer sequences, plasmids, and strains are given
in Table S1. All oligonucleotides were synthesized by Sigma-Aldrich. To delete ccmAB from
pRGK385 (pGEX ∆GH), primers “delABloop_BglII_Fwd” and “delABloop_BglII_Rev” were
104

used to PCR amplify around pRGK385, excluding ccmAB. The resulting PCR product was gel
purified, digested and re-circularized by ligation at the resulting BglII sites to yield pRGK427
(pGEX ∆GH delAB). All nucleotide substitutions were generated using the QuikChange I SiteDirected Mutagenesis Kit (Agilent Technologies) per the manufacturer’s recommendations.
Substitutions were engineered into pBAD-based pRGK388 for cytochrome reporter assays, or
into pGEX-based pRGK385 (pGEX ∆GH) for protein expression and purification. To engineer
the double P-His1Ala/P-His2Ala mutation, primers “ccmF_H303A_Fwd” and
“ccmF_H303A_Rev” were used to introduce the P-His2Ala substitution into pRGK429 (pGEX
∆GH P-His1Ala). Each of the final constructs was sequenced to verify the mutation(s).
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Figures
Fig 1. Current working model of the system I cytochrome c biogenesis pathway.
Model includes trafficking and oxidation states of heme as well as apocytochrome translocation
and reduction. Adapted from (Kranz, Richard-Fogal et al. 2009).
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Fig 2. The CcmF-holoCcmE complex.
(A) Coomassie blue staining of purified CcmF:His6 showing 54-kDa CcmF. (B) Anti-CcmF
immunoblot of purified CcmF:His6 showing 54-kDa CcmF. (C) Heme staining of purified
CcmF showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE. (D) Anti-CcmE
immunoblot showing co-purified 20-kDa CcmE. For (A)-(D), abbreviations are CS, crude
sonicate; S, soluble fraction; L, load (DDM-solubilized membranes); W1, wash 1; W2, wash 2;
W3, wash 3; E1, elution 1; E2, elution 2; E3, elution 3; E4, elution 4; M, molecular weight
standards. (E) UV-Vis absorption spectra of CcmF-holoCcmE complex as purified (dotted line)
or reduced with sodium dithionite (solid line). The region from 500-700 nm has been multiplied
by a factor of 3. (Inset) Sodium dithionite-reduced pyridine hemochrome spectrum of purified
CcmF-holoCcmE complex from 500-600 nm. Absorption maxima are indicated.
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Fig 3. HoloCcmE co-purifies with CcmF in the absence of CcmGH.
(A) Coomassie blue staining of TALON-purified proteins from ∆FGH, ∆EGH, ∆GH, and pSysI
backgrounds showing purified 54-kDa CcmF. (B) Anti-CcmF immunoblot of TALON-purified
proteins showing 54-kDa CcmF. (C) Anti-CcmH immunoblot of TALON-purified proteins
showing 34 kDa CcmH. (D) Heme staining of TALON-purified proteins showing free heme
(CcmF b-heme) and co-purified 20-kDa holoCcmE. (E) Anti-CcmE immunoblot of TALONpurified proteins showing co-purified 20-kDa CcmE. For (A)-(E), 6 ug purified protein was
analyzed. (F) Heme staining of DDM-solubilized membrane fractions from ∆FGH, ∆EGH,
∆GH, and pSysI backgrounds showing 20 kDa holoCcmE. (G) Anti-CcmE immunoblot of
DDM-solubilized membrane fractions showing 20 kDa CcmE. For (F) and (G), 70 ug total
protein was analyzed. (H) Quantification of the results of heme staining (holoCcmE) and antiCcmE immunoreactivity (total CcmE) from TALON-purified fractions from three independent
experiments. (I) Quantification of the results of heme staining and anti-CcmE immunoreactivity
from DDM-solubilized membrane fractions from three independent experiments. For (H) and
(I), percent holoCcmE and total CcmE is relative to ∆GH, which has been set at 100%. Error
bars denote SD.
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Fig 4. HoloCcmE must be released from CcmABCD to interact with CcmF.
(A) Coomassie blue staining of TALON-purified proteins from ∆GH and ∆GH delAB
backgrounds showing purified 54-kDa full-length CcmF. (B) Anti-CcmF immunoblot of
purified CcmF proteins showing 54-kDa full-length CcmF. (C) Heme staining of purified CcmF
proteins showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE. (D) Anti-CcmE
immunoblot of purified CcmF proteins showing co-purified 20-kDa CcmE. For (A)-(D), 5 ug
purified protein was analyzed. (E) Heme staining of DDM-solubilized membrane fractions from
∆GH and ∆GH delAB backgrounds showing 20 kDa holoCcmE. (F) Anti-CcmE immunoblot of
DDM-solubilized membrane fractions showing 20 kDa CcmE. For (E) and (F), 70 ug total
protein was analyzed. (G) Quantification of the results of heme staining (holoCcmE) and antiCcmE immunoreactivity (total CcmE) from purified fractions from three independent
experiments. (H) Quantification of the results of heme staining and anti-CcmE immunoreactivity
from DDM-solubilized membrane fractions from three independent experiments. For (G) and
(H), percent holoCcmE and total CcmE is relative to ∆GH, which has been set at 100%. Error
bars denote SD. (I) Coomassie blue staining of purified GST-tagged CcmC from ∆GH delAB
showing 48-kDa full-length GST-CcmC, 26-kDa GST, and 20 kDa CcmE. (J) Heme staining of
purified GST-tagged CcmC showing co-purified 20-kDa holoCcmE. (K) Anti-GST immunoblot
of purified GST-tagged CcmC showing 48-kDa full-length GST-CcmC and 26-kDa GST. (L)
Anti-CcmE immunoblot of purified GST-tagged CcmC showing co-purified 20-kDa CcmE.
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Fig 5. ApoCcmE does not co-purify with CcmF.
(A) Coomassie blue staining of TALON-purified proteins from ∆GH and ∆GH mutE (CcmE
His130Ala) backgrounds showing purified 54-kDa CcmF. (B) Anti-CcmF immunoblot of
purified CcmF proteins showing 54-kDa CcmF. (C) Heme staining of purified CcmF proteins
showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE. (D) Anti-CcmE
immunoblot of purified CcmF proteins showing co-purified 20-kDa CcmE. For (A)-(D), 5 ug
purified protein was analyzed. (E) Heme staining of DDM-solubilized membrane fractions from
∆GH and ∆GH mutE backgrounds showing 20 kDa holoCcmE. (F) Anti-CcmE immunoblot of
DDM-solubilized membrane fractions showing 20 kDa CcmE. For (E) and (F), 70 ug total
protein was analyzed. (G) Quantification of the results of heme staining (holoCcmE) and antiCcmE immunoreactivity (total CcmE) from purified fractions from three independent
experiments. (H) Quantification of the results of heme staining and anti-CcmE
immunoreactivity from DDM-solubilized membrane fractions from three independent
experiments. For (G) and (H), percent holoCcmE and total CcmE is relative to ∆GH, which has
been set at 100%. Error bars denote SD.

118

119

Fig 6. Topology of the CcmF and CcmH integral membrane proteins from E. coli.
Possible histidine axial ligands to heme are starred (His173=P-His1; His303=P-His2;
His261=TM-His1; His491=TM-His2). The highly conserved WWD domain is shaded as are the
hydrophobic patches. Completely conserved amino acids (red) were identified by individual
protein alignments using CcmF ORFs from selected organisms, as described in (Kranz, RichardFogal et al. 2009). Diagram is from (Kranz, Richard-Fogal et al. 2009).
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Fig 7. Maturation of cytochrome c4 in the presence or absence of imidazole.
Heme staining of B-PER cell extracts showing 24-kDa holocytochrome c4 matured by full
system I with the indicated substitutions at CcmF P-His1 (A) or P-His2 (B) in the presence or
absence of 10 mM imidazole added to culture. P-His1 and P-His2 were each changed to the
indicated residues. M, molecular weight standards; C, vector control. 100 ug total protein was
analyzed. Quantification of chemiluminescent signal from heme staining of B-PER isolated
proteins from three independent experiments for P-His1 substitutions (C) or P-His2 substitutions
(D). Holocytochrome c4 signal is relative to WT, which has been set at 100%. Error bars denote
SD. ND, no signal detected.
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Fig 8. CcmF P-His1 and P-His2 are required for co-purification of holoCcmE.
(A) Coomassie blue staining of TALON-purified proteins from ∆GH, ∆GH (P-His1Ala), ∆GH
(P-His2Ala), and ∆GH (P-His1Ala/P-His2Ala) backgrounds showing 54-kDa CcmF. (B) AntiCcmF immunoblot of purified CcmF proteins showing 54-kDa CcmF. (C) Heme staining of
purified CcmF proteins showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE.
(D) Anti-CcmE immunoblot of purified CcmF proteins showing co-purified 20-kDa CcmE. For
(A)-(D), 6 ug purified protein was analyzed. (E) Heme staining of DDM-solubilized membrane
fractions from ∆GH and each ∆GH mutant background showing 20 kDa holoCcmE. (F) AntiCcmE immunoblot of DDM-solubilized membrane fractions showing 20 kDa CcmE. For (E)
and (F), 70 ug total protein was analyzed. (G) Quantification of the results of heme staining
(holoCcmE) and anti-CcmE immunoreactivity (total CcmE) from purified fractions from three
independent experiments. (H) Quantification of the results of heme staining and anti-CcmE
immunoreactivity from DDM-solubilized membrane fractions from three independent
experiments. For (G) and (H), percent holoCcmE and total CcmE is relative to ∆GH, which has
been set at 100%. Error bars denote SD.
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Fig 9. CcmF b-heme is required for co-purification of holoCcmE.
(A) Coomassie blue staining of TALON-purified proteins from ∆GH, ∆GH (TM-His1Ala), and
∆GH (TM-His2Ala) backgrounds showing 54-kDa CcmF. (B) Anti-CcmF immunoblot of
purified CcmF proteins showing 54-kDa CcmF. (C) Heme staining of purified CcmF proteins
showing free heme (CcmF b-heme) and co-purified 20-kDa holoCcmE. (D) Anti-CcmE
immunoblot of purified CcmF proteins showing co-purified 20-kDa CcmE. For (A)-(D), 5 ug
purified protein was analyzed. (E) Heme staining of DDM-solubilized membrane fractions from
∆GH and each ∆GH mutant background showing 20 kDa holoCcmE. (F) Anti-CcmE
immunoblot of DDM-solubilized membrane fractions showing 20 kDa CcmE. For (E) and (F),
70 ug total protein was analyzed. (G) Quantification of the results of heme staining (holoCcmE)
and anti-CcmE immunoreactivity (total CcmE) from purified fractions from three independent
experiments. (H) Quantification of the results of heme staining and anti-CcmE
immunoreactivity from DDM-solubilized membrane fractions from three independent
experiments. For (G) and (H), percent holoCcmE and total CcmE is relative to ∆GH, which has
been set at 100%. Error bars denote SD.
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Fig 10. Mechanisms for formation of holoCcmE and cytochrome c.
Proposed reaction mechanisms for formation of holoCcmE (His130) (A) and holocytochrome c
(B). Noted are the oxidation states of iron (Fe3+ or Fe2+); red half arrows are one-electron
transfers, and full red arrows are two-electron transfers. Transfer of the proton from the
imidazolium to the alpha carbon in (A) is probably solvent- or protein-mediated (i.e., the proton
may be abstracted at an early step, with a solvent- or protein-mediated protonation of the alpha
carbon occurring at a later step). Reduction of heme (from Fe3+ to Fe2+) could favor ejection of
the CcmE His130 imidazole adduct (reverse blue arrow) and is required for holocytochrome c
formation. For simplicity, only a single vinyl of heme is shown. Adapted from (Kranz, RichardFogal et al. 2009).
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Summary
Cytochrome c maturation (ccm) in many bacteria, archaea, and plant mitochondria requires eight
membrane proteins, CcmABCDEFGH, called system I. This pathway delivers and attaches
heme covalently to two cysteines (of Cys-Xxx-Xxx-Cys-His) in the cytochrome c. All models
propose that CcmFH facilitates covalent attachment of heme to the apocytochrome; namely, that
it is the synthetase. However, holocytochrome c synthetase activity has not been directly
demonstrated for CcmFH. We report formation of holocytochromes c by CcmFH and CcmG, a
periplasmic thioredoxin, independent of CcmABCDE (we term this activity CcmFGH-ind).
Cytochrome c produced in the absence of CcmABCDE is indistinguishable from cytochrome c
produced by the full system I, with a cleaved signal sequence and two covalent bonds to heme.
We engineer increased cytochrome c production by CcmFGH-ind, with yields approaching those
from the full system I. Three conserved histidines in CcmF (TM-His1, TM-His2, and P-His1)
are required for activity, as are the conserved cysteine pairs in CcmG and CcmH. These findings
establish that CcmFH is the system I holocytochrome c synthetase, and provide unique
mechanistic and evolutionary insights into cytochrome c biosynthesis.
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Introduction
C-type cytochromes are heme proteins that carry out essential electron transfer reactions
in organisms from every kingdom of life. These cytochromes function outside of the
cytoplasmic membrane in prokaryotes, in the lumen of chloroplasts, and in the intermembrane
space of mitochondria. Cytochromes c are characterized by covalent attachment between the
heme and the apoprotein (via thioether linkages between the 2- and 4-vinyls of heme and two
thiols of a conserved Cys-Xxx-Xxx-Cys-His motif in the apoprotein). Because c-type
cytochromes are assembled at their site of action (separated from heme biosynthesis by a lipid
bilayer), holocytochrome c formation poses unique challenges to heme trafficking and posttranslational modification. Three major pathways (called systems I, II, and III) exist in nature to
direct the covalent attachment of heme to cytochrome c. In many bacteria, plant and protozoal
mitochondria, and archaea, holocytochrome c formation is carried out by the cytochrome c
maturation (ccm) pathway, called system I, which comprises eight membrane proteins (in E. coli,
CcmABCDEFGH) (Hamel et al., 2009; Kranz et al., 2009; Mavridou et al., 2013; Sanders et al.,
2010; Sawyer and Barker, 2012).
At the center of heme trafficking in system I is the periplasmic heme chaperone protein,
CcmE. CcmE forms a unique and well-studied covalent intermediate with heme, between a
conserved histidine (His130, in E. coli CcmE) and the β carbon of the heme 2-vinyl (Lee et al.,
2005; Stevens et al., 2003; Uchida et al., 2004). Heme in “holo” (heme bound) CcmE is
transferred to the apocytochrome (putatively, by the action of CcmFH), but details of this aspect
of system I are just emerging. CcmABCD (an ABC transporter complex) are involved in
formation and ATP-dependent release of holoCcmE, presumably now free to associate with
CcmF (Christensen et al., 2007; Feissner et al., 2006a; Goldman et al., 1997; Schulz et al.,
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1999). CcmF forms an integral membrane complex with CcmH (Rayapuram et al., 2008; Ren et
al., 2002; Richard-Fogal et al., 2009; Sanders et al., 2008), and is believed to be the site of
thioether formation between the heme and the apocytochrome. CcmF contains a separate, stably
bound non-covalent heme b (Richard-Fogal et al., 2009; San Francisco et al., 2011), which we
have proposed is involved in reducing the incoming heme from holoCcmE (Kranz et al., 2009;
Richard-Fogal et al., 2009; San Francisco et al., 2011). Reduced heme (Fe2+) is required for
thioether formation with the apocytochrome (Barker et al., 1993; Nicholson and Neupert, 1989),
and reduction of the heme in holoCcmE would also favor discharge of heme from the covalent
His130 intermediate (Kranz et al., 2009; Richard-Fogal and Kranz, 2010; San Francisco et al.,
2011). CcmG (Beckman and Kranz, 1993; Di Matteo et al., 2010; Ouyang et al., 2006) and
CcmH (Di Matteo et al., 2007; Zheng et al., 2012) are membrane-tethered thioredox-active
proteins that likely maintain the thiol groups of the apocytochrome (in the conserved Cys-XxxXxx-Cys-His motif) in the reduced state (Meyer et al., 2005; Monika et al., 1997; Setterdahl et
al., 2000; Turkarslan et al., 2008).
CcmF (in complex with CcmH) has been referred to extensively as the “cytochrome c
heme lyase” or “cytochrome c synthetase” of system I, although the assignment of this function
to CcmF is largely circumstantial. It is well-established that CcmF forms a complex with CcmH
(Rayapuram et al., 2008; Ren et al., 2002; Richard-Fogal et al., 2009; Sanders et al., 2008), and
there is evidence that CcmH interacts directly with the apocytochrome (Di Matteo et al., 2007;
Di Silvio et al., 2013; Meyer et al., 2005; Verissimo et al., 2011). However, interaction(s)
between holoCcmE (the protein assumed to deliver heme to site of thioether formation with the
apocytochrome) and CcmFH have not been demonstrated (an earlier report only studied
interaction of apoCcmE with CcmF (Ren et al., 2002), so the physiological significance of this
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result is unclear). The absence of direct experimental evidence demonstrating that CcmFH is the
cytochrome c synthetase thus constitutes a major gap in our understanding of the system I
pathway.
Here, we report maturation of holocytochrome c by CcmFH and CcmG, in the absence of
CcmABCDE. The cytochrome c produced by the CcmABCDE-independent pathway (here
termed “CcmFGH-ind”) is biochemically and spectroscopically indistinguishable from
cytochrome c produced by the full system I, and we engineer production of cytochrome c by the
CcmFGH-ind pathway at levels approaching those of the full system I. Three of the conserved
histidines in CcmF (TM-His1, TM-His2, and P-His1), as well as the conserved cysteine pairs in
the thioredox proteins CcmG and CcmH, are required for holocytochrome formation by
CcmFGH-ind. These findings establish that CcmFH is the holocytochrome c synthetase for
system I (with thioreduction mediated by CcmG). We discuss evolutionary and mechanistic
implications, comparing CcmFGH-ind with the system II cytochrome c synthetase, CcsBA.
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Results
CcmFH and CcmG mature cytochrome c in the absence of CcmABCDE
Conceptually, system I occurs in two steps: i) formation and release of holoCcmE (by
CcmABCD), and ii) heme delivery to CcmFH (by holoCcmE), the putative site of
holocytochrome c formation (hence, the “cytochrome c synthetase”). Studies in our lab
(Feissner et al., 2006a; Goldman et al., 1997; Richard-Fogal and Kranz, 2010; Richard-Fogal et
al., 2009) and others (Christensen et al., 2007; Ren and Thony-Meyer, 2001) have addressed step
one, analyzing intermediates during formation of holoCcmE (such as the stable CcmCDE
complex), and the ATP-dependent release of holoCcmE. However, less is known about the
second step. To study the two steps independently, we engineered the IPTG-inducible pGEX
with the genes encoding step one of the pathway, ccmABCDE, and an arabinose-inducible
pBAD-based plasmid with the genes encoding step two, ccmFGH. Heme staining of BPER cell
extracts revealed that expression of all Ccm proteins with the arabinose-inducible chromosmallyintegrated cytochrome c4 (San Francisco et al., 2011), led to robust production of
holocytochrome c4 (Fig 1A, lane 5). Note that, typically, only heme that is covalently bound
remains with the cytochrome c after denaturing SDS-PAGE, and this heme is readily detectable
by heme stain (Feissner et al., 2003). Surprisingly, we noticed that cells containing only
CcmFGH (i.e., lacking ccmABCDE), also produced holocytochrome c4 (Fig 1A, lane 4). Thus,
it appeared that holocytochrome formation could proceed in the absence of CcmABCDE, albeit
at levels less than one-tenth those when CcmABCDE were present, under these conditions. We
confirmed chromosomal deletion of the ccmA-H operon in our E. coli ∆ccm strains (Feissner et
al., 2006b; San Francisco et al., 2011) by genomic PCR (Fig S1).
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The holocytochrome c synthetase activity of CcmFGH-ind is not limited to the di-heme
cytochrome c4, but also extends to the mono-heme cytochrome c2 (Fig 1B and C, lane 4). The
cytochrome c2 plasmid used here has an in-frame C-terminal fusion to E. coli alkaline
phosphatase (Pho), expressed from an IPTG-inducible promoter (Beckman et al., 1992). We
conclude that CcmFGH, in the absence of other Ccm components, can attach heme to two
unrelated (other than the Cys-Xxx-Xxx-Cys-His motif) cytochrome c substrates. Furthermore,
since alkaline phosphatase is secreted to the periplasm, covalent heme attachment to the
cytochrome c2:Pho fusion protein must occur in the periplasm (i.e., where CcmFGH function).
Properties of cytochrome c produced by CcmFGH-ind
We wanted to further characterize the di-heme holocytochrome c4 produced by
CcmFGH-ind. To confirm proper periplasmic secretion (and cleavage of the periplasmic signal
sequence), and to analyze the spectral properties of the cytochrome c produced by CcmFGH-ind,
we grew 1L cultures and purified hexahistidine-tagged holocytochrome c4 from the soluble
fraction (Fig 2A-C). The full-length 24 kDa holocytochrome c4 and the proteolyzed 12 kDa
holocytochrome c4’ were detectable by Coomassie blue staining of SDS-PAGE (Fig 2A, lane 8
“E1”). Note that it is common for endogeneous proteolysis of the 24 kDa cytochrome to occur,
yielding two 12 kDa mono-heme forms (Feissner et al., 2006b); however, only the C-terminal of
these products is purified (along with the full-length 24 kDa protein) since the hexahistidine tag
is at the C-terminus of the protein. The purified 24 and 12 kDa forms contained covalent heme
(Fig 2B, lane 8), and reacted with cytochrome c4 antisera (Fig 2C, lane 8). The UV-Vis
absorption spectrum (Fig 2D, red line) and reduced pyridine hemochrome (Fig 2D, inset, red
line) of the purified cytochrome c4 are consistent with two covalent attachments between the
thiols of cytochrome c (in Cys-Xxx-Xxx-Cys-His) and the vinyls of heme. The spectral features
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of cytochrome c4 produced by CcmFGH-ind (e.g., 552-nm absorption maximum in the spectrum
of the reduced sample, and 550-nm absorption maximum in the reduced pyridine hemochrome
spectrum) are indistinguishable from those of the cytochrome c4 produced when all system I
proteins are present (CcmABCDEFGH; Fig 2D, blue line; Fig 2D, inset, blue line). Mass
spectral analysis of cytochrome c4 purified from cells expressing CcmFGH-ind or the full
system I identified species of the expected molecular weights in each preparation (i.e., within 2
Daltons of the published molecular weights for the full-length holocytochrome c4 and
proteolyzed holocytochrome c4’ (Feissner et al., 2006b); Fig S2). This further confirmed
covalent attachment of heme and proper cleavage of the periplasmic secretion signal (Fig S2B).
In these large-scale cultures, yields of holocytochrome c via CcmFGH-ind were approximately
one-sixth those of the full system I.
Engineering optimal holocytochrome c production by CcmFGH-ind
To engineer increased cytochrome c maturation in the absence of CcmABCDE, we
piloted the following strategies: i) increasing the concentration of inducer (arabinose; “↑ arab”
condition), ii) raising intracellular heme levels by addition of the heme biosynthetic precursor αaminolevulinic acid (ALA; “ALA” condition), iii) decreasing oxygen tension by reduced shaking
during growth (“↓ rpm” condition), and iv) engineering the cytochrome c4 gene for increased
expression (by gene dosage) from a single pBAD-based vector, downstream of ccmF:His6GH
(“p-c4” condition). Addition of ALA and increasing cytochrome c4 gene dosage led to the
largest increases in yields of holocytochrome c (Fig 3A, lanes 4 and 6, respectively; Fig 3B, red
and orange lines; quantified in Fig 3C). Additively, with each of the four modifications together,
levels of holocytochrome c4 produced by CcmFGH-ind increased approximately 6-fold (up to
0.3 mg per L culture), similar to yields of holocytochrome c4 when CcmABCDE are present (Fig
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3A, compare lanes 7 and 9; Fig 3B, compare light blue and brown lines; quantified in Fig 3C).
In cells carrying CcmABCDE in the absence of CcmFGH, no holocytochrome c formation was
detected (Fig 3A, lane 8). In the presence of CcmABCDE and CcmFGH (i.e., full system I) and
each of the four modifications described above, yields of cytochrome c4 were approximately 1
mg per L culture (Fig 3A, lane 10; Fig 3B, top blue line; quantified in Fig 3C). Analysis of
membrane fractions by immunoblot confirmed the presence of CcmF and CcmH, respectively
(except in the strain carrying only pGEX CcmABCDE; Fig 3D and 3E, lane 8), and the absence
of CcmE (except for those cells carrying pGEX CcmABCDE; Fig 3F). These results
demonstrate that, under optimized conditions, CcmFGH-ind is a robust synthetase capable of
producing substantial levels of periplasmic holocytochrome c.
The role of conserved histidines in CcmF in CcmFGH-ind
CcmF contains four conserved histidine residues: TM-His1 and TM-His2 in
transmembrane domains 5 and 12, respectively, and P-His1 and P-His2, located in periplasmic
loops flanking the WWD domain (see Fig 4A). P-His1 and P-His2 are proposed to ligate heme
from holoCcmE when it is bound in the WWD domain, en route to covalent attachment to
apocytochrome c; TM-His1 and TM-His2 are ligands to the stable heme b (San Francisco et al.,
2011), which may play a role in reducing the holoCcmE heme (bound in the WWD domain)
prior to covalent attachment. In the context of the full system I, each of the four histidines is
essential for holocytochrome c formation (Richard-Fogal et al., 2009; San Francisco et al.,
2011). To test whether holocytochrome c formation via CcmFGH-ind required these four
histidines, we engineered substitutions at each residue (in pRGK388) and assayed for heme
attachment to cytochrome c4. Substitutions at TM-His1, TM-His2, and P-His1 abolished
holocytochrome formation to undetectable levels, indicating that these residues are absolutely
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required for heme attachment to cytochrome c via the CcmABCDE-independent pathway (Fig
5A, lanes 3, 4, and 6; quantified in Fig 5B). Substitution of P-His2 with glycine supported
holocytochrome formation at approximately 20 % levels of WT (Fig 5A, lane 5; quantified in Fig
5B). This contrasts with the absolute requirement for P-His2 in the context of the full system I
(i.e., in the presence of CcmABCDE), and may be suggestive of a holoCcmE-specific role for PHis2 in cytochrome c formation (see Discussion).
To test whether other substitutions could support holocytochrome formation at P-His1 or
P-His2, we engineered alanine, cysteine, methionine, or tyrosine substitutions at P-His1 or PHis2. While no P-His1 substitution supported holocytochrome c formation (Fig 5C, upper
panel), we discovered that P-His2Cys supported cytochrome c assembly at approximately 60 %
WT levels (Fig 5C, lower panel, lane 4; quantified in Fig 5D). P-His2Ala was similar to
substitution with glycine (20 % function relative to WT; Fig 5C, lower panel, lane 3; quantified
in Fig 5D) while methione and tyrosine substitutions were 3 % and 10 % WT levels, respectively
(Fig 5C, lower panel, lanes 5 and 6; quantified in Fig 5D). The inability for any engineered
substitution at P-His1 to support holocytochrome formation indicates that this residue cannot
vary from the natural histidine, similar to results with full system I.
Conserved cysteines in CcmG and CcmH are required for CcmFGH-ind
CcmG and CcmH each contain a conserved pair of thioredox-active cysteines that are
required for cytochrome c synthesis in the context of the full system I (Fabianek et al., 1998;
Fabianek et al., 1999; Robertson et al., 2008). To test whether holocytochrome c formation by
CcmFGH-ind required these thioredoxin functions, we engineered serine substitutions at the
conserved cysteine pairs in CcmG or CcmH and assayed for cytochrome c formation. Similar to
the full system I, in the absence of the conserved cysteine pair in either CcmG or CcmH, no
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holocytochrome formation was observed (Fig 6A, lanes 3 and 4; quantified in Fig 6B). Thus, the
redox-active cysteine pairs of CcmG and CcmH are required for holocytochrome c formation via
CcmFGH-ind.
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Discussion
CcmF has been referred to as the “cytochrome c heme lyase” or the “cytochrome c
synthetase” in nearly every review on system I in the last decade (e.g., (Hamel et al., 2009;
Kranz et al., 2009; Mavridou et al., 2013; Sanders et al., 2010; Sawyer and Barker, 2012)).
However, direct experimental evidence demonstrating this activity for CcmF has been lacking.
Here, we demonstrate that holocytochrome c formation can occur completely (and robustly) in
the absence of the CcmABCDE components of the system I pathway, thus establishing that the
cytochrome c synthetase activity of system I inheres in CcmFH (and CcmG). We suspect that
the synthetase activity of CcmFH (with CcmG) has gone unnoticed thus far due to challenges in
expressing these membrane proteins and engineering conditions for optimal biogenesis. Only of
late have we been able to express and purify CcmF in sufficient quantities to begin biochemical
characterization of this protein (Richard-Fogal et al., 2009; San Francisco et al., 2011). Indeed,
the discovery that CcmF contained a stable heme b (coordinated by TM-His1 and TM-His2) was
made only recently (Richard-Fogal et al., 2009). Thus, we attribute our observation of this
“new” CcmFGH-ind synthetase activity to our recent ability to successfully modulate expression
of stable, functional CcmFH and CcmG in E. coli, and control the expression of substrate
cytochromes c (e.g., the diheme cytochrome c4 and monoheme cytochrome c2 used here).
Requirements for CcmFGH-ind versus the full system I
Many of the requirements for cytochrome c assembly by the full system I extend to
CcmFGH-ind. In system I, the thio-active proteins CcmG and CcmH each contain a conserved
pair of cysteines that are required for holocytochrome formation (Fabianek et al., 1998; Fabianek
et al., 1999; Robertson et al., 2008). CcmG and CcmH are involved in maintaining the thiols of
the apocytochrome (at Cys-Xxx-Xxx-Cys-His) in the reduced state, which is a requirement for
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thioether formation with the heme vinyls. The conserved cysteines in CcmG (which are reduced
by the membrane protein DsbD) likely function to reduce the thiols of CcmH (Meyer et al.,
2005; Monika et al., 1997; Setterdahl et al., 2000; Turkarslan et al., 2008). CcmH also has a
direct apocytochrome binding function (Di Matteo et al., 2007; Di Silvio et al., 2013; Meyer et
al., 2005; Verissimo et al., 2011), and it is proposed that, via interaction with CcmF, CcmH
physically positions the apocytochrome (with reduced cysteine thiols) for covalent heme
attachment (Meyer et al., 2005; Verissimo et al., 2011). We discovered that mutation of either
of the cysteine pairs in CcmG or CcmH abolished holocytochrome formation by CcmFGH-ind
(Fig 6). The requirement for the conserved redox-active cysteine pairs in CcmG and CcmH
demonstrates that the CcmFGH-ind pathway is “intact” with regard to handling of the
apocytochrome. This suggests that the lower cytochrome c maturation activity of CcmFGH-ind
(relative to full system I) is likely due to less efficient heme delivery (i.e., the absence of the
holoCcmE “heme reservoir” (Feissner et al., 2006b); see below). This finding also highlights the
significant evolutionary advantage of the full system I.
Holocytochrome c formation by the full system I requires conserved histidines in CcmF:
mutation of any of the four (Fig 4A) renders the system non-functional (Ren et al., 2002;
Richard-Fogal et al., 2009; San Francisco et al., 2011). We have shown experimentally that TMHis1 and TM-His2 are ligands to the b-heme (San Francisco et al., 2011), while P-His1 and PHis2 are proposed to ligate the incoming heme from holoCcmE when it is bound in the WWD
domain (Kranz et al., 2009; Richard-Fogal et al., 2009; San Francisco et al., 2011). For
CcmFGH-ind, we found that TM-His1, TM-His2, and P-His1 were each indispensable for
holocytochrome formation. However, CcmFGH-ind was only partially dependent on P-His2
(Ala or Gly substitutions at this position retained approximately 20 % activity, and Cys, 60 %,
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relative to WT). Since these same substitutions show no activity in the context of the full system
I, we propose that P-His2 may have a function that is specific to the system I heme chaperone,
holoCcmE. The lack of a requirement for P-His2 likely reflects the fundamentally different
mechanism of heme trafficking to the WWD domain in CcmFGH-ind. Below, we suggest two
possible trafficking routes for the endogeneous heme that is attached to cytochrome c by
CcmFGH-ind.
Similarities between CcmFGH-ind and CcsBA: evolutionary insights
The assignment of the synthetase (heme lyase) activity of system I to CcmF has been
based in part on its topological similarity to the cytochrome c synthetase of system II, CcsBA
(see Fig 4). System II is present in many gram positive (and other) bacteria, cyanobacteria, and
the chloroplasts of plants and algae (Ahuja et al., 2009; Simon and Hederstedt, 2011; Xie and
Merchant, 1998). CcsBA, when expressed heterologously in E. coli ∆ccm is sufficient for
assembly of cytochrome c (Feissner et al., 2006b; Frawley and Kranz, 2009; Kern et al., 2010;
Richard-Fogal et al., 2012); thus, it is the system II holocytochrome c synthetase. CcsBA is
proposed to traffick heme across the cytoplasmic membrane, in addition to facilitating thioether
formation between the heme and apocytochrome (Frawley and Kranz, 2009; Hamel et al., 2003;
Kranz et al., 2009; Merchant, 2009). Thus, it is a heme transporter and a holocytochrome c
synthetase. The membrane topologies of CcmF and CcsBA are strikingly similar (see Fig 4):
each contains four completely conserved His residues (two in transmembrane domains, here
called TM-His1 and TM-His2; and two in extra-cytoplasmic loops, here called P-His1 and PHis2) and the conserved WWD domain, a hydrophobic, extra-cytoplasmic feature that has been
shown (in the system I protein CcmC) to interact directly with heme (Richard-Fogal and Kranz,
2010). Additionally, both CcsBA (Frawley and Kranz, 2009) and CcmF (Richard-Fogal et al.,
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2009) bind a non-covalent heme b (see Fig 4). However, in CcsBA, this heme b is ultimately
attached to cytochrome c, whereas the stable heme b in CcmF (in the context of the full system I)
may play a role in reducing heme bound in the WWD domain (from holoCcmE).
The marked similarities between CcmF and CcsBA, coupled with the finding here that
CcmF (together with CcmH and CcmG) is a cytochrome c synthetase, raise several interesting
questions. First, how is heme trafficked to the site of thioether formation with the
apocytochrome (presumably, at the CcmF WWD domain with axial ligation by P-His1) in
CcmFGH-ind synthesis? We envision two possible scenarios: i) heme enters the WWD domain
of CcmF directly from the cytoplasmic membrane outer leaflet, possibly, (where it is
subsequently reduced by the transmembrane heme b), or ii) similar to the proposed mechanism
for CcsBA, the transmembrane heme b may be channeled to the external WWD domain for
attachment to the apocytochrome. While experiments addressing these hypotheses will be
challenging, the possibility that the CcmFGH-ind synthetase may be CcsBA-like (with respect to
the channeling of heme from the transmembrane binding site to the WWD domain) is intriguing
from an evolutionary perspective.
The complex phylogenetic distribution of systems I and II suggest significant lateral
transfer (Goldman and Kranz, 1998), making it difficult to discern clear evolutionary patterns.
We have shown previously that system I can mature cytochromes c at 5-fold lower heme
concentrations than can system II (Richard-Fogal et al., 2007), and that holoCcmE can function
as a “heme reservoir” (i.e., when heme synthesis is completely inhibited) (Feissner et al., 2006a).
On the basis of these results, we have speculated that the holoCcmE reservoir aspect of system I
may have evolved for cytochrome c synthesis under conditions of iron (or heme) scarcity. The
ability to use heme at very low levels, and as a reservoir when no iron is present, represents a
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possible selection advantage. Since the CcmFGH-ind synthetase lacks the holoCcmE reservoir,
it might be considered a “prototype” of an intermediate, or a “transition,” on the evolutionary
path from system II to the full system I. CcmFGH-ind synthesis thus provides a unique
opportunity to directly compare holocytochrome c formation (under low heme conditions) by
system I with and without the holoCcmE reservoir.
CcmFGH-ind: a viable candidate for in vitro reconstitution
One of the remaining challenges in the field of cytochrome c biogenesis is in vitro
reconstitution of each of the systems for holocytochrome formation. Reconstitution of the
synthetase reactions would be especially informative, as they are common to all three major
pathways. To date, system II has been a more attractive candidate for in vitro reconstitution than
system I, since it consists of a single protein complex. Our findings here demonstrate that the
system I synthetase (CcmFGH-ind) is now a viable candidate for in vitro reconstitution as well.
The CcmFGH-ind synthetase activity reported here thus represents a significant advance for the
field, in terms of the proof of its function, the unique evolutionary and mechanistic insights it
provides, and the potential for in vitro reconstitution.
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Experimental Procedures
Bacterial Growth Conditions. Unless otherwise noted, Escherichia coli strains (Table S1) were
grown at 37oC by shaking at 230 rpm in Luria-Bertani broth (LB; Difco) supplemented with the
appropriate antibiotics (Sigma-Aldrich) and other media additives at the following
concentrations: carbenicillin, 50 µg mL-1; chloramphenicol, 20 µg mL-1; gentamicin, 10 µg mL-1;
kanamycin, 20 µg mL-1; IPTG (Gold Biotechnology), 1 mM; arabinose (Gold Biotechnology),
0.2 % (wt/vol); ALA (Sigma-Aldrich), 50 µg ml-1.
Protein Expression and Purification. E. coli ∆ccm strains RK103 (Feissner et al., 2006b) or
RK111 (∆ccm carrying the arabinose-inducible chromosomal integrate of the cyt c4:His6 gene)
(San Francisco et al., 2011) (Table S1) were used for expression. Starter cultures were
inoculated from a single colony and grown overnight in 10 mL of LB with the appropriate
antibiotics. 1 L of LB was inoculated with the 10 mL starter culture and grown to an OD600 of
1.8, then induced with IPTG and/or arabinose for 14-16 hr. Cells were harvested at 5,000 x g
and frozen at -80oC. Cell pellets were thawed and resuspended in PBS (100 mM NaCl, 7.5 mM
Na2HPO4, 2 mM NaH2PO4, pH 7) and treated with 1 mM PMSF (Sigma-Aldrich) and 100 µg ml1

egg white lysozyme (Sigma-Aldrich) for 30 min while shaking on ice. Cells were disrupted by

repeated sonication for 30 sec bursts on a Branson 250 sonicator (50% duty, 8 output) until
clearing of the suspension was observed. Crude sonicate was centrifuged at 24,000 x g for 20
min to clear cell debris, and the soluble and membrane fractions were separated by centrifugation
at 100,000 x g for 45 min. Soluble fractions (L; load) were passed over TALON resin per the
manufacturer’s recommendations and washed in 1 x modified TALON buffer with increasing
concentrations of imidazole (wash 1 (W1), 0 mM imidazole; wash 2 (W2), 2 mM imidazole;
wash 3 (W3), 5 mM imidazole). Bound hexahistidine-tagged protein was eluted in 1 x modified
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TALON buffer containing 150 mM imidazole (E; elution). Total protein concentration was
determined using the Nanodrop 1000 spectrophotometer (Thermo Scientific). For growth by
shaking at 120 rpm (“↓ rpm” condition), starter cultures were initiated from a single colony and
grown overnight in 100 mL of LB with the appropriate antibiotics. 1 L of LB was inoculated
with the 100 mL starter culture and grown to an OD600 of 1.8, then induced with IPTG and/or
arabinose for 14-16 hr. For the “↑ arabinose” condition, expression was induced with 0.4 %
arabinose rather than 0.2 %. For the “ALA” condition, 50 µg mL-1 ALA was added to culture at
the time of induction. For analysis of crude membrane fractions, membrane pellets (isolated by
centrifugation at 100,000 x g) were solubilized in a modified 1x TALON (Clontech) buffer (50
mM Tris-HCL, pH 7; 300 mM NaCl) with 1 % (wt/vol) dodecyl maltoside (DDM, Anatrace) by
agitation on ice for 1 hr, and then centrifuged at 24,000 x g for 20 min to remove unsolubilized
material.
Heme stains and other methods. Heme stains and immunoblots were performed as described
previously (Feissner et al., 2003; Feissner et al., 2006b). Proteins were separated by 12.5 %
SDS-PAGE and transferred to Hybond C nitrocellulose membranes (GE Healthcare). For
immunoblots, anti-CcmF antibodies were used at a dilution of 1:10000, anti-CcmE antibodies at
1:10000, anti-cytochrome c4 antibodies at 1:10000, and anti-CcmH antibodies at 1:5000.
Protein A peroxidase (Sigma-Aldrich) was used as the secondary label. The chemiluminescent
signal for heme stains was developed using the SuperSignal Femto kit (Thermo Scientific) or, for
immunoblots, the Immobilon Western kit (Millipore), and detected with an LAS-1000 Plus
detection system (Fujifilm-GE Healthcare). The abundance of holocytochrome c4 was
determined by pyridine extraction as described in (Berry and Trumpower, 1987), or by
densitometry analysis of the chemiluminescent signal from heme staining using the Science Lab
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99-Image Gauge version 3.4 software (Fujifilm-GE Healthcare) as described in (Richard-Fogal
et al., 2007). Protein purity was assessed by Coomassie Blue staining of SDS-PAGE.
UV/Vis absorption spectroscopy. UV-visible absorption spectra were recorded with a Shimadzu
UV-2101 PC UV-Vis scanning spectrophotometer at room temperature as described previously
(Frawley and Kranz, 2009). All spectra were recorded in the same buffer (modified 1x TALON
buffer) in which the proteins were purified. Chemically reduced spectra were generated by
addition of sodium dithionite (sodium hydrosulfite).
Construction of plasmids. All oligonucleotide primer sequences, plasmids, and strains are given
in Table S1. The single pBAD-based plasmid containing ccmF:His6GH and cyt c4:His6 was
constructed by PCR amplification of the cyt c4:His6 gene (and the upstream RBS) from
pRGK332 (Feissner et al., 2006b) and insertion of the resulting fragment into the single PstI site
downstream of ccmF:His6GH in pRGK388 (Richard-Fogal et al., 2009) to create pRGK448.
The resulting plasmids were screened by restriction digest to confirm correct orientation of the
insert, and then sequenced. All substitutions in pRGK388 (i.e., CcmG (Cys80Ser/Cys83Ser),
CcmH (Cys43Ser/Cys46Ser), CcmF(His261Gly), and CcmF(His491Ala)) were engineered using
the QuikChange I Site-Directed Mutagenesis Kit (Agilent Technologies) per the manufacturer’s
recommendations. All oligonucleotides were synthesized by Sigma-Aldrich. Each of the final
constructs was sequenced to verify the mutation(s).
Proteomics analysis. Proteomics analyses were carried out by the Washington University
Resource for Biomedical and Bio-organic Mass Spectrometry Facility. Briefly, TALON-purified
holocytochrome c4:His6 samples (produced by the full system I or by CcmFGH-ind) were
loaded onto an Agilent 2.1 X 15 mm C8 Zorbax Cartridge-Column and eluted using a 9.5 min
gradient with a flow rate of 200 µL/min. A positive ion mass spectrum was acquired using a
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Bruker Maxis Q-ToF mass spectrometer equipped with an electrospray ionization source.
Protein molecular ions were identified with multiple charge states and deconvoluted to identify
the molecular weight(s) of the main species.
Genomic PCR. E. coli strains (WT E. coli K-12 MG1655; ∆ccm (RK103); ∆ccm cyt c4:His6
chromosomal integrate (RK111); and RK111 carrying pBAD ccmF:His6GH) were streaked onto
LB plates containing the appropriate antibiotics and incubated at 37 C overnight. Single colonies
were resuspended in 100 µL H2O by vortexing, placed at 90 C for 10 min to lyse cells, and
centrifuged at 16 000 x g for 5 min to remove cell debris. 1 µL of the supernatant (containing
cellular DNA) was used as the template in each of four PCRs with the following primer sets: A)
delCcmF-right + delCcmH-left, B) delCcmC-right + delCcmF-left, C) delCcmB-right +
delCcmE-left, D) menBflank-right + menBflank-left. Oligonucleotide primer sequences are
given in Table S1. PCRs were performed using GoTaq Green Master Mix (Promega) for 25
cycles, per the manufacturer’s recommendations. PCR products were visualized by ethidium
bromide staining of agarose gels (0.8 %).
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Figures
Fig 1. CcmFGH attaches heme to cytochrome c in the absence of CcmABCDE.
(A) Heme staining of BPER cell extracts showing synthesis of 24-kDa holocytochrome c4:His6
as a function of expression of separate Ccm components, as indicated. (B) Heme staining and
(C) anti-cytochrome c2 immunoblot of BPER cell extracts showing synthesis of 106-kDa
holocytochrome c2:Pho by CcmFGH as a function of induction with IPTG and/or arabinose.
One hundred µg total protein was loaded in each lane. MW, molecular weight standards (lanes
1).
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Fig 2. Characterization of cytochrome c produced by CcmFGH-ind.
(A) Coomassie blue staining of purified cytochrome c4:His6 showing full length 24-kDa
holocytochrome c4 and proteolyzed 12-kDa holocytochrome c4’. (B) Heme staining of purified
cytochrome c4 showing 24-kDa and 12-kDa forms. (C) Anti-cytochrome c4 immunoblot
showing 24-kDa and 12-kDa holocytochrome c4. For (A)-(C), abbreviations are M, molecular
weight standards; S, soluble fraction; FT, flow through; W1, wash 1; W2, wash 2; W3, wash 3;
W4, wash 4; E1, elution 1; E2, elution 2; E3, elution 3. (D) UV-Vis absorption spectra of
purified, sodium dithionite-reduced holocytochrome c4 produced by the full system I (blue line)
or in the absence of CcmABCDE (red line). (Inset) Sodium dithionite-reduced pyridine
hemochrome spectrum of purified holocytochrome c4 produced by the full system I (blue line) or
in the absence of CcmABCDE (red line) from 500-600 nm. Absorption maxima are indicated.
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Fig 3. Optimization of holocytochrome c4 produced by CcmFGH-ind.
(A) Heme staining of TALON-purified proteins showing relative levels of holocytochrome c4
synthesized for each indicated condition. “↑ arab,” increase in arabinose from 0.2 % to 0.4 %;
“ALA,” addition of ALA to 50 µg mL-1; “↓ rpm,” decrease in shaking during growth from 230
rpm to 120 rpm; “p-c4,” single plasmid system with cytochrome c4 engineered into pBAD
CcmFGH; “***,” each of the four additives/conditions together. (B) Sodium dithionite-reduced
pyridine hemochrome spectra of TALON-purified proteins for each condition, from 500-600 nm.
Absorption maxima are indicated. (C) Quantification of yields of holocytochrome c4 (based on
550 nm. absorption in reduced pyridine hemochrome) for each condition from three independent
experiments. Error bars denote standard deviation. ND, none detected. (D) Anti-CcmF
immunoblot of DDM-solubilized membrane fractions showing 54-kDa CcmF. (E) Anti-CcmH
immunoblot of DDM-solubilized membrane fractions showing 37-kDa CcmH. (F) Anti-CcmE
immunoblot of DDM-solubilized membrane fractions showing 20-kDa CcmE. Labels are as in
(A).
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Fig 4. Topologies of CcmF and CcsBA.
Topology of the system I CcmF protein from Escherichia coli (A) and the system II CcsBA
fusion protein from Helicobacter hepaticus (B). Possible histidine axial ligands to heme are
starred, and are designated P-His1, P-His2, TM-His1, and TM-His2. The highly conserved
WWD domain and the hydrophobic patches are shaded. Completely conserved amino acids
(red) were identified by individual protein alignments using CcmF or the CcsB and CcsA ORFs
from selected organisms, as described in (Kranz et al., 2009). Diagram is modified from (Kranz
et al., 2009).
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Fig 5. Role of conserved His residues in CcmF in CcmFGH-ind.
(A) Heme staining of purified holocytochrome c4 assembled by WT and site-directed variants of
CcmF. (B) Quantification of the results of heme staining (24 kDa holocytochrome c4) from
purified fractions from three independent experiments. (C) Heme staining of purified
holocytochrome c4 assembled by WT and the indicated site-directed variants at CcmF P-His1
(upper panel) or P-His2 (lower panel). (D) Quantification of the results of heme staining from
purified fractions from three independent experiments. For (B) and (D), synthesis of
holocytochrome c4 is relative to WT, which has been set at 100 %. Error bars denote standard
deviation. ND, none detected.
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Fig 6. Conserved cysteines in CcmG and CcmH are required for CcmFGH-ind.
(A) Heme staining of purified holocytochrome c4 assembled by WT and the indicated sitedirected variants at CcmG and CcmH. “Gmut” is a Cys80Ser/Cys83Ser double mutant, and
“Hmut” is a Cys43Ser/Cys46Ser double mutant. (B) Quantification of the results of heme
staining (24 kDa holocytochrome c4) from purified fractions from three independent
experiments. Synthesis of holocytochrome c4 is relative to WT, which has been set at 100 %.
ND, none detected.
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Supplementary Material
Fig S1. Confirmation of ∆ccm by genomic PCR.
Ethidium bromide staining of the products from 4 separate PCRs using the indicated genomic
DNA templates. Primer sets A, B, and C anneal to different regions of the ccm operon (panel C),
and control primer set D anneals to regions flanking E. coli menB. For WT E. coli, all PCRs
yielded products of the expected sizes (panel A, lanes 1-4). No products corresponding to the
ccm operon were detected for any of the ∆ccm strains (panels A and B), with the exception of
primer set A for strain ∆ccm c4:His6 int + pBAD CcmF:His6GH, as expected since this strain
carries the ccmFGH genes on a plasmid. PCRs using control primer set D yielded products of
the expected size for each strain. This confirms that our ∆ccm strains lack the endogeneous
genes for cytochrome c synthesis; therefore, holocytochrome c formation in these strains is
completely dependent on plasmid-based expression of the ccm genes. Lanes 5 and 10 in (A) and
(B) contain MW markers; bp indicates base pairs.
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Fig S2. Mass spectral analysis of holocytochrome c4:His6.
Mass spectral analysis of holocytochrome c4:His6 produced by CcmFGH in the presence (A) or
absence (B) of CcmABCDE. After deconvolution of the positive ion mass spectra, two species
were identified from each sample with the indicated molecular weights (each was within 2
Daltons of the reported average masses for full length holocytochrome c4:His6 and proteolyzed
holocytochrome c4:His6’, respectively). (C) Amino acid sequence of the Bordetella pertussis
cytochrome c4:His6. The signal sequence is underlined and heme attachment sites (Cys-XxxXxx-Cys-His) are in bold. Arrows indicate the periplasmic signal cleavage site and the site of
endogeneous proteolysis giving rise to holocytochrome c4:His6’. The presence of identical
molecular weight species in preparations of holocytochrome c4:His6 produced by full system I
and by CcmFGH-ind confirms proper cleavage of the cytochrome c4 periplasmic secretion
sequence, and covalent attachment of heme.
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Table S1. Strains, plasmids, and oligonucleotide primers
Strain
RK103
RK111

Plasmid
-pRGK332
pRGK388
pRGK402
pRGK434
pRGK435
pRGK436
pRGK437
pRGK438
pRGK439
pRGK440
pRGK441
pRGK442
pRGK443
pRGK444
pRGK445
pRGK446
pRGK447
pRGK448

Description
MG1655 ∆ccm
MG1655 ∆ccm cyt c4:His6 chromosomal integrate

Description
pUCA6 cyt c2:Pho
pBAD cyt c4:His6
pBAD ccmF:His6GH
pGEX ccmABCDE
pBAD ccmF(His173Ala):His6GH
pBAD ccmF(His173Gly):His6GH
pBAD ccmF(His173Cys):His6GH
pBAD ccmF(His173Met):His6GH
pBAD ccmF(His173Tyr):His6GH
pBAD ccmF(His303Ala):His6GH
pBAD ccmF(His303Gly):His6GH
pBAD ccmF(His303Cys):His6GH
pBAD ccmF(His303Met):His6GH
pBAD ccmF(His303Tyr):His6GH
pBAD ccmF(His261Gly):His6GH
pBAD ccmF(His491Ala):His6GH
pBAD ccmF:His6G(Cys80Ser/Cys83Ser)H
pBAD ccmF:His6GH(Cys43Ser/Cys46Ser)
pBAD ccmF:His6GH—cyt c4:His6

Primer
C4:His_PstI_RBS_Fwd
C4:His_PstI_Rev
ccmG_C80A/C83A_Fwd
ccmG_C80A/C83A_Rev
ccmH_C43A/C46A_Fwd
ccmH_C43A/C46A_Rev
ccmF_H261G_Fwd
ccmF_H261G_Rev
ccmF_H491A_Fwd
ccmF_H491A_Rev
A.Fwd (delCcmF_right)
A.Rev (delCcmH_left)
B.Fwd (delCcmC_right)
B.Rev (delCcmF_left)
C.Fwd (delCcmB_right)
C.Rev (delCcmC_left)
D.Fwd (menBflank_right)
D.Rev (menBflank_left)

Reference
(Feissner et al., 2006)
(San Francisco et al., 2011)

Reference
(Beckman et al., 1992)
(Feissner et al., 2006)
(Richard-Fogal et al., 2009)
(San Francisco et al., 2011)
(San Francisco et al., submitted)
(San Francisco et al., submitted)
(San Francisco et al., submitted)
(San Francisco et al., submitted)
(San Francisco et al., submitted)
(San Francisco et al., submitted)
(San Francisco et al., submitted)
(San Francisco et al., submitted)
(San Francisco et al., submitted)
(San Francisco et al., submitted)
This work
This work
This work
This work
This work

Sequence (5’-3’)
GATCTGCAGAGGAGGAATATCATATGAAGCGTGTGCTGTCCCGG
GATCTGCAGTCAGTGGTGGTGGTGGTGGTG
CTGGGCGACCTGGGCTCCGACCGCCCGTGCGGAACAT
ATGTTCCGCACGGGCGGTCGGAGCCCAGGTCGCCCAG
CTCACTGAAGAACTGCGCGCCCCGAAAGCCCAGAACAACAGCATTGC
GCAATGCTGTTGTTCTGGGCTTTCGGGGCGCGCAGTTCTTCAGTGAG
GGACTGCGCTGATGGGCTCACTGGCGGTCA
TGACCGCCAGTGAGCCCATCAGCGCAGTCC
GGGATGGTGGCGGCTGCCCTTGGGCTGGC
GCCAGCCCAAGGGCAGCCGCCACCATCCC
GCCGGAGGCCATATGAAGCGCAAAGTATTGTTA
GCGCCAATAAAAAGCTTATTGTGCGGCCTCCTT
AAGAGGCCGCATATGACCCCTGCATTTGCTTCC
CCGAATTCTGGCATCATATGGCTGGGTCCTTAT
GGTATCGAACATATGAGGAAAACACTGCATCAACT
AGTGTTTTCCACATATGTTCGATACCAGACTCG
CGCAGGCAAACATACAGCCC
CGGACATAACGCGCATCGG
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Purpose
pRGK448
pRGK448
pRGK446
pRGK446
pRGK447
pRGK447
pRGK444
pRGK444
pRGK445
pRGK445
gPCR
gPCR
gPCR
gPCR
gPCR
gPCR
gPCR
gPCR
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Abstract
Proper functioning of the mitochondrion requires the orchestrated assembly of respiratory
complexes with their cofactors. Cytochromes c, essential electron carriers in mitochondria and
critical components of the apoptotic pathway, contain a heme cofactor covalently attached to the
protein at a conserved CXXCH motif. While it has been known for over two decades that heme
attachment requires the mitochondrial protein holocytochrome c synthase (HCCS), the
mechanism has remained unknown. We purified the membrane-bound human HCCS with
endogenous heme, and in complex with its cognate human apocytochrome c. Spectroscopic
analyses of HCCS alone and complexes of HCCS with site-directed variants of cytochrome c
revealed the fundamental steps of heme attachment and maturation. A conserved histidine in
HCCS (His154) provided the key ligand to the heme iron. Formation of the HCCS:heme
complex served as the platform for interaction with the apocytochrome c. Heme was the central
molecule mediating contact between HCCS and apocytochrome c. A conserved histidine in
apocytochrome c (His19 of CXXCH) supplied the second axial ligand to heme in the trapped
HCCS:heme:cytochrome c complex. We also examined the substrate specificity of human
HCCS and converted a bacterial cytochrome c into a robust substrate for the HCCS. The results
allow us to describe the molecular mechanisms underlying the holocytochrome c synthase
reaction.
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Introduction
Renewed interest in mitochondria stems from recent associations of malfunctioning
mitochondria with many cancers (1), neurological diseases (2-4), and even reduced life span (5).
The basis for these associations lies in the respiratory chains that power aerobic life. Threedimensional structures for many respiratory complexes and carriers (6-8) have elucidated the
detailed mechanisms of electron transport, proton pumping, the reduction of oxygen to water,
and ATP formation. Less is known about the biogenesis of these respiratory chain components.
The synthesis and insertion of cofactors (e.g., heme and metals) into large, multi-subunit
membrane complexes represents a new frontier in the study of mitochondrial function. C-type
cytochromes, among the best-studied players in mitochondrial electron transport (9, 10), are
redox active heme proteins whose biosynthesis is only just emerging. Cytochrome c is a soluble
electron carrier in the intermembrane space (IMS) of mitochondria that functions in electron
transport between the quinol:cytochrome c oxidoreductase (complex III, or cytochrome bc1) and
the cytochrome c oxidase (complex IV, or cytochrome a/a3). In addition to its role in
mitochondrial respiration, cytochrome c plays a crucial role in apoptotic signaling (11). A
second, membrane-bound c-type cytochrome, cytochrome c1, is an integral part of complex III.
Cytochromes c differ from other cytochromes in that the heme is covalently attached to
the protein via two thioether linkages between the heme vinyls and two cysteine residues of a
conserved CysXxxXxxCysHis (CXXCH) heme binding motif. Two major pathways have been
identified for the biogenesis of cytochromes c in mitochondria: CCM (cytochrome c maturation)
(12-15) and CCHL (cytochrome c heme lyase), also called HCCS (holocytochrome c synthase,
which will be used here) (16, 17). The CCM system is composed of eight or nine integral
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membrane proteins and functions in the mitochondrial inner membrane of plants and some
protozoa, as well as the cytoplasmic membranes of alpha- and gamma-proteobacteria (18). Most
mitochondria (e.g., those of fungi, invertebrates, vertebrates, and some protozoa) use HCCS for
synthesis of cytochrome c. In fungi, there are two related homologs, HCCS and HCC1S,
dedicated to maturation of cytochrome c and cytochrome c1, respectively (19, 20), whereas in
animals a single HCCS enzyme is active toward both cytochrome c and cytochrome c1 (17, 21).
Additionally, in yeast and other fungi, the FAD-containing protein Cyc2p is required for heme
attachment to apocytochrome c (22-24).
The human HCCS has been increasingly implicated in disease. For example,
chromosomal mutations in the gene encoding HCCS can lead to a condition called
microphthalmia with linear skin defects syndrome (MLS; (25, 26)). Additionally, a role for
HCCS in apoptosis (separate from that of cytochrome c) has been described in injured motor
neurons (27). Despite the identification of HCCS as the gene product responsible for heme
attachment to cytochrome c in S. cerevisiae over twenty-five years ago (19), the enzyme has
never been purified or characterized and the mechanism of covalent heme attachment is
unknown (16, 17). In yeast, HCCS is nuclear-encoded and is imported directly into the
mitochondrial IMS from the cytosol via the translocase of the outer membrane (TOM) complex
(20, 28, 29). Studies in S. cerevisiae have shown that HCCS is membrane-associated in
mitochondria and is exposed to the IMS (28-30). The apparent absence of transmembrane
helices suggests that membrane association is likely peripheral. Pioneering studies by Neupert
and Sherman and colleagues have demonstrated that HCCS also plays an essential role in the
import of the apocytochrome c from the cytosol to the mitochondrion (30-33). It is unknown
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how heme enters the IMS from its site of synthesis in the mitochondrial matrix, although early
studies showed that reduced heme (Fe2+) is necessary for covalent attachment to cytochrome c
(34, 35). Preliminary genetic results suggested that heme binding by HCCS occurred at partially
conserved “Cys-Pro” sequences (36), which serve as heme-regulatory motifs in several other
proteins. However, neither of the Cys-Pro sequences in S. cerevisiae HCCS is required for heme
attachment to cytochrome c (37), and several HCCS proteins lack Cys-Pro sequences entirely.
Both the mechanism by which HCCS mediates covalent heme attachment to the
apocytochrome, and the specificity determinants for recognition of heme and the apocytochrome
c are poorly understood. Recombinant systems for production of mitochondrial cytochromes c in
E. coli, developed by Mauk and colleagues (38), have facilitated some progress in this regard
(e.g., (39-41)) (see SI Appendix, Table S1). The N-terminal region of the apocytochrome c
substrate (including the CXXCH motif) is important for recognition by S. cerevisiae HCCS
(reviewed in (16)), and a few residues in this region have been identified as important for
holocytochrome c maturation (42, 43). However, the features of the cytochrome c substrate that
are recognized by the human HCCS have never been examined. Here, we report successful
purification and characterization of the human holocytochrome c synthase from recombinant E.
coli. The human HCCS is membrane associated and is purified with endogenous heme
coordinated by conserved His154. We define the amino acids in the human cytochrome c that
are required for holocytochrome c formation by HCCS, and we successfully convert a nonsubstrate cytochrome c, cytochrome c2 from the alpha-proteobacterium Rhodobacter capsulatus,
into a robust substrate for the human HCCS by introducing three sequence alterations. Finally,
we report purification of trapped heme-containing complexes between cytochrome c and HCCS,
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with heme ligands coming from His19 (of the CXXCH motif) in cytochrome c and His154 of
HCCS. We show that mutation of either Cys in the conserved CXXCH motif of the cytochrome
c leads to accumulation of trapped cytochrome c, with a single covalent attachment to the
remaining cysteine, on the HCCS enzyme. Our results suggest mechanisms for heme binding,
interaction with apocytochrome c, thioether formation, and a requirement for release of mature
holocytochrome c from HCCS.
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Results
Purified human HCCS contains heme.
Despite longstanding interest in HCCS, the enzyme has remained refractile to successful
purification and biochemical characterization(e.g., (43-45)). To address this, we engineered the
cDNA for the human HCCS in three different vectors (pET Blue-2 with an N-terminal His6 tag,
pTXB1 with a C-terminal Intein fusion, and pGEX with an N-terminal GST fusion) for
expression and purification in E. coli. Early attempts at purifying HCCS from cytoplasmic
fractions were largely unsuccessful for each of the above constructs. However, upon
fractionation of E. coli expressing GST-HCCS, we observed that the membrane fraction
appeared to be enriched for a polypeptide of 57 kDa, the predicted molecular weight for the
GST-HCCS fusion protein (SI Appendix, Fig S1). Thus, we directed our efforts towards
purifying human HCCS from membranes, by solubilization in n-dodecyl β-D-maltopyranoside
(DDM) (Fig 1A, B, C) or Triton X-100. Purified full-length GST-HCCS (~57 kDa) and three
minor proteolytic products each reacted with GST antisera (Fig 1B, lane 9). Note that soluble
(cytoplasmic) fractions contained mostly the degraded products and very low levels of fulllength GST-HCCS (Fig 1B, lane 2). Densitometry analysis indicated that over 98 % of the
purified, Coomassie-stained protein from the membrane fraction was GST-HCCS. Analysis by
LC-MS/MS confirmed that the 57 kDa species was the GST-HCCS fusion protein (SI Appendix,
Fig S2). To test the function of human HCCS, it was co-expressed with an arabinose-inducible
gene encoding the human cytochrome c. Maturation of the 12 kDa holo-cytochrome c (Fig 1D)
confirmed that the GST-HCCS fusion protein was active in heme attachment to cytochrome c
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(see below). Approximately 3-4 mg of human holocytochrome c was produced per liter of E.
coli culture.
Preparations of purified GST-HCCS were tinted red, and heme-staining revealed that
full-length GST-HCCS contained heme (Fig 1C, lane 9). Heme proteins exhibit characteristic
absorptions in the UV and visible regions of the spectrum, referred to as the α, β, and Soret
bands. These spectral features can provide information about the identity of the axial ligands,
and the spin and oxidation states of the heme iron (46). Purified human HCCS showed a Soret
peak at 423 nm and three broad shoulders at 540 nm, 570 nm, and 660 nm (Fig 1E, black line).
Longer wavelength Soret absorptions (like 423 nm) are often characteristic of hexacoordinate,
reduced heme (Fe2+) (46). Addition of the reducing agent sodium dithionite to purified GSTHCCS caused no shift in the Soret maximum. However, the Soret band sharpened (due to loss of
its lower-wavelength shoulder) and absorbance increased, along with the appearance of small
peaks at 559 nm and 530 nm (Fig 1E, red line). These spectral features, in combination with the
556 nm absorption in the reduced pyridine hemochrome spectrum (Fig 1E, inset) (47), are
consistent with non-covalent, or b-type, heme. Since some heme remains with HCCS upon
SDS-PAGE (Fig 1C), we cannot absolutely rule out the possibility that some heme may be
covalently bound. However, our spectral results and the detection of variable amounts of free
heme in heme stains lead us to favor that heme in HCCS is b-type. Addition of the oxidizing
agent ammonium persulfate to purified GST-HCCS caused the Soret band to shift 13 nm to 410
nm, a wavelength typical of hexacoordinate, oxidized heme (Fe3+), and diminished the shoulders
at 540 nm, 570 nm, and 660 nm (Fig 1E, blue line). These observations suggest a mixture of
oxidized heme and hexacoordinate, reduced heme in purified GST-HCCS.
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To further interrogate the heme-binding environment in HCCS, exogenous imidazole was
added to purified GST-HCCS and UV-Vis absorption spectra were recorded. Imidazole is the
side-chain of histidine, and is often used to probe heme-ligand interactions in vitro (e.g., (48,
49)). Upon addition of 100 mM imidazole, the Soret peak shifted from 423 nm to 413 nm (Fig
1F, purple line). Subsequent addition of sodium dithionite to GST-HCCS in the presence of
imidazole (Fig 1F, red line) caused a shift in the Soret from 413 nm to 422 nm, and resulted in
the appearance of pronounced absorptions at 530 nm and 559 nm. These spectral features are
hallmarks of hexacoordinate reduced heme with bis-His axial ligation but are rarely observed in
hemes with His-Cys, His-Tyr, or His-Met axial ligation (50-52). These observations are
consistent with at least one natural histidine axial ligand in HCCS, and an unknown axial ligand
(possibly a small molecule) that can be replaced by exogenous imidazole.
His154 is a heme ligand in HCCS.
There are two histidines (His154 and His211 in human HCCS) conserved in HCCSs from
a wide variety of organisms (SI Appendix, Fig S3). Given the established role of His residues as
axial heme ligands, and our spectroscopic analyses of pure HCCS, we reasoned that one or both
of these histidines might coordinate heme in HCCS. We engineered substitutions of each His
residue and, to test the function of the resulting HCCS variants, co-expressed each with WT
human cytochrome c in E. coli ∆ccm (Fig 2A, top panel). HCCS His154 is essential for heme
attachment; mutation to Ala, Gly, or Tyr completely abolished synthesis of human
holocytochrome c (Fig 2A, top panel, lanes 1-3). For His211, substitutions showed only minor
effects on heme attachment (Fig 2A, top panel, lanes 5-8).
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To further investigate the function of His154, we tested whether the cytochrome c
assembly defect of the His154 mutants could be restored by addition of exogenous imidazole to
E. coli culture. In vivo chemical complementation by imidazole has been used to correct the
heme binding function of histidine mutants for recombinant myoglobin (53), and the cytochrome
c synthetases CcsBA (54) and CcmF (55). Addition of 10 mM imidazole restored the
cytochrome c assembly defects of the H154A and H154G HCCS mutants to approximately 40 %
of WT levels (Fig 2A, bottom panel, lanes 1 and 2) but HCCS H154Y was not corrected (lane 3).
This is consistent with our previous findings on correction of His mutants in CcmF (55), which
showed that amino acids with bulkier side chains (like tyrosine) do not accommodate imidazole
in the heme binding “cavity,” and thus are not functionally complemented. For the His211
substitutions in HCCS, imidazole addition had no effect on cytochrome c assembly (Fig 2A,
bottom panel, lanes 5-8). To directly test whether His154 was required for binding of heme to
HCCS, we expressed and purified the non-functional GST-HCCS(H154A) (Fig 2B and C).
GST-HCCS(H154A) was purified as a stable polypeptide with yields similar to the WT GSTHCCS, but GST-HCCS(H154A) contained no detectable heme by heme stain (Fig 2D, lane 9) or
UV-Vis absorption spectroscopy (Fig 2E, orange line). We conclude that His154 is an axial
ligand to the heme iron in HCCS.
Key determinants in human cytochrome c for maturation by the human HCCS.
To define the apocytochrome c substrate requirements of the human HCCS, we utilized
the IPTG-inducible human GST-HCCS and a compatible, arabinose-inducible pBAD plasmid
carrying the human cytochrome c. Based on previous studies with S. cerevisiae HCCS (see SI
Appendix, Table S1) we focused on several conserved residues in the amino-terminus of the H.
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sapiens cytochrome c (Lys6, Phe11, Cys15, Cys18, and His19; see Fig 3A, bolded residues).
Throughout our report we refer to the initiation methionine of human cytochrome c as residue 1.
Cell extracts of recombinant E. coli expressing both human HCCS and cytochrome c were
assayed for covalent heme attachment (to human cytochrome c) by SDS-PAGE followed by
heme stain (Fig3B, C) and UV-Vis absorption spectroscopy (Fig 3D). In the absence of HCCS,
no holocytochrome c was detected by heme stain (Fig 3B, lane 10) or spectrally (Fig 3D, vector
control). Co-expression of human HCCS and cytochrome c resulted in the production of a 12
kDa holocytochrome c (Fig 3B, lane 11) that showed a UV-Vis absorption spectrum consistent
with covalent heme attachment, based on the typical α maximum at 550 nm (Fig 3D, WT).
Replacement of Lys6 with Ala, Arg, or Asp did not impair maturation of human cytochrome c
(Figs 3B, C, and D). Substitution of Phe11 with Ala impaired heme attachment to cytochrome c
by approximately 75 % relative to WT under these conditions (Figs 3B and C). Human
cytochrome c1 contains a Tyr residue instead of the Phe at this position (Fig 3A); to test whether
Tyr could substitute for Phe in human cytochrome c, we engineered a Tyr substitution at Phe11.
Co-expression of the F11Y variant with human HCCS resulted in levels of heme attachment
equal to WT cytochrome c (Fig 3B and C), and the peak at 550 nm in the UV-Vis absorption
spectrum confirmed covalent heme attachment (Fig 3D). We also engineered substitutions at the
two Cys residues and the single His residue of the CXXCH motif (Cys15, Cys18, and His19) in
human cytochrome c. The C15S and C18A substitutions were matured at approximately 8 %
and < 3 % of WT levels, respectively (Fig 3B and C). Substitution of Ala for His19 resulted in
undetectable levels of cytochrome c (Fig 3B and C).
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Our results with regard to the importance of Phe11 differ somewhat from two previous
studies which showed that an F11A variant of cytochrome c was not detectably matured by S.
cerevisiae HCCS in the E. coli cytoplasm (42, 43). This could be due to the broader substrate
specificity of the human HCCS relative to the S. cerevisiae HCCS. In S. cerevisiae, there are
two related homologs, HCCS and HCC1S, that are dedicated to maturation of cytochrome c and
cytochrome c1, respectively, whereas in humans (and all animals), a single HCCS matures both
the mitochondrial cytochrome c and cytochrome c1.
Requirements for recognition of bacterial cytochromes c by the human HCCS.
Previous studies have shown that S. cerevisiae HCCS is unable to mature certain
bacterial cytochromes c (44) despite the structural and functional similarities to the
mitochondrial cytochrome c (SI Appendix, Fig S4). Recently, it was shown that a chimeric
cytochrome c composed of the N-terminal 18 amino acids of yeast cytochrome c followed by the
C-terminal region of cytochrome c550 from Paracoccus denitrificans (including the CXXCH
motif from P. denitrificans) could be matured by S. cerevisiae HCCS (43). Using the R.
capsulatus cytochrome c2, where the methionine start codon of the human cytochrome c is the
engineered initiation codon (Fig 4A), holo-cytochrome c2 was not detected above background
levels upon co-expression with the human HCCS (Fig 4B, lane 1). A notable difference between
the N-terminal sequences of R. capsulatus cytochrome c2 and human cytochrome c is the amino
acid spacing between the conserved Phe (Phe11 in human cytochrome c) and the CXXCH motif
(refer to boxed region in Fig 4A). To test whether a three-residue spacing is a requirement for
recognition by human HCCS, we engineered an Ala insertion between Asn11 and Lys12 (human
numbering) in R. capsulatus cytochrome c2 and co-expressed it with the human HCCS (in E. coli
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∆ccm). Analysis of cell extracts by heme stain showed that cyt c2(Ala-ins) was also not matured
(Fig 4B, lane 3).
An additional difference between R. capsulatus cyt c2 and human cytochrome c is the
local charge in the region preceding the conserved Phe (Fig 4A); specifically, cytochrome c2
contains two negatively charged Glu residues (Fig 4A, bolded residues). We engineered E8K
and E10I substitutions in the WT cyt c2 and the cyt c2(Ala-ins) variant. Co-expression of cyt
c2(E8K/E10I/Ala-ins) with the human HCCS led to the production of high levels of a 13 kDa
species with covalent heme (Fig 4B, lane 6; Fig 4D). Immunoblotting with cytochrome c2
antisera confirmed that this covalent heme species was R. capsulatus cytochrome c2 (Fig 4C,
lane 7). UV-Vis absorption spectra confirmed covalent heme attachment to cyt
c2(E8K/E10I/Ala-ins) (Fig 4E). Approximately 1-2 mg of holocytochrome c2(E8K/E10I/Alains) was produced per liter of E. coli culture. By contrast, cyt c2(E8K/E10I), containing its
natural two-residue spacing between Phe11 and CXXCH, was not matured (Fig 4B, lane 2; Fig
4D). We also engineered each single Glu substitution into cyt c2(Ala-ins) to generate cyt
c2(E8K/Ala-ins) and cyt c2(E10I/Ala-ins), and although both cyt c2(E8K/Ala-ins) and cyt
c2(E10I/Ala-ins) were matured at higher levels than WT cyt c2 (Fig 4B, lanes 4 and 5; Fig 4D),
neither was as high as the double substitution.
While our manuscript was in preparation, a report was published on the conversion of R.
capsulatus cytochrome c2 into a substrate for S. cerevisiae HCCS (56), with results that are
consistent with our findings utilizing the human HCCS. In their study, a Lys insertion was
engineered (instead of an alanine) and Glu10 was replaced with Leu (instead of Ile). Our results
here indicate that positively charged and neutral residues at positions 8 and 10, respectively, and
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proper spacing between Phe11 and CXXCH, constitute the minimal determinants for maturation
by human HCCS. We describe evolutionary implications of these results in Supporting
Information (see SI Appendix).
HCCS co-purifies with human cytochrome c.
To further investigate interactions between HCCS and the substrate cytochrome c, we coexpressed several of the human cytochrome c variants (F11A, C15S, C18A, H19A) or WT
cytochrome c with the human HCCS and analyzed the soluble and membrane fractions. We
noticed that the detergent-solubilized membrane fractions from cells expressing the C15S or the
C18A cytochrome c variant (along with HCCS) had higher levels of holocytochrome c than the
soluble fractions (see SI Appendix, Fig S5C and D, lanes 3, “L” fractions). Membrane fractions
from cells expressing the WT, F11A or H19A variants of cytochrome c contained low levels of
holocytochrome c (see SI Appendix, Fig S5A, B, E, lanes 3, “L” fractions).
To investigate whether the apparent membrane localization of the cytochrome c variants
was related to the association of HCCS with the E. coli membrane, we purified GST-HCCS and
analyzed each preparation for the presence of the human cytochrome c. In each case, GSTHCCS was purified from detergent-solubilized membranes as a stable polypeptide with minimal
degradation (Fig 5A). In addition to the full-length GST-HCCS fusion protein (~57 kDa) we
observed in the elution fraction a 12 kDa polypeptide of the molecular weight for cytochrome c
(SI Appendix, Fig S6A). Analysis by LC-MS/MS (SI Appendix, Fig S7) and immunoblotting
with cytochrome c antisera (Fig 5B) confirmed that cytochrome c co-purified with GST-HCCS.
Table I quantifies the heme and apocytochrome bound in each complex, and summarizes the
spectral properties of each complex. Heme staining after SDS-PAGE revealed that the WT
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cytochrome c and each of the variants contained heme, although at very low levels for the H19A
variant (Fig 5C). Covalent heme attachment to the 12 kDa cytochrome c was confirmed by
retention of the heme through SDS-PAGE after boiling and treatment with 8 M urea (SI
Appendix, Fig S8). HCCS complexes with C15S and C18A variants contained approximately 8fold more heme than HCCS alone, and the WT, F11A, and H19A complexes contained
approximately 4-fold more heme (Table 1, column C). Total heme in each complex was
proportional to the amount of cytochrome c polypeptide bound in each complex (Table 1,
column B), suggesting that the interaction of HCCS with heme is stabilized by the presence of
the cytochrome c acceptor. To determine the role of heme in formation of the complex between
HCCS and cytochrome c, we investigated whether HCCS(H154A), which is defective in heme
binding (see Fig 2), co-purified with any of the cytochrome c variants. Purified HCCS(H154A)
(Fig 5D) contained no detectable cytochrome c (Fig 5E) or heme (Fig 5F), just as HCCS(H154A)
alone had no heme. The failure of HCCS(H154A) to co-purify with cytochrome c indicates that
heme binding by HCCS (through His154) is a requirement for interaction with the
apocytochrome c.
Spectral analyses of the HCCS:heme:cytochrome c complexes.
UV-Vis spectra were recorded on each of the purified complexes to gain additional
insight into the heme:protein interactions within each complex. In the absence of residue His19
of apocytochrome c (i.e., the HCCS-H19A complex), the UV-Vis absorption spectrum is
reminiscent of the spectrum of HCCS alone, with a Soret absorption at 425 nm and broad
absorptions at 540 nm and 570 nm (Fig 5G, black line). Addition of the reducing agent sodium
dithionite to the purified HCCS-H19A complex caused minor changes in the Soret peak and the
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α-β region of the spectrum (Fig 5G, red line). To further probe ligand interactions in the HCCSH19A complex, we added 100mM imidazole to purified HCCS-H19A and recorded spectra (Fig
5H, purple line). The effect of imidazole addition on heme in the HCCS-H19A complex was
similar to that observed with HCCS alone, with a blue-shift in the Soret band to 418 nm. Upon
addition of sodium dithionite to HCCS-H19A in the presence of imidazole, the Soret band
shifted to 425 nm and pronounced α and β absorptions at 559 nm and 530 nm were observed (Fig
5H, red line). These results suggest that in the HCCS:heme:cytochrome c(H19A) complex,
His154 of HCCS provides one axial ligand and that exogenous imidazole can occupy the second
axial coordination site. In contrast, the spectra of each of the other complexes of cytochrome c
with HCCS (Fig 5I; full spectra are shown in SI Appendix, Fig S9) were markedly different from
that of HCCS alone, and imidazole caused no change in the spectra of these complexes (SI
Appendix, Fig S10). We propose that, in the C15S, C18A, F11A, and WT complexes of
cytochrome c with HCCS, heme is coordinated by His154 of HCCS and His19 of cytochrome c.
To analyze the heme environment in each complex (see Table 1, columns G, H, and I),
we focused on the sodium dithionite-reduced absorptions in the α-β region of the spectrum (500
nm to 600 nm; see Fig 5I), which are diagnostic for covalent heme attachment and ligand
interactions with the heme iron (46). The reduced spectrum of the HCCS-cytochrome c(WT)
complex exhibited α and β maxima at 555 nm and 523 nm, respectively (Fig 5I, purple line).
The complex of HCCS with the F11A variant of cytochrome c showed α and β absorptions at
552 and 524 nm (Fig 5I, orange line). The HCCS-C15S complex exhibited a unique and rare
split α maximum (57) at 555-560 nm and a split β peak at 526-535 nm (Fig 5I, blue line). We
note that a split α absorption has been observed at room temperature for heme in the CcmCDE
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complex (58, 59), where, similarly, there is a single covalent attachment to a heme vinyl and bisHis coordination of the heme iron. The HCCS-C18A complex exhibited a strong α absorption at
561 nm and a β peak at 531 nm (Fig 5I, black line). For the C18A variant, since the α maximum
was atypical for a c-type heme (i.e., 561 nm absorption; Fig 5I, black line) we confirmed
covalent attachment of the heme group to the protein by mass spectrometry, where a trypsinized
peptide corresponding to the heme binding motif of this variant plus covalent heme was detected
(SI Appendix, Fig S11).
Thus, for each complex of cytochrome c with HCCS, there are signature absorptions in
the reduced UV-Vis spectrum that are diagnostic for the specific heme-protein interactions of
that complex. We note that the spectra of the complexes of HCCS with WT cytochrome c and
the C15S variant are markedly different from the spectra that have been reported for released,
mature WT holocytochrome c (41, 44) and site-directed variants of Cys15 (60, 61), respectively.
This supports our contention that the spectra of the complexes are indeed reflective of
interactions with the heme by both the HCCS and the cytochrome c. We propose that these
complexes are isolated, trapped intermediates on the path to full maturation and release of the
human cytochrome c by the human HCCS.
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Discussion
Our results are discussed in the context of four distinct steps in the synthesis of
holocytochrome c by the human HCCS: heme binding, apocytochrome c substrate recognition,
thioether formation, and release of holocytochrome c (Fig 6A). We also address longstanding
questions on the mechanisms of heme binding by HCCS and the roles of individual residues in
both HCCS and the apocytochrome c substrate. A major conclusion is that heme is the central
molecule mediating interaction between HCCS and apocytochrome c.
Step 1. Heme binding by HCCS.
The human HCCS is purified from membrane fractions as a full-length GST fusion
protein with endogenous heme. Given that the function of HCCS is to covalently attach heme to
apocytochrome c, heme binding by this enzyme has long been suspected (34, 36, 62) but has
never been shown directly. Spectral studies provided insight into the HCCS heme-binding
environment, suggesting that one ligand to the heme iron was a histidine and that the second
axial coordination site was occupied by an unknown ligand that could be replaced by exogenous
imidazole in vitro. Various approaches were used to demonstrate that residue His154 in HCCS
was an axial ligand to the heme in HCCS (Fig 2). First, HCCS(H154A) did not purify with
heme. Additionally, HCCS(H154A) was not functional in holocytochrome c synthesis, but
activity was corrected in vivo by addition of exogenous imidazole. Finally, HCCS(H154A) did
not form ternary complexes with heme and cytochrome c (Fig 5). We therefore conclude that it
is the heme-bound form of HCCS to which apocytochrome c binds (see step 2).
Step 2. Recognition of apocytochrome c by HCCS:heme.
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We undertook two approaches to define the substrate determinants in the apocytochrome
c that the human HCCS requires for formation of a mature holocytochrome c. The first was to
identify key residues in the N-terminus of the cognate human apocytochrome c that were
required for holocytochrome formation, and the second was to convert a non-substrate bacterial
cytochrome c (R. capsulatus cytochrome c2) into a substrate for the human HCCS. For the
human apocytochrome c, residues Phe11, Cys15, Cys18, and His19 were important (although to
differing degrees) for optimal holocytochrome c maturation (Fig 3C). Maturation of cytochrome
c2 by HCCS required insertion of an Ala residue between Phe11 and Cys15 and substitution of
Glu residues 8 and 10 (Fig 4). Predicted structures of the cytochrome c2 N-terminus demonstrate
that the Ala insertion significantly repositions Phe11 and the two Glu residues (SI Appendix,
compare Fig S12A to B); therefore, both amino acid spacing and charge (SI Appendix, compare
Fig S12A to C) are critical for heme attachment by HCCS. Fig 6B shows the predicted structure
of the first twenty residues in the human apocytochrome c, with each of the critical determinants
highlighted.
We gained remarkable insight into HCCS substrate recognition when we discovered that
each human cytochrome c variant (F11A, C15S, C18A, H19A) co-purified with HCCS (Fig 5
and Table 1). Each of the HCCS:heme:cytochrome c complexes comprised a unique heme
environment (Fig 5F), suggesting that each variant complex represented a distinct, intermediate
in maturation. Thus, these variants are not defective in step 2 (recognition by and binding to
HCCS:heme) but are defective in a later step in maturation, as described below. Our results are
consistent with prior genetic studies in yeast, where a class of mutant apocytochromes c
(including variants at Cys15, Cys18, and His19) were found to be competent for mitochondrial
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import (in an HCCS-dependent manner), and therefore were still recognized by HCCS, but were
not matured into holocytochromes c (63).
Fig 6C diagrams the central role of heme in the formation of the complex of HCCS (blue)
with the apocytochrome c N-terminus (PEP-FOLD generated structure, green). Each complex of
HCCS with apocytochrome c (including HCCS-H19A) contained more total heme than HCCS
alone (Table 1, column C). This indicates that apocytochrome c binding stabilizes heme in the
HCCS:heme:cytochrome c ternary complex (Fig 6A, step 2). His19 of the apocytochrome
CXXCH supplies the 2nd axial ligand to heme iron in the complex with HCCS, and HCCS
His154 provides the first (Fig 6C). This is suggested by spectral analyses of the
HCCS:heme:cytochrome c(H19A) complex compared to those of the complexes with WT and
other cytochrome c variants. That the HCCS:heme:cytochrome c(H19A) complex contained
more total heme than HCCS alone further indicates that other residues in apocytochrome c (in
addition to His19) likely interact with heme. The spectral features and biochemical
characterization of these ternary complexes also inform us of the later steps in holocytochrome c
synthesis.
Step 3. Formation of thioether bonds.
Each of the complexes of cytochrome c with HCCS contained at least WT-levels of
covalent 12 kDa heme, with the exception of the H19A variant (Table 1, column D). While
heme in the complex with HCCS was still stabilized by binding of cytochrome c(H19A) (Table
1, column C), thioether formation was very low for this variant. We conclude that His19 of
CXXCH in the apocytochrome c is essential for efficient thioether formation. We propose that
coordination of the heme iron by His19 in the HCCS:heme:cytochrome c complex positions the
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two cysteines for stereospecific ligation to reduced (Fe2+) heme, preparing it for thioether bond
formation. This is consistent with the effect of exogenous imidazole on the heme environment in
the HCCS:heme:cytochrome c(H19A) complex, as described in results (Fig 5H and I). The
essential role of His19 in step 3 is further supported by the complete absence of released
holocytochrome c(His19) (Table 1, column E; Fig 3B and C).
Holocytochromes C15S and C18A were bound to HCCS at steady-state levels two-fold
higher than the WT holocytochrome c (Table 1, columns B and D). Since the levels of mature
holocytochrome c were very low relative to WT (8 % for C15S and < 3 % for C18A), it appears
that these variants are trapped in HCCS, unable to undergo release. Thus, covalent bond
formation at both cysteines appears to be required for efficient release from HCCS.
Interestingly, Wang and colleagues (1996) observed a class of mutant apocytochromes c
(including variants in the Cys residues of CXXCH) whose expression inhibited the maturation of
normal cytochrome c when co-expressed in S. cerevisiae. They speculated that this class of
variant apocytochromes might be forming “dead-end” complexes with HCCS. Here, we show
that the Cys variant apocytochromes are indeed bound in non-productive complexes with HCCS,
consistent with the “dominant” cytochrome c variants observed in the aforementioned study. It
is striking that the ratio of released to “trapped” WT cytochrome c is one hundred times higher
(than the C18A variant), highlighting the consequences of thioether formation for full release and
maturation. Additionally, that both the C15S and C18A single-cysteine complexes contained
covalent heme suggests that there may not be a preferred order for thioether formation.
Step 4. Release of holocytochrome c from the complex.
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In addition to the requirement for formation of two thioether bonds (step 3), optimal
production of mature holocytochrome c requires a mechanism for release from HCCS (Fig 6A).
A number of studies on mitochondrial import of apocytochrome c in whole yeast cells (30, 33,
63) and in isolated yeast mitochondria (31, 64) have concluded that apocytochrome residues
important for heme attachment may only represent a subset of residues involved in mitochondrial
import. Thus, there are likely multiple residues in the apocytochrome (in addition to Phe11,
Cys15, Cys18, and His19) that mediate interaction with HCCS:heme. We propose that a
dedicated release mechanism (step 4) is essential for the cognate human holocytochrome c
because of multiple, stable interactions between HCCS:heme and the apocytochrome that are
related to HCCS-mediated import of the apocytochrome c into the mitochondrion.
Binding of the human HCCS to its cognate cytochrome c in the ternary complex is
surprisingly stable, as demonstrated by the fact that the HCCS:heme:cytochrome c complex can
be purified (in the oxidized state) and maintained in vitro. We speculate that, in the cell, the
proper milieu (e.g., reducing environment) promotes folding of the WT holocytochrome c, which
provides the energy to release heme (and the holocytochrome) from the HCCS active site.
Although we have not addressed the mechanisms in step 4 directly in our study, a rich history
exists on the analysis of holocytochrome c folding in vitro, which is useful to consider here. For
example, reduced cytochrome c (Fe2+) shows a notable difference in folding relative to oxidized
cytochrome c (Fe3+), exhibiting greater stability towards denaturation (65). Even the binding of
small axial ligands like carbon monoxide, which can replace the natural methionine axial ligand,
has significant impacts on the folding and unfolding processes (66). Thus, the importance of
reduced heme (Fe2+) both for thioether formation and holocytochrome c release might be
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considered for HCCS-mediated cytochrome c maturation. Possible factors involved in this
reduction in mitochondria have been described (24). Release of holocytochrome c from the
ternary complex clearly demands that HCCS axial ligand His154 be discharged from the heme
iron (Fig 6C), which may be facilitated by interaction of the heme with other residues in the
cytochrome c during folding. Although the second axial coordination site in mature
holocytochrome c is occupied by Met81 (Fig 6D), there is ample evidence that this Met residue
can be replaced and still yield mature cytochrome c (67). Therefore, other residues in
cytochrome c may play a role, during folding, in displacing HCCS His154 from the heme.
Besides a molecular understanding of the mechanisms underlying HCCS function, our study
provides the foundation for future analyses of other key residues in the human HCCS and the
cytochrome c, and the framework for delineating the steps in which those residues are involved.
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Materials and Methods
Bacterial Growth Conditions. Escherichia coli strains (SI Appendix, Table S2) were grown at
37oC in Luria-Bertani broth (LB; Difco) supplemented with the appropriate antibiotics (SigmaAldrich) and other media additives at the following concentrations, unless otherwise noted:
carbenicillin, 50 µg ml-1; chloramphenicol, 20 µg ml-1; isopropyl-β-D-thiogalactopyranoside
(IPTG, Gold Biotechnology), 0.1 mM; arabinose (Gold Biotechnology), 0.2 % (w/v).
Protein Expression and Purification. For HCCS expression (with or without co-expression of
cytochrome c), E. coli ∆ccm strain RK103 (68) or RK112 (69) was used. Starter cultures were
initiated from a single colony and grown overnight at 37oC with shaking at 200 rpm in 100 mL
of LB with the appropriate antibiotics. 1 L of LB was inoculated to 10 % and was grown with
shaking at 120 rpm for 1 hr (OD600 < 1.0), at which point the culture was induced with 0.1 mM
IPTG for pET Blue-2, pTXBI, or pGEX-based expression for 5 hr. For co-expression of pBADbased cytochrome c, the culture was induced with 0.2 % arabinose (w/v) 3 hr after inoculation (2
hr after induction of HCCS expression) and grown 3 additional hr. Cells were harvested at 5,000
x g for 10 min and frozen at -80oC overnight. Cell pellets were thawed and resuspended in
phosphate-buffered saline (100 mM NaCl, 7.5 mM Na2HPO4, 2 mM NaH2PO4) and treated with
phenylmethanylsulfonylfluoride (PMSF, Sigma-Aldrich; 1 mM) and egg white lysozyme
(Sigma-Aldrich; 100 µg ml-1) for 30 min while shaking on ice. Cells were disrupted by repeated
sonication for 30 sec bursts with a Branson 250 sonicator (50% duty, 60% output) until clearing
of the suspension was observed. Crude sonicate was centrifuged at 24,000 x g for 15 min to
clear cell debris, and membranes were isolated by centrifugation at 100,000 x g for 45 min.
Membrane pellets were solubilized in a modified 1 x glutathione S-transferase (GST) buffer (150
196

mM NaCl, 50 mM Tris, pH 8; Pierce) with 1 % (w/v) n-dodecyl maltopyranoside (DDM,
Anatrace) or Triton X-100 (Sigma-Aldrich) on ice for 1 hour. Detergent-solubilized membranes
were centrifuged at 24,000 x g for 15 min to remove unsolubilized material. Solubilized
membranes (L; load) were passed over glutathione agarose (Pierce) per the manufacturer’s
recommendations and washed in 1 x modified GST buffer with 0.02 % (w/v) DDM or Triton X100. Bound GST-tagged protein was eluted in 1 x modified GST buffer containing 0.02 % (w/v)
DDM or Triton X-100 and 20 mM reduced glutathione (E; elution). The purified protein was
concentrated and subjected to buffer exchange in an Amicon Ultra Centrifugal Filter 30,000
MWCO (Millipore) after purification (called “EC”; concentrated elution). Total protein
concentration was determined using the Bradford Reagent (Sigma-Aldrich) per the
manufacturer’s instructions and samples were measured with a PowerWave XS2 Microplate
Spectrophotometer (BioTek).
Cytochrome Reporter and Imidazole Complementation Assays. Human holocytochrome c and R.
capsulatus holocytochrome c2 production were assayed in RK103 (68) harboring pGEX:GSTHCCS and one of the following pBAD-based plasmids (human cytochrome c: K6A, K6R, K6D,
F11A, C15S, C18A, H19A, WT; R. capsulatus cytochrome c2: c2(WT), c2(Ala-ins), c2(E8K/Alains), c2(E10I/Ala-ins), c2(E8K/E10I), c2(E8K/E10I/Ala-ins); see Table S2). Cultures were grown
at 37oC with shaking at 200 rpm in 5 mL LB with appropriate antibiotics for 3 hr and induced for
an additional 3 hr with 0.8 % arabinose (w/v) and 1 mM IPTG. Cells were harvested by
centrifugation at 10,000 x g and the cell pellet was resuspended in 200 µL of BPER (Thermo
Scientific) to lyse cells and extract protein. Total protein concentration was determined using the
Nanodrop 1000 spectrophotometer (Thermo Scientific) and 100 µg was analyzed by SDS-PAGE
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followed by heme stain. Imidazole complementation assays were performed in the same way
with the exception that 10 mM imidazole (pH 7) was added to culture prior to inoculation.
Heme stains and other methods. Heme stains and immunoblots were performed as described in
(70). BPER fractions were mixed 1:1 (v/v) with loading dye without reducing agents and boiled
for 5 min and were separated by 12.5 % SDS-PAGE and transferred to Hybond C nitrocellulose
membranes (GE Healthcare). Purified proteins (unboiled) were mixed 1:1 (v/v) with loading dye
without reducing agents prior to separation by 12.5 % SDS-PAGE and transfer to nitrocellulose.
Antiserum to human cytochrome c (Santa Cruz) was used at a dilution of 1:5000. Anti-GST
antibody (Sigma-Aldrich) was used at a dilution of 1:10000. Protein A peroxidase (SigmaAldrich) was used as the secondary label. The chemiluminescent signal for heme stains and anticytochrome c immunoblots was developed with the SuperSignal Femto kit (Thermo Scientific),
or the Immobilon Western kit (Millipore) for anti-GST immunoblots. Chemiluminescent signal
was detected with the LAS-1000 Plus detection system (Fujifilm-GE Healthcare) or the
ImageQuant LAS-4000 Mini detection system (Fujifilm-GE Healthcare). Heme concentration in
purified preparations was determined by pyridine extraction as described in (47), heme stain as
described in (71), or quantification of the indicated UV-Vis spectral absorptions. The relative
abundances of purified GST-HCCS and co-purified human cytochrome c were quantified by
densitometry analysis of the chemiluminescent signal from anti-GST and anti-cytochrome c
immunoblots, respectively, and normalized to WT levels. Protein purity was assessed by
Coomassie Blue staining of SDS-PAGE.
UV/Vis absorption spectroscopy. UV-Visible absorption spectra were recorded with a Shimadzu
UV-2101 PC UV-Vis scanning spectrophotometer at room temperature as described in (54). All
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spectra were recorded in same buffer in which the proteins were purified: 150 mM NaCl, 50 mM
Tris pH 8, 0.02 % (wt/vol) DDM or Triton X-100. Chemical reduction and oxidation of samples
was achieved by addition of several grains of sodium ditihionite (sodium hydrosulfite) or
ammonium persulfate, respectively. To analyze the effect of imidazole on the electronic
spectrum, small quantities of a concentrated imidazole solution (1 M, pH 7) were added to
purified protein and spectra were recorded.
Three-dimensional models. Three-dimensional models of the N-terminus of human cytochrome
c and the cytochrome c2 variants from Rhodobacter capsulatus were generated by PEP-FOLD,
an online resource for de novo three-dimensional peptide structure prediction (72, 73)
(http://bioserv.rpbs.univ-paris-diderot.fr/PEP-FOLD). Each of the peptides shown represents the
lowest energy conformation of the five structures generated by PEP-FOLD. X-ray crystal
structures for E. caballus cytochrome c (pdb HRC1) and R. capsulatus cytochrome c2 (pdb 1c2r)
were obtained from the RCSB Protein Data Bank (http://www.rcsb.org/pdb/home/home.do).
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Figures
Fig 1. Purified HCCS is a heme protein.
(A) Coomassie blue stain of purified GST-tagged HCCS showing 57 kDa full-length GSTHCCS. (B) anti-GST immunoblot of purified GST-tagged HCCS showing 57 kDa full-length
GST-HCCS, 44 kDa GST-HCCS**, 32 kDa GST-HCCS*, and 29 kDa GST. (C) Heme stain of
purified 57 kDa full-length GST-HCCS. For (A), (B), and (C) abbreviations are: CS, crude
sonicate; S, soluble fraction; L, load (DDM-solubilized membranes); FT, flow through; W1,
wash 1; W2, wash 2; W3, wash3; E, elution; EC, concentrated elution; M, molecular weight
standards. (D) Heme stain of cytoplasmic extracts (BPER) showing synthesis of the human
holocytochrome c as a function of HCCS expression and arabinose concentration. 12 kDa
holocytochrome c is indicated by arrows. 100 µg of total protein was loaded in each lane. For
(C) and (D), pre-stained molecular weight standards were overlaid in red onto the heme stains.
(E) UV-visible absorption spectra of purified GST-HCCS (black line), reduced with sodium
dithionite (red line), or oxidized with ammonium persulfate (blue line). Inset, sodium dithionitereduced pyridine hemochrome spectrum of purified GST-HCCS from 500 nm to 600 nm. (F)
UV-visible absorption spectra of purified GST-HCCS (black line), in the presence of imidazole
(purple line), and in the presence of imidazole reduced with sodium dithionite (red line). For (E)
and (F), the region from 500 nm to 700 nm has been multiplied by a factor of three. Absorption
maxima are indicated by arrows.
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Fig 2. HCCS His154 is a heme ligand.
(A) Heme stain of cell extracts (BPER) showing covalent 12 kDa holocytochrome c assembled
by WT and site-directed mutants of HCCS in the E. coli cytoplasm in the absence (top panel) or
presence (bottom panel) of 10 mM imidazole added to culture. His154 was changed to Ala (lane
1), Gly (lane 2), or Tyr (lane 3); His211 was changed to Ala (lane 5), Gly (lane 6), Tyr (lane 7),
or Cys (lane 8). Additional labels: WT, wild type; VC, vector control, M, molecular weight
standards. (B) Coomassie blue stain showing purified 57 kDa full-length GST-tagged
HCCS(H154A). (C) anti-GST immunoblot showing 57 kDa full-length GST-tagged
HCCS(H154A), 44 and 32 kDa degradation products, and 29 kDa GST. (D) Heme stain of
purified 57 kDa full-length GST-HCCS. For (B), (C), and (D) abbreviations are as follows: CS,
crude sonicate; S, soluble fraction; L, load (DDM-solubilized membranes); FT, flow through;
W1, wash 1; W2, wash 2; W3, wash3; E, elution; EC, concentrated elution; M, molecular weight
standards. For (A) and (D), pre-stained molecular weight standards were overlaid in red onto the
heme stains. (E) UV-visible absorption spectra of purified GST-HCCS(H154A) (orange line),
shown with the spectrum of purified GST-HCCS(WT) (black line).
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Fig 3. Maturation determinants in human cytochrome c.
(A) Amino acid sequence alignment of the region encompassing the heme attachment site
(CXXCH) for the indicated cytochromes c and c1. The amino acids mutated in this work are
bolded and indicated by arrows; numbering begins at the N-terminal Met in H. sapiens
cytochrome c. (B) Representative heme stain of BPER extracts showing synthesis of 12 kDa
WT holocytochrome c and the indicated cytochrome c variants by the human HCCS; WT, wild
type; VC, vector control, M, molecular weight standards. 100 µg of total protein was loaded in
each lane. Pre-stained molecular weight standards were overlaid in red onto the heme stain. (C)
Quantification of the results of heme staining of BPER extracts from three independent
experiments. Percent heme attachment for each variant is relative to synthesis of WT
cytochrome c, which has been set at 100 %. Error bars denote standard deviation. (D) UV-Vis
absorption spectra of BPER extracts from cells expressing HCCS along with the indicated
cytochrome c variant.
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Fig 4. Sequence requirements for maturation of bacterial cytochrome c2.
(A) Amino acid sequence alignment of the N-terminal region (including CXXCH) for the
indicated cytochromes c and cytochrome c2 variants. The amino acids mutated in this work are
bolded and indicated by arrows. The boxed region corresponds to the location of the Ala
insertion; numbering refers to the H. sapiens cytochrome c N-terminal Met. (B) Representative
heme stain and (C) anti-cytochrome c2 immunoblot of BPER extracts showing synthesis of the
indicated 12 kDa cytochrome c2 variants; M, molecular weight standards. 100 µg of total protein
was loaded in each lane. Pre-stained molecular weight standards were overlaid in red onto the
heme stain. (D) Quantification of the results of heme staining of BPER extracts from three
independent experiments. Percent heme attachment for each indicated variant is relative to
synthesis of cytochrome c2(E8K/E10I/Ala-ins), which has been set at 100 %. Error bars denote
standard deviation. (E) UV-Vis absorption spectra of whole cell extracts expressing HCCS and
the indicated cytochrome c2 variant. Absorption maxima are indicated by arrows.
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Fig 5. Cytochrome c co-purifies with HCCS.
(A) Anti-GST immunoblot showing full-length 57 kDa GST-HCCS, (B) anti-cytochrome c
immunoblot showing 12 kDa cytochrome c, and (C) heme stain showing 12 kDa
holocytochrome c, from elution fractions of co-purifications of each cytochrome c variant with
GST-HCCS(WT). (D) Anti-GST immunoblot showing full-length 57 kDa GST-HCCS, (E) anticytochrome c immunoblot, and (F) heme stain, from elution fractions of co-purifications of each
cytochrome c variant with GST-HCCS(H154A). For (A)-(F), 5 µg of purified total protein was
loaded in each lane. See Fig S6 for full panels. For (C) and (F), pre-stained molecular weight
standards were overlaid in red onto the heme stains. (G) UV-visible absorption spectra of GSTHCCS co-purified with cytochrome c(H19A) (black line) and reduced with sodium dithionite
(red line). (H) UV-visible absorption spectra of GST-HCCS co-purified with cytochrome
c(H19A) (black line), in the presence of imidazole (purple line), and in the presence of imidazole
reduced with sodium dithionite (red line). The region from 500 nm to 700 nm has been
multiplied by a factor of three. (I) The α-β region showing the characteristic sodium dithionitereduced UV-visible absorption spectrum for each indicated cytochrome c variant co-purified
with GST-HCCS. Spectra have been offset for clarity. Absorption maxima are indicated by
arrows.
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Fig 6. Steps in the maturation of cytochrome c by human HCCS.
(A) Diagram depicting the 4 steps in holocytochrome c maturation by HCCS (discussed in text).
(B) PEP-FOLD generated model of the N-terminal 20 amino acid helix in human cytochrome c
before interaction with HCCS. Amino acids important for maturation are indicated by arrows.
Selected oxygen atoms are shown in red, nitrogens in blue, sulfurs in yellow, the heme
macrocyle is in pink, and the Fe atom at the heme center is orange. (C) The
HCCS:heme:cytochrome c complex (modeled with heme, pink) before thioether formation.
Heme is coordinated by His19 of apocytochrome c (PEP-FOLD ribbon diagram, green, as in B)
and His154 of HCCS (overlaid cartoon, blue). Amino acids and heme vinyls important for
maturation are indicated by arrows. (D) The N-terminal 20 amino acids from the X-ray crystal
structure of mature, released E. caballus holocytochrome c (pdb HRC1). Amino acids important
for maturation are indicated by arrows. Heme is coordinated by His19, as in the complex with
HCCS, and cytochrome c Met81, which replaces HCCS His154 in the folded, released
holocytochrome c. PyMOL was used for displays in B, C, and D. Amino acid numbering refers
to the H. sapiens cytochrome c N-terminal Met, as shown in Fig 3A (because the initiation Met
is processed off, pdb HRC1 refers to Lys8 as Lys7, His19 as His18, Met81 as Met80, etc).
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Table 1. Characterization of the complexes of HCCS with cytochrome c
A

HCCS
alone

B

C

D

E

F

G

H

I

Released
holo-cyt
c3

Reduced α
band
absorption4

2nd heme
axial
ligand5

1st heme
axial
ligand5

Thioether
bond
formation5

--

559

HCCS
His154

Unknown

None

cyt c His19

GSTHCCS
levels1

CYCS
bound (in
complex)1

Total
heme (in
complex)2

Covalent
12 kDa
heme (in
complex)3

1.01 ±
0.04

--

0.27 ± 0.09

--

Cys15-2vinyl
Cys18-4vinyl
Cys15-2vinyl
Cys18-4vinyl

HCCS +
cyt
c(WT)

1

1

1

1

1

555

HCCS
His154

HCCS +
cyt
c(F11A)

1.03 ±
0.14

0.94 ± 0.14

0.83 ± 0.13

1.02 ± 0.02

0.25 ±
0.05

552

HCCS
His154

cyt c His19

HCCS +
cyt
c(C15S)

1.00 ±
0.11

2.07 ± 0.10

1.84 ± 0.01

2.22 ± 0.24

0.08 ±
0.03

555/560 split

HCCS
His154

cyt c His19

Cys18-4vinyl

HCCS +
cyt
c(C18A)

0.98 ±
0.16

1.97 ± 0.07

1.93 ± 0.08

2.24 ± 0.36

0.03 ±
0.01

561

HCCS
His154

cyt c His19

Cys15-2vinyl

HCCS +
cyt
c(H19A)

1.00 ±
0.15

0.83 ± 0.02

0.89 ± 0.01

0.25 ± 0.10

Not
detected

559

HCCS
His154

Unknown

Mature
cyt c
(WT)

--

--

--

--

--

550

Met80

His19

Cys15-2vinyl
Cys18-4vinyl
Cys15-2vinyl
Cys18-4vinyl

Each value is relative to the complex of HCCS with WT cytochrome c, which has been set at 1, and is based on at least three separate
experiments.
1

The amount of GST-HCCS and CYCS protein in each complex was calculated by densitometry analysis of the chemiluminescent signal from

anti-GST and anti-cytochrome c immunoblots, respectively.
2

Total heme in each complex was calculated from the Soret absorption in the UV-Vis absorption spectrum and adjusted for total protein

concentration.
3

Covalent 12 kDa heme in each complex and released holocytochrome c in BPER fractions were calculated by densitometry analysis of the

chemiluminescent signal from heme stains.
4

The reduced α absorption (nm.) for each complex is from the UV-Vis absorption spectrum in the presence of sodium dithionite.

5

The axial ligands to the heme in each complex and thioether formation between the Cys residues in the cytochrome c and the heme vinyls are

based on experimental data shown here.
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Supporting Materials and Methods
Construction of strains and plasmids. All oligonucleotide primer sequences, plasmids, and
strains are given in Supplemental Table 2. E. coli strains TB1 and HB101 were used as host
strains for cloning. To generate N-terminal hexahistidine-tagged HCCS, the human HCCS gene
was PCR amplified from a cDNA clone (Origene) as described previously (1), digested, and
ligated into the NcoI and HindIII sites in pET Blue-2 (EMD Biosciences) to generate pRGK402.
To generate N-terminal GST-tagged HCCS, the human HCCS gene was PCR amplified from
pRGK402, digested and ligated into the EcoRI and XhoI sites in pGEX 4T-1 (GE Healthcare) to
generate pRGK403. To generate C-terminal Intein-tagged HCCS, the human HCCS gene was
PCR amplified from pRGK402, digested, and ligated into the NdeI and SapI sites in pTXB21
(NEB) to generate pRGK404. The human cytochrome c gene (CYCS) was PCR amplified from
cDNA clone MGC12367 (ATCC), digested, and ligated into the EcoRI and PstI sites in
pRGK330 (2) to generate pRGK405. The cytochrome c2 gene from Rhodobacter capsulatus
(CYCA) was PCR amplified from pRGK389 (1), with an engineered initiation codon to exclude
the native periplasmic signal sequence as depicted in Figure 4, digested, and ligated into the
NcoI and XbaI sites of pRGK330 (2) to generate pRGK406. All nucleotide substitutions and
insertions were engineered using the QuikChange I Site-Directed Mutagenesis Kit (Agilent
Technologies) per the manufacturer’s recommendations, and oligonucleotides were synthesized
by Sigma-Aldrich. Each of the final constructs was sequenced to verify the mutation(s).
Proteomics analysis. Identification of GST-HCCS and co-purified cytochrome c was achieved
by ESI-MS by the Donald Danforth Plant Science Center Proteomics and Mass Spectrometry
Facility. Briefly, Coomassie-blue stained bands corresponding to 57 kDa GST-HCCS and the
co-purified 12 kDa cytochrome c for the WT, C15S, and C18A variants were excised, washed
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and digested with trypsin overnight. Tryptic peptides were run on a 1hr gradient LC-MS/MS
using an LTQ-Orbitrap. The data was searched using Scaffold (for GST-HCCS) or Mascot (for
the cytochrome c variants) against a custom database including the sequences provided for each
of the cytochrome c variants and the following variable modifications: deamidation on Asn and
Glu, pyroglutamate formation, glutathione and heme on Cys, and Met oxidation. To confirm
covalent heme attachment to the C18A variant of cytochrome c, the 12 kDa band corresponding
to cytochrome c was excised, washed, and digested with trypsin overnight as described in (3).
Digested samples were subjected to matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) using an IonSpec ProMALDI FT-MS 7.4 T mass spectrophotometer by the
Washington University in St. Louis NCRR Mass Spectrometry Facility.
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Supporting Figure Legends
Figure S1. Full-length GST-HCCS localizes largely to the membrane. Anti-GST immunoblot
showing cleared sonicate (CS), soluble (S) and DDM-solubilized membrane (M) fractions from
E. coli cells expressing N-terminal GST-tagged HCCS. Note the increase in full-length 57 kDa
GST-HCCS in the DDM-solubilized membrane fraction (M, lane 3) relative to the soluble
fraction (S, lane 2).
Figure S2. Identification of purified human HCCS by mass spectrometry. The results of LCMS/MS on trypsin-digested, full-length 57 kDa GST-HCCS. 23 unique peptides were identified
corresponding to human HCCS covering 57 % of the HCCS protein sequence. The sequence of
each unique peptide along with the modification and the mass (in Daltons) is given.
Figure S3. Multiple sequence alignment of HCCS and HCC1S genes from Homo sapiens,
Saccharomyces cerevisiae, Mus musculus, Caenorhabditis elegans, Drosophila melanogaster,
Plasmodium falciparum, Dictyostelium discoideum, Volvox carteri, Chlamydomonas reinhardtii,
and Neurospora crassa. Two histidine residues (boxed, arrows), His154 and His211 in the
human HCCS, are completely conserved.
Figure S4. The X-ray crystal structures of (A) E. caballus cytochrome c (pbd HRC1) and (B) R.
capsulatus cytochrome c2 (pdb 1c2r) exhibit similar three-dimensional folding (4). Selected
oxygen atoms are shown in red, nitrogens in blue, sulfurs in yellow, the heme macrocyle is in
pink, and the Fe atom at the heme center is orange. Note the similar three-dimensional
localization of the indicated residues (arrows) with respect to the heme group in the two
structures. With the exception of R. capsulatus cytochrome c2 Met95, amino acid designations
in (A) and (B) refer to the H. sapiens cytochrome c N-terminal Met, as in Fig 3 and 4A (even
though the initiation Met is cleaved off). PyMOL was used for displays.
Figure S5. Human cytochrome c variants co-purify with GST-HCCS. Heme stains showing the
co-purification of each cytochrome c variant (WT, F11A, C15S, C18A, and H19A) with GSTHCCS. CS, cleared sonicate; S, soluble fraction; L, load (detergent-solubilized membranes);
W1-W3, wash 1-wash 3; E, elution; M, molecular weight standards. In all cases, 12 kDa
cytochrome c co-purified with HCCS (E, lanes 7). 12 kDa holocytochrome c is indicated by
arrows. Note the abundance of holocytochrome c in the detergent-solubilized membrane
fractions (L, lanes 3) and in the subsequent purified elution fractions (E, lanes 7) for the C15S
and C18A variants relative to that in the soluble fractions (S, lanes 2). Relative levels of
holocytochrome c bound to HCCS are shown in Fig 5A and quantified in Table 1.
Figure S6. Analysis of GST-HCCS and co-purified human cytochrome c. (A) Coomassie stain
showing concentrated elution fractions for each of the complexes of HCCS with cytochrome c.
Full-length 57kDa GST-HCCS and the co-purified 12 kDa cytochrome c variants are indicated
by arrows. Note the abundance of the C15S and C18A variants relative to the WT, F11A, and
H19A variants, quantified in Table 1. (B) Coomassie stain, (C) anti-GST immunoblot, and (D)
heme stain showing a representative co-purification of a cytochrome c variant (C18A) with GSTHCCS. Note the absence of the 12 kDa cytochrome c in the wash fractions of the heme stain
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(panel D, lanes 5-7), indicative of a stable interaction between the co-purified cytochrome c and
HCCS.
Figure S7. Identification of co-purified cytochrome c by mass spectrometry. The results of LCMS/MS identifying WT, C15S, and C18A variants of cytochrome c co-purified with GSTHCCS. These data confirmed that the 12 kDa species co-purified with HCCS were variants of
human cytochrome c. The sequence of each unique peptide along with the modification and the
mass (in Daltons) is given.
Figure S8. Heme is stably attached (covalent) to the co-purified cytochrome c. Anti-GST
immunoblot, anti-cytochrome c immunoblot, and heme stain of purified elution fractions for
each cytochrome c variant co-purified with HCCS(WT) comparing unboiled samples (lanes 2-7)
to those boiled and treated with 8 M urea (lanes 9-14). The full-length 57 kDa GST-HCCS and
12 kDa cytochrome c (apo- and holo- forms) are indicated by arrows. Boiling and treatment
with 8 M urea did not remove the heme from the co-purified cytochrome c variants, suggesting
that heme binding to cytochrome c in the complex with HCCS is covalent.
Figure S9. Spectroscopic analyses of the indicated HCCS:heme:cytochrome c complexes. UVVis absorption spectra (360 nm-700 nm) for the complexes of HCCS with (A) WT, (B) F11A,
(C) C15S, and (D) C18A cytochrome c variants. Maxima are indicated by arrows, and the
region from 500 nm to 700 nm has been multiplied by a factor of three.
Figure S10. Spectroscopic analyses of the indicated HCCS:heme:cytochrome c complexes in
the presence of imidazole. UV-Vis absorption spectra (360 nm-700 nm) for the complexes of
HCCS with (A) WT, (B) F11A, (C) C15S, and (D) C18A cytochrome c variants in the presence
of imidazole (100 mM). Imidazole addition did not alter the spectra of any complex of HCCS
with cytochrome c, with the exception of the H19A variant (Figure 5B). Maxima are indicated
by arrows, and the region from 500 nm to 700 nm has been multiplied by a factor of three.
Figure S11. Heme is covalently attached to the HCCS-co-purified cytochrome c(C18A) variant.
The results of MALDI-TOF mass spectrometry on trypsin-digested 12 kDa C18A cytochrome c
variant co-purified with HCCS. The peak corresponding to the species with mass of 1617.381
Daltons was within 0.3 Daltons of the calculated neutral monoisotopic mass predicted for a
covalent heme-containing peptide of the mutated heme binding motif in the C18A variant of
cytochrome c (CSQAHTVEK). The presence of this species indicates that heme is bound
covalently to the C18A variant of cytochrome c (through Cys15) in the complex with HCCS.
Figure S12. Predicted structural outcomes of the R. capsulatus cytochrome c2 variants
engineered in this study. Comparison of the PEP-FOLD-generated three-dimensional structures
of the N-termini (19-20 residues) of (A) WT R. capsulatus cytochrome c2 (B) cyt c2(Ala-ins) and
(C) cyt c2(E8K/E10I/Ala-ins). Selected oxygen atoms are shown in red, nitrogens in blue, and
sulfurs in yellow. Each structure has been oriented such that residue Cys15 is in the same
position. Amino acids important for maturation are indicated by arrows. For clarity, amino acid
designations refer to the H. sapiens cytochrome c N-terminal Met. Neither WT cyt c2 nor cyt
c2(Ala-ins) were detectably matured by human HCCS, while cyt c2(E8K/E10I/Ala-ins) was a
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robust substrate for the human HCCS. Note the shift in orientation of E8, E10, and F11 in (B) as
a result of the insertion of an Ala residue. Also note that in each case, residue His19 was not part
of the predicted helix, suggesting that it may have some flexibility, possibly related to its
function as a ligand to the heme in HCCS.
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Comment on the evolutionary implications of cytochrome c2 maturation by human HCCS.
The evolution of the HCCS enzyme occurred after the endosymbiotic event that led to the
eukaryotic mitochondrion. This is supported by the fact that the mitochondria of some
eukaryotes (e.g., all plants and some protozoa) have retained CCM for the synthesis of c-type
cytochromes. CCM is utilized by alpha proteobacteria, which are the ancestors of the eukaryotic
mitochondrion. CCM is “promiscuous” with regard to substrate specificity, requiring little else
than the conserved CXXH heme binding motif for recognition and heme attachment. Most alpha
proteobacterial cytochromes c (~90 %, or 173 out of 200 analyzed) have a two-residue spacing
between conserved Phe and the CXXCH motif. However, for all major groups of alpha
proteobacteria, there are some cytochromes c with a three-residue spacing, and some that lack
the Phe altoghether. Thus, there is not a strictly conserved N-terminal architecture in the alpha
proteobacterial cytochromes c, which is not unexpected given the flexible substrate requirements
of CCM (e.g., Phe is not a requirement for CCM recognition and heme attachment). Indeed, the
fact that 90 % of the alpha proteobacteria have retained any conservation of N-terminal
architecture (other than CXXCH) is surprising, and may reflect the importance of the conserved
Phe, for example, in cytochrome c function(s) post-maturation by CCM.
By contrast, all eukaryotic mitochondrial cytochromes c, regardless of whether they are
matured by CCM or HCCS, contain a conserved N-terminal architecture that consists of a threeresidue spacing between conserved Phe (F11) and the CXXCH motif. Although the conservation
of this architecture in the CCM-containing mitochondria is surprising, the fact that all HCCScontaining mitochondria possess cytochromes c with a three-residue spacing supports the idea
that HCCS evolved with this specific architecture, and it is now “locked” into using it for
attaching heme to its substrate. Furthermore, the conservation of N-terminal architecture in
cytochromes c throughout eukarya suggests that the three-residue spacing may have originated in
the cytochrome c of the mitochondrial progenitor. Consequently, the three-residue spacing is
now embedded as part of the specificity determinants for recognition and maturation by HCCS.
Animal HCCSs, like the human HCCS studied here, are less discriminatory, recognizing motifs
within cytochrome c and cytochrome c1 (e.g., such that Tyr11 can replace Phe11).
It is of note that the organisms from the Euglenozoa phylum, for which no cytochrome c
assembly system has been discovered, contain cytochromes c with this same conserved Nterminal architecture (although lacking the first Cys of the heme binding motif). Allen and
colleagues (5) have shown that a Euglenozoa (T. brucei) cytochrome c is matured by yeast
HCCS in E. coli at very low levels (less than 1 % WT), even when the cytochrome has been
engineered to contain the first Cys of the heme binding motif. T. brucei cytochrome c has the
equivalent of Glu8 (as in R. capsulatus cytochrome c2-see Figure 4), which might explain the
low levels of maturation, but this has not been explored.
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Figure S1
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Figure S2

Sequence
(K)DEDISQKDMYNIIR(I)
(K)DEDISQKDmYNIIR(I)
(K)DEDISQKDmYNIIR(I)
(K)DEDISQKDMYNIIR(I)
(K)ENLDPSNLMPPPNQTPAPDQPFALSTVREESSIPR(A)
(K)ENLDPSNLmPPPNQTPAPDQPFALSTVREESSIPR(A)
(R)GTAAENKENLDPSNLmPPPNQTPAPDQPFALSTVR(E)
(R)GTAAENKENLDPSNLmPPPNQTPAPDQPFALSTVR(E)
(R)GTAAENKENLDPSNLMPPPNQTPAPDQPFALSTVR(E)
(R)GTAAENKENLDPSNLmPPPNQTPAPDQPFALSTVREESSIPR(A)
(R)GTAAENKENLDPSNLMPPPNQTPAPDQPFALSTVREESSIPR(A)
(R)HDWIINR(C)
(R)IHNQNNEQAWK(E)
(R)IHNQNNEQAWKEILK(W)
(R)IHNQNNEQAWKEILK(W)
(K)KTYSVPAHQER(A)
(K)KWVYPSEQmFWNAMLK(K)
(K)KWVYPSEQMFWnAMLK(K)
(K)KWVYPSEQMFWNAMLKK(G)
(K)KWVYPSEQMFWNAmLKK(G)
(R)SWmGYELPFDR(H)
(R)SWMGYELPFDR(H)
(R)SWmGYELPFDR(H)
(R)SWmGYELPFDRHDWIInR(C)
(R)SWmGYELPFDRHDWIINR(C)
(K)TYSVPAHQER(A)
(K)WKDEDISQK(D)
(K)WKDEDISQKDmYNIIR(I)
(K)WKDEDISQKDmYNIIR(I)
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(K)WKDEDISQKDMYNIIR(I)
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(K)WKDEDISQKDMYNIIR(I)
(K)WVYPSEQMFWNAMLK(K)
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(K)WVYPSEQmFWNAmLK(K)
(K)WVYPSEQmFWnAmLK(K)
(K)WVYPSEQmFWNAMLK(K)
(K)WVYPSEQmFWNAmLK(K)
(K)WVYPSEQmFWNAmLK(K)
(K)WVYPSEQMFWNAmLK(K)
(K)WVYPSEQMFWNAMLK(K)
(K)WVYPSEQMFWNAmLK(K)
(R)YVIDYYDGGEVNK(D)
(R)YVIDYYDGGEVNKDYQFTILDVRPALDSLSAVWDR(M)
(K)WKDEDISQKDMYNIIR(I)
(R)GTAAENKENLDPSNLmPPPNQTPAPDQPFALSTVR(E)
(R)IHNQNNEQAWK(E)
(K)KTYSVPAHQER(A)
(R)GTAAENKENLDPSNLMPPPNQTPAPDQPFALSTVR(E)

Modifications
Oxidation (+16)
Oxidation (+16)
Oxidation (+16)
Oxidation (+16)
Oxidation (+16)
Oxidation (+16)

Oxidation (+16)
Deamidation (+1)
Oxidation (+16)
Oxidation (+16)
Oxidation (+16)
Oxidation (+16), Deamidation (+1)
Oxidation (+16)
Oxidation (+16)
Oxidation (+16)
Oxidation (+16)
Oxidation (+16), Oxidation (+16)
Oxidation (+16), Oxidation (+16)
Oxidation (+16), Deamidation (+1),
Oxidation (+16)
Oxidation (+16)
Oxidation (+16), Oxidation (+16)
Oxidation (+16), Oxidation (+16)
Oxidation (+16)
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Observed
580.6139
585.9449
878.4138
870.4168
1,282.30
1,287.63
1,245.28
934.209
1,239.94
1,511.40
1,506.07
477.2509
691.333
622.3253
932.985
439.2316
1,037.50
1,029.99
729.3695
1,101.55
708.8176
700.8187
708.8178
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594.2949
574.7818
690.6702
518.2537
685.3389
514.256
1,035.50
1,027.50
965.4558
981.4504
654.6355
654.9654

Actual Mass
1,738.82
1,754.81
1,754.81
1,738.82
3,843.87
3,859.87
3,732.81
3,732.81
3,716.81
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1,380.65
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2,072.98
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2,351.10
2,350.09
1,186.58
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1,960.89
1,960.88
1,961.87
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118
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111
221
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M_musculus_HCCS
C_elegans_HCCS
D_melanogaster_HCCS
P_falciparum_HCCS
P_falciparum_HCC1S
D_discoideum_HCCS
V_carteri_VOLCADRAFT_75232
V_carteri_VOLCADRAFT_105944
C_reinhardtii_XP_001699246.1
C_reinhardtii_XP_001697002.1
N_crassa_OR74A_HCCS_NCU05601
N_crassa_OR74A_HCC1S

----MGLSPSAPAVAVQASNAS----ASPPSGCPMHEGKMKGCPVNTEPS
----MGWFWAD----QKTTG---------KDIGGAAVSSMSGCPVMH-----MMSSDQQGKCPVDEETKKLWLR--------EHGNEAHPGATAPGNQ----MGASASSPATAVNASNASDGQPASPPSGCPMHKGQRKGCPVTAATS
----MGSSQSTPKVQDANADAERIRKAQHSMAAAGGGSQ---CPLTPEQR
----MGNTAIT-RVQMEATKSVPVDHAKYMSGSGAPPPE---CPMHQKHG
----------------MQNLSPACTFNKNEEKIKCPSSTKLGCSDGTKII
-----------------------------------------------------MG---------DDNTNNTSITKSSPTDAMG--------------------------------------------------------------------MGNQQSS----APSSPPAACAA-CADGQPSAKEAP--SCPVNPRHR
-----------------------------------------------------MGNQQSA----SAPPPATSAAP-CAEAAAAAGAEPPSSCPVNPKYK
----MGWFWAD----GNASAAAPVVPPSHKDLAASGAVPPPSCPMHNKTM
MAGQAGAGSEDKCPVDHKTRELWLQQAKQAKAAQEAAAAAGGSTAPSPEN
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P_falciparum_HCC1S
D_discoideum_HCCS
V_carteri_VOLCADRAFT_75232
V_carteri_VOLCADRAFT_105944
C_reinhardtii_XP_001699246.1
C_reinhardtii_XP_001697002.1
N_crassa_OR74A_HCCS_NCU05601
N_crassa_OR74A_HCC1S

GPTCEKKTY--------------------SVPAHQERAYEYVECPIRGTA
--------------------------------ESSSSSPPSSECPVMQGD
-------------------------------LECSANPQDNDKTPEY--DLTSESKAH--------------------TVPAHQDRAYDYVECPVTGAR
AAASGE------------------------------NCGAGGACPVG--DAKSAS-----------------------AVPPHP-KMQAASECPVQ--QH-----------------------------------------------------------------------------------------------------------------------------------------GGCPIA---------------------------------------------------NP-AVYNVYG-------------------ERINDPNNPQPKSPLQSIQGA
-------------------------------------------------NP-AVYNVYG-------------------QRINDPNSQAKPSPLASITGA
DALSAHKPVT-------------------PAPEPTPAAAAPSKCPVNHGA
AFTTPVVPAPQQPPTQTPIPQPAQQTAVPAALPTSQQQQQSSSSSSWSSW
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65
36
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S_cerevisiae_HCC1S_cyt2p
M_musculus_HCCS
C_elegans_HCCS
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P_falciparum_HCCS
P_falciparum_HCC1S
D_discoideum_HCCS
V_carteri_VOLCADRAFT_75232
V_carteri_VOLCADRAFT_105944
C_reinhardtii_XP_001699246.1
C_reinhardtii_XP_001697002.1
N_crassa_OR74A_HCCS_NCU05601
N_crassa_OR74A_HCC1S

AENK----------------------------ENLDPSN-LMPPPNQTPA
ND-------------------------------RINPLNNMP-ELAASKQ
----------------------------------------HTT------AKDK----------------------------ESLDPSN-LMPPPNQTPS
-ADK----------------------------ASINPLNNELEHPNQKPA
-HDN----------------------------SDVNPLN-MMPPANQQPA
---------------------------------EINERNMMPEIPNVSLT
----------------------------------MNEQ----KKENINIK
--------------------------------HDINPAN-HMYKPNQNPH
----------------------------------MAPPSKLP--PHQQ-DM--------------------------------LDPKNNMPLEPNQLPC
----------------------------------MAPPDKLP--PHQA-DV--------------------------------LDPKNNMPLEPNQLPC
KDTLAAAAAAVAPKQPQPENHQPAAASEPSFFSKLNPLNYMFSSISQEPA
LP------------------------------FMSSSSGSTTTGAAAAAG
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C_reinhardtii_XP_001697002.1
N_crassa_OR74A_HCCS_NCU05601
N_crassa_OR74A_HCC1S

PDQPFALSTVREESSIPRAD-------------------SEKKWVYPSEQ
PGQKMDLPVDRTISSIPK-S-----------------PDSNEFWEYPSPQ
----VDLSQSREVSTIPRTN-------------------SDRNWIYPSEK
PDQPFTLSTSREESSIPRAD-------------------SEKKWVYPSEQ
PDQPFALPTKREKSTIPKAG------------------TETETWTYPSPQ
ADQPFPLPTDRQTSTIPKVTE----------------DGSVQFWQYPSQQ
DENDFTFNKKRHVSSIPKNNNE--------------------YWVYPSSQ
NISNHNNSDGKEKSSIPSKNG---------------------SWYYPSQK
PDQTKPLSTERITSTIPRTE--------------------KDNWQYPSPQ
PGHDY--------------------------------------WVYPSEQ
PGQRKPLSTERVASTIPKGG-----------------TDGT--WLFPSPQ
PGQQN--------------------------------------WVYPSEQ
PGQRKPLSTERVASNIPKGG-----------------TEST--WLFPSPQ
PNQAIALPTERDPSSIPKGT-----------------GDGN--WEYPSPQ
ATPQLNLGEHREISSIPRAATTGPSACPSNAEQETGADTSTGNWVYPSEK
* :** :
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84
128
113
119
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41
74
24
118
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C_reinhardtii_XP_001699246.1
C_reinhardtii_XP_001697002.1
N_crassa_OR74A_HCCS_NCU05601
N_crassa_OR74A_HCC1S

MFWNAMLKKGWKWKDEDISQKDMYNIIRIHNQNNEQAWKEILKWEA---QMYNAMVRKGKIGGSGEVAEDAVESMVQVHNFLNEGCWQEVLEWEK---QFYEAMMKKNWD-----PNSDDMKVVVPLHNSINERVWNYIKSWEDKQGMFWNAMLRKGWKWKDDDISQKDMYNIIRIHNQNNEQAWKEILKWEA---MFWNAMLKKGWRWQDDSLSKSDMENIISIHNANNEEAWREVLKWEN---MFWNAMLRKGWRWKTEDVSQKDMGDIIRIHNANNEQAWQEVLKWEA---QFYNSLIRKNK-----DIDKNYIDAVVSVHNEVNEESWKQILKYEH---QFYNTTKKKGY-----SFSQEDLNMALKIHNAVNEETWNKIMKKEQ---MFFNAMKKKQYEPKEE-----DMSVVISIHNTVNEKCWEDVLQWEN---MFYNAMKRK-----GWDPQTEDMRNVVAIHNSVNERAWREVMAWER---MVFNALRRKGK---GDDVTEDDMDGFIAAHNSMNEATWQRVMLWES---MFYNAMKRK-----GWDPQAEDMRSVVGIHNTVNEQAWHQVLAWER---MVFNALKRKGK---GDDVTEDDMDGFIAAHNSMNEATWQRVAQWEM---QMYNALLRKG----YTDTDITAVESMVAVHNFLNEGAWNEIVEWERRFGK
QFYEAMKRKGHDG----ASAADMKTVVPIHNAVNERAWAEILRWEKPFT.::: :*
:
: ** ** * :
*

170
144
128
174
159
165
124
82
115
65
161
65
163
200
215

H_sapiens_HCCS
S_cerevisiae_HCCS_cyc3p

------------------------LHAAECPCGPSLIRFGGKAKEYSPRA 196
------------------------PHTDESHVQPKLLKFMGKPGVLSPRA 170

21
39
41
42
50

27
69
71
73
100

His154

228

S_cerevisiae_HCC1S_cyt2p
M_musculus_HCCS
C_elegans_HCCS
D_melanogaster_HCCS
P_falciparum_HCCS
P_falciparum_HCC1S
D_discoideum_HCCS
V_carteri_VOLCADRAFT_75232
V_carteri_VOLCADRAFT_105944
C_reinhardtii_XP_001699246.1
C_reinhardtii_XP_001697002.1
N_crassa_OR74A_HCCS_NCU05601
N_crassa_OR74A_HCC1S

------------------------GEACG---GIKLTNFKGDSKKLTPRA
------------------------LHAHECPCGPSLVRFGGKAREYSPRA
------------------------LLHPECAE-PKLKSFKGDAKNLSPRA
------------------------LHAKECGN-PRLKSFGGKAKDFSPRA
-------------------------MHKRSCTDVTLHRFLGKFDDLSIKA
-------------------------KYFDICKEQKLIKFVGYPTKLSIKA
------------------------DYKDVCPN-PKLKKFKGKATDFSPKA
------------------------LHCEECP-NPRLKRFQGRPSDLSPKA
------------------------LHRPECD-YPTLLRFQGKPHDLSPLA
------------------------LHCDECA-TPRLKRFQGRPSDLSPKA
------------------------LHRGECD-TPTLLRFQGKPHDLSPLA
GLMRGWEIMKRGEENAPMMLRRLEAQENDPEPQPTLIRFQGRPKDMTPKA
------------------------GEACGCAEGPKLQSFMGESKRMTPKA
* * *
: *
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200
184
190
149
107
140
90
186
90
188
250
241

H_sapiens_HCCS
S_cerevisiae_HCCS_cyc3p
S_cerevisiae_HCC1S_cyt2p
M_musculus_HCCS
C_elegans_HCCS
D_melanogaster_HCCS
P_falciparum_HCCS
P_falciparum_HCC1S
D_discoideum_HCCS
V_carteri_VOLCADRAFT_75232
V_carteri_VOLCADRAFT_105944
C_reinhardtii_XP_001699246.1
C_reinhardtii_XP_001697002.1
N_crassa_OR74A_HCCS_NCU05601
N_crassa_OR74A_HCC1S

RIR-SWMGYEL--------PFDRHDWIINRCG----------TEVRYVID
RWM-HLCGLLFPSHFSQELPFDRHDWIVLRGERKAEQQPPTFKEVRYVLD
WFRSRILHLAK--------PFDRHDWQIDRCG----------KTVDYVID
RIR-SWMGYEL--------PFDRHDWIINRCG----------TEVRYVID
RFRNLFLGYDL--------PFDRHDWIVDRCGT---------KQVQYVID
RFR-SWLGYEL--------PFDRHDWIVDRCG----------KDVRYVID
RFRSIFSSMGR--------PFDRHDWYVNRCG----------TQVKYILD
FMLTLIG-YNK--------PFDRHEWYIDRCG----------NTIKYIID
KFLNTFLGYKL--------PFDRHDWIVDRNG----------KEVRYVID
RLL-NFVGFGL--------PFDRHDWVVDR----------CGREVRYVID
WIR-NLLGGPA--------PFDRHDWIVDR----------CGREVRYVID
RLL-NFVGFGL--------PFDRHDWVVDR----------CGKEVRYIID
WVR-HMLGGPA--------PFDRHDWVIDR----------CGKEVRYIID
ALL-QVLGRIN-SKYATEPPFDRHDWYVSRDENGQK------KEVRYVID
RLNT-LLGYTA--------PFDRHDWIVDRCG----------TRVDYVID
*****:* : *
: *::*

227
219
183
231
217
221
181
138
172
121
217
121
219
292
272
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YYDGGEVN-KD-YQFTI-LDVRPALDSLSAVWDRMKVAWWRWTS-----FYGGPDDEN---GMPTFHVDVRPALDSLDNAKDRMTRFLD---RMISGPS
FYSTDLNDANSQQQPLIYLDVRPKLNSFEGFRLRFWKSLGF--------YYDGGEVN-KE-YQFTI-LDVRPAFDSFSAVWDRMKVAWWRWTS-----YYDGGAVDPSS-KLFTI-LDVRPAVNDIGNIWDRMVVAYWRFKFETLG-F
YYDGGLVD-KD-YRFAL-LDVRPAMDSVDNVWDRMRVAYMRWKYELFEKF
YYN-DESINDD---KNIYIDVRPAMNSFSNVWDRLRYPFYEFYFKYVKKD
YYDGKKEKNSA---VSIYIDARPQLN-HQNAIDNVKIIYIKICRFLNN-FYEGRINKDSG-KSIGIYIDVRPAIDDFSSLKDRVLHFFK---------FYNGAPQPGQA-APVAFFLDVRPALDSVEAVWDRIRMQVAWVVSGRWMER
FYFYDDKAG---TPEAFEIVARPAVDSLESALDRVKMNIYIKFAEWGLPC
FYNGAPQPGQS-AAAAFFLDVRPALDSVEAAWDRLRMQ-------WW--FYFFDDKAG---TPQAFEIVARPAVDSVEAALDRVKMNIYLKFAEWGLPC
FYSAPPEPT---GEPVFYLDVRPAVT-VTGACERLLRWGG---DVWWKAS
FYAGRNNDRAGAGKLNFYLDVRPKLNTWEGVKMRALRFVGMN-------:*
: : .** .
.
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263
224
272
264
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227
182
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170
264
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335
314
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---------------------------------SSSSAP-------------------------------------------------------------------------TPSLPIPPTEGHNVNH------------GSADGGKVTAGSD---------------ELFK-------------------------LF---------------------------------------------------------------------------------PITGHSGTVVAKQQQQQQQVAQPSGAGSS
----------------------------PITGQAGAVAQAAAAAG---GQQAASGSS
-----GGEVRERERSK-----------------------------------------

His211
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184
293
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346
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Figure S4
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Figure S5
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Figure S6
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Figure S7
Peptide sequence: WT cytochrome c
KIFIMK
KIFIMK
KIFIMK + ox (M)
HKTGPNLHGLFGR
HKTGPNLHGLFGR + deam (NQ)
TGPNLHGLFGR
TGPNLHGLFGRK
TGPNLHGLFGRK + deam (NQ)
KTGQAPGYSYTAANK
KTGQAPGYSYTAANKNK
KTGQAPGYSYTAANKNK + deam (NQ)
TGQAPGYSYTAANK
TGQAPGYSYTAANKNK
GIIWGEDTLMEYLENPK + ox (M)
GIIWGEDTLMEYLENPK + ox (M); deam (NQ)
KYIPGTK
MIFVGIK
MIFVGIK + ox (M)
MIFVGIKK
MIFVGIKK + ox (M)
EERADLIAYLK
EERADLIAYLKK
ADLIAYLK
ADLIAYLKK

Seq.
9-14
9-14
9-14
27-39
27-39
29-39
29-40
29-40
40-54
40-56
40-56
41-54
41-56
57-73
57-73
74-80
81-87
81-87
81-88
81-88
90-100
90-101
93-100
93-101

m/z (obs)
390.2439
390.2445
398.2412
359.1977
359.4485
584.8093
432.9085
433.2413
778.8813
600.3039
600.6311
714.8368
557.6061
1012.4795
1012.9840
403.7397
404.2414
412.2377
468.2883
476.2863
660.8589
483.6068
453.7657
345.5434

Mr (expt)
778.4732
778.4745
794.4678
1432.7615
1433.7649
1167.6040
1295.7036
1296.7020
1555.7480
1797.8899
1798.8716
1427.6589
1669.7966
2022.9444
2023.9534
805.4648
806.4681
822.4608
934.5620
950.5580
1319.7032
1447.7985
905.5169
1033.6084

Mr (calc)
778.4775
778.4775
794.4724
1432.7688
1433.7528
1167.6149
1295.7099
1296.6939
1555.7630
1797.9009
1798.8849
1427.6681
1669.8060
2022.9608
2023.9448
805.4698
806.4724
822.4673
934.5674
950.5623
1319.7085
1447.8034
905.5222
1033.6171

MGDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKAANKNKGHWGEDTLMEYLE
NPKKYIPGTKMIFVGIKKKEKATNE
76 % protein sequence coverage
Peptide sequence: C18A cytochrome c
KIFIMK
KIFIMK + ox (M)
KIFIMKCSQAHTVEK
CSQAHTVEK
HKTGPNLHGLFGR
HKTGPNLHGLFGR + deam (NQ)
TGPNLHGLFGR
TGPNLHGLFGR + deam (NQ)
TGPNLHGLFGRK
TGPNLHGLFGRKTGQAPGYSYTAANK
TGPNLHGLFGRKTGQAPGYSYTAANK + deam (NQ)
KTGQAPGYSYTAANK
KTGQAPGYSYTAANK + deam (NQ)
KTGQAPGYSYTAANKNK
KTGQAPGYSYTAANKNK + deam (NQ)
TGQAPGYSYTAANK
TGQAPGYSYTAANKNK
NKGIIWGEDTLMEYLENPK + ox (M)
NKGIIWGEDTLMEYLENPKK
NKGIIWGEDTLMEYLENPKK + ox (M)
NKGIIWGEDTLMEYLENPKK + ox (M); deam (NQ)
GIIWGEDTLMEYLENPK
GIIWGEDTLMEYLENPK + ox (M)
GIIWGEDTLMEYLENPKK
GIIWGEDTLMEYLENPKK + ox (M)
GIIWGEDTLMEYLENPKK + ox (M); deam (NQ)
GIIWGEDTLMEYLENPKKYIPGTK + ox (M)
KYIPGTK
MIFVGIK
MIFVGIK + ox (M)
MIFVGIKK
MIFVGIKK + ox (M)
KEERADLIAYLK
EERADLIAYLK
EERADLIAYLKK
ADLIAYLK
ADLIAYLKK
ADLIAYLKKATNE

Seq.
9-14
9-14
9-23
15-23
27-39
27-39
29-39
29-39
29-40
29-54
29-54
40-54
40-54
40-56
40-56
41-54
41-56
55-73
55-74
55-74
55-74
57-73
57-73
57-74
57-74
57-74
57-80
74-80
81-87
81-87
81-88
81-88
89-100
90-100
90-101
93-100
93-101
93-105

233

m/z (obs)
390.2448
398.2414
441.4909
501.7349
359.1978
359.4484
584.8106
585.3031
432.9061
677.3450
677.5961
778.8821
519.9261
600.3038
600.6306
714.8366
557.6059
756.0371
793.4031
798.7358
599.5536
1004.4884
1012.4834
712.6916
1076.5340
718.3563
937.8090
403.7396
404.2420
412.2395
468.2863
476.2867
724.9061
660.8576
483.6065
453.7653
517.8129
725.3977

Mr (expt)
778.4750
794.4683
1761.9345
1001.4552
1432.7622
1433.7644
1167.6066
1168.5917
1295.6964
2705.3510
2706.3554
1555.7497
1556.7563
1797.8895
1798.8700
1427.6586
1669.7958
2265.0895
2377.1873
2393.1854
2394.1851
2006.9622
2022.9522
2135.0529
2151.0534
2152.0471
2810.4051
805.4647
806.4695
822.4645
934.5581
950.5588
1447.7976
1319.7006
1447.7977
905.5161
1033.6113
1448.7809

Mr (calc)
778.4775
794.4724
1761.9270
1001.4600
1432.7688
1433.7528
1167.6149
1168.5989
1295.7099
2705.3674
2706.3514
1555.7630
1556.7471
1797.9009
1798.8849
1427.6681
1669.8060
2265.0987
2377.1987
2393.1936
2394.1777
2006.9659
2022.9608
2135.0609
2151.0558
2152.0398
2810.4200
805.4698
806.4724
822.4673
934.5674
950.5623
1447.8034
1319.7085
1447.8034
905.5222
1033.6171
1448.7874

MGDVEKGKKIFIMKCSQAHTVEKGGKHKTGPNLHGLFGRKAANKNKGHWGEDTLMEYLE
NPKKYIPGTKMIFVGIKKKEKATNE
89 % sequence coverage
Peptide sequence: C15S cytochrome c
KIFIMK
KIFIMK + ox (M)
SSQCHTVEK
HKTGPNLHGLFGR
HKTGPNLHGLFGR + deam (NQ)
HKTGPNLHGLFGRK
TGPNLHGLFGR
TGPNLHGLFGRK
TGPNLHGLFGRK + deam (NQ)
TGPNLHGLFGRKTGQAPGYSYTAANK
KTGQAPGYSYTAANK
KTGQAPGYSYTAANKNK
KTGQAPGYSYTAANKNK + deam (NQ)
TGQAPGYSYTAANK
GIIWGEDTLMEYLENPK + ox (M)
KYIPGTK
MIFVGIK + ox (M)
MIFVGIKK
MIFVGIKK + ox (M)
EERADLIAYLK
EERADLIAYLKK
ADLIAYLK
ADLIAYLKK
ADLIAYLKK
ADLIAYLKKATNE
ADLIAYLKKATNE + deam (NQ)

Seq.
9-14
9-14
15-23
27-39
27-39
27-40
29-39
29-40
29-40
29-54
40-54
40-56
40-56
41-54
57-73
74-80
81-87
81-88
81-88
90-100
90-101
93-100
93-101
93-101
93-105
93-105

m/z (obs)
390.2450
398.2414
509.7303
359.1981
478.9312
391.2221
584.8117
432.9092
433.2384
677.3450
778.8844
600.3039
600.6327
714.8344
1012.4833
403.7400
412.2379
468.2899
476.2862
660.8595
483.6070
453.7666
517.8122
517.8149
483.9343
484.2661

Mr (expt)
778.4754
794.4683
1017.4461
1432.7633
1433.7719
1560.8593
1167.6089
1295.7058
1296.6933
2705.3510
1555.7542
1797.8898
1798.8762
1427.6543
2022.9520
805.4654
822.4612
934.5652
950.5579
1319.7044
1447.7993
905.5187
1033.6099
1033.6152
1448.7811
1449.7766

Mr (calc)
778.4775
794.4724
1017.4549
1432.7688
1433.7528
1560.8637
1167.6149
1295.7099
1296.6939
2705.3674
1555.7630
1797.9009
1798.8849
1427.6681
2022.9608
805.4698
822.4673
934.5674
950.5623
1319.7085
1447.8034
905.5222
1033.6171
1033.6171
1448.7874
1449.7715

MGDVEKGKKIFIMKSSQCHTVEKGGKHKTGPNLHGLFGRKAANKNKGHWGEDTLMEYLE
NPKKYIPGTKMIFVGIKKKEKATNE
88 % sequence coverage
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Figure S8
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Figure S9
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Figure S10
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Figure S11
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Figure S12
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Table S1. Published studies on maturation of cytochrome c by HCCS
Reference
Verissimo et al.
(2012) Biochem
Biophys Res Comm

Stevens et al. (2011)
FEBS Lett

Compartment
E. coli cytoplasm

E. coli cytoplasm

HCCS
S. cerevisiae

Cytochrome c
S. cerevisiae iso2-cyt c

R. capsulatus cyt
c2

Iso-2-cyt c/cyt c2
chimera

Cyt c2-insK11

Cyt c2-E9L

Cyt c2-insK11 +
E9L

Cyt c2-insK11 +
N12T

E. caballus cyt c

S. cerevisiae iso1-cyt c

P. denitrificans
cyt c550

Iso-1-cyt c/cyt
c550 chimera


S. cerevisiae













Kleingardner and
Bren (2011)
Metallomics

E. coli cytoplasm




S. cerevisiae




Fulop et al. (2009)
FEBS J

E. coli cytoplasm



S. cerevisiae



Rosell and Mauk
(2002) Biochem

E. coli cytoplasm



S. cerevisiae



E. caballus cyt c
E. caballus cyt c
1x-ins
E. caballus cyt c
3x-ins
E. caballus cyt c
G13 ins
E. caballus F10A



T. brucei cyt c
WT (AAQCH)
T. brucei cyt
c(CAQCH)
S. cerevisiae iso1-cyt c
S. cerevisiae iso1-cyt c(C14S)
S. cerevisiae iso1-cyt c(C17S)










Silkstone et al.
(2002) Biophysical
Chem

E. coli cytoplasm

S. cerevisiae



S. cerevisiae iso1 cyt
c(M80D/E/S/A)



Rumbley et al.
(2002)
Biochemistry

E. coli cytoplasm

S. cerevisiae



E. caballus cyt
c(E5G)
E. caballus cyt
c(K9G)
E. caballus cyt
c(V12G)
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Results
R. capsulatus cyt c2 not
matured
Iso-2-cyt c/cyt c2 chimera (and
truncated chimera) fully
matured
Cyt c2-insK11 matured at low
level
Cyt c2-insK11 + E9L matured
at high levels
Cyt c2-E9L not matured
Cyt c2-insK11 + N12T not
matured
G6A, F10A in E. caballus not
matured
F15A (but not G11A) in S.
cerevisiae not matured
D2A, E4A, K7A, K5A, K8A
matured at WT levels
P. denitrificans cyt c550 not
matured
Chimera with S. cerevisiae Nterm up to but not including
CXXCH fused to P.
denitrificans cyt c550 matured
at WT levels
E. caballus cyt c 1x-ins not
matured
Cyt c 3x-ins matured at 1/3
levels
Cyt c G13 ins matured at 1/3
levels but spectrally
heterogeneous
Cyt c F10A not matured at
detectable levels
Both T. brucei cyts c matured
at very low levels; 0.25 % the
level of S. cerevisiae iso-1-cyt
c

Iso-1-cyt c(C14S) matured at
1/10 levels of WT; spectrally
distinct from WT
Iso-1-cyt c(C17S) expression
20-fold lower than C14S
variant; apparently did not
permit enough to conduct
analysis
S. cerevisiae iso-1 cyt c Met80
variants were matured
efficiently
E. caballus cyt c E5G, K9G,
V12G variants all matured, but
with increasing proximity to
CXXCH, level of mis-attached
heme increased (attributed to
interference with formation of
N-terminal helix)
Starting E. caballus cyt c
construct carried H26N, H33N

Sanders et al.
(2001) Mol Micro

E. coli cytoplasm

S. cerevisiae



Sanders and Lill
(2000) BBA

E. coli cytoplasm

S. cerevisiae






Corvest et al.
(2010) Genetics

Whole S. cerevisiae
cells

S. cerevisiae



Bernard et al.
(2003) JBC

Whole S. cerevisiae
cells

Plasmid S.
cerevisiae
HCCS and
HCC1S





Plasmid H.
sapiens HCCS

Wang et al. (1996)
JBC

Whole S. cerevisiae
cells



Plasmid M.
musculus
HCCS
Chromosomal +
plasmid S.
cerevisiae








Fumo et al. (1995)
Gene

Whole S. cerevisiae
cells



Chromosomal
S. cerevisiae

S. cerevisiae iso2-cyt c/P.
denitrificans cyt
c550 chimera
S. cerevisiae iso1-cyt c
S. cerevisiae iso2-cyt c
P. denitrificans
cyt c
Synechocystis sp.
PCC 6803 cyt
c553
S. cerevisiae cyt
c1(CA[/P/T/H/L/
S]CH)



S. cerevisiae cyt
c
S. cerevisiae cyt
c1 WT (CAACH)
S. cerevisiae cyt
c1(CAPCH)
S. cerevisiae cyt
c1(CADCH)



S. cerevisiae iso2-cyt
c([S/A]XX[S/A]
H)
S. cerevisiae iso2-cyt c(F19A)
S. cerevisiae iso2-cyt c(H27A)
S. cerevisiae iso2-cyt c(∆Ala1Lys14)
S. cerevisiae iso2-cyt c(∆Gly15Leu18)



S. cerevisiae iso1-cyt c(H18A)






















Tanaka et al.

Whole S. cerevisiae



Chromosomal

241

H. sapiens cyt



mutations
Chimera (with N-term and
CXXCH from iso-2-cyt c)
matured
S. cerevisiae iso-1 and iso-2 cyt
c matured at high levels
P. denitrificans and
Synechocystis cyt c not matured
at detectable levels

Cyt c1(CAPCH) depends on
HCCS and Cyc2p for
maturation; HCC1S maturation
achieved by overexpression of
HCC1S or substitution of P
with H/L/S/T
S. cerevisiae HCC1S cannot
mature cyt c
S. cerevisiae, H. sapiens, and
M. musculus HCCS can
complement HCC1S deletion
for respiratory growth (i.e.,
they are active towards both cyt
c an cyt c1)
S. cerevisiae HCCS can mature
CAPCH and CADCH mutants
of cyt c1
Iso-2-cyt c(S/AXXS/AH)
variants not matured, but
imported into mitochondria
(when HCCS was
overexpressed on plasmid)
Iso-2-cyt c(F19A) not matured;
10 % mitochondrial import
Iso-2-cyt c(H27A)not matured;
40 % associated with
mitochondria but only 10 %
internalized into mitochondria
Iso-2-cyt c(∆Ala1-Lys14)
matured at low levels (10 %)
Iso-2-cyt c(∆Gly15-Leu18) not
matured; 10 % mitochondrial
import
Iso-1-cyt c(H18A) is
nonfunctional (did not support
growth in medium with liquid
lactate, a nonfermentable
carbon source)
Iso-1-cyt c(H18A) was not
detected spectrally in intact
cells
In targeted random mutagenesis
experiment, only His was found
as a.a. 18
Iso-1-cyt c(H18R) integrated
chromosomally not support
growth in lactate medium and
holo-cyt c(H18R) was not
detected in low temperature
difference spectroscopy
H. sapiens cyt c(C14A)

(1990) J Biochem

cells

S. cerevisiae

Sorrell et al. (1989)
JACS

Whole S. cerevisiae
cells

Chromosomal
S. cerevisiae

c(C14A)



S. cerevisiae iso2-cyt c(H18R)





Tong and
Margoliash (1998)
JBC

Purified S. cerevisiae
mitochondria “in
vitro”



Chromosomal +
plasmid S.
cerevisiae




Veloso et al. (1983)
JBC

Purified S. cerevisiae
mitochondria
“in vitro”



Chromosomal
S. cerevisiae

D. melanogaster
cyt c(C14S)
D. melanogaster
cyt c(C17S)
D. melanogaster
cyt
c(C14S/C17S)



N-terminal 25
residues of E.
caballus cyt c








efficiently matured and
complemented CYC1
deficiency in yeast on lactate
medium
Iso-2-cyt c(H18R) on a plasmid
weakly complemented yeast
strain lacking cytochrome c on
glycerol or lactate media
Less than 1 mg/10 L culture
were purified; spectrally
identical to WT iso-2-cyt c
Iso-2-cyt c(H18R) has slower
rate of electron transfer than
WT
D. melanogaster cyt c(C14S)
matured, but at lower levels
than WT
D. melanogaster cyt c(C17S)
was matured at “trace” amounts
D. melanogaster cyt
c(C14S/C17S) was
undetectable
Heme was attached to E.
caballus cyt c(N-term 25) at 25
% levels of full apocytochrome
c
No maturation when Gly
replaced Cys in CXXCH

Catalogue of published studies on the effects of cytochrome c mutations on maturation by
HCCS. Studies are organized according to the biological compartment in which the study was
conducted (i.e., E. coli cytoplasm, whole S. cerevisiae cells, or isolated S. cerevisiae
mitochondria) and then in reverse chronological order. Full citations for each of the studies
above are provided in the references section of the main text.
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Table S2. Oligonucleotide primers, plasmids, and strains used in this research.
Oligonucleotide

Sequence (5’-3’)

CYCS_K6A_Fwd
CYCS_K6A_Rev
CYCS_K6R_Fwd
CYCS_K6R_Rev
CYCS_K6D_Fwd
CYCS_K6D_Rev
CYCS_F11A_Fwd
CYCS_F11A_Rev
CYCS_F11Y_Fwd
CYCS_F11Y_Rev
CYCS_C15S_Fwd
CYCS_C15S_Rev
CYCS_C18A_Fwd
CYCS_C18A_Rev
CYCS_H19A_Fwd
CYCS_H19A_Rev
HCCS_H154A_Fwd
HCCS_H154A_Rev
HCCS_H154G_Fwd
HCCS_H154G_Rev
HCCS_H154Y_Fwd
HCCS_H154Y_Rev
HCCS_H211A_Fwd
HCCS_H211A_Rev
HCCS_H211G_Fwd
HCCS_H211G_Rev
HCCS_H211Y_Fwd
HCCS_H211Y_Rev
HCCS_H211C_Fwd
HCCS_H211C_Rev
pTXB1_HCCS_Nde1_Fwd
pTXB1_HCCS_SapI_Rev
pBAD_CYTC2_Nco1_Fwd
pBAD_CYTC2_XbaI_Rev
CYTC2_Ala-ins_Fwd
CYTC2_Ala-ins_Rev
CYTC2_E8K_E10I_Fwd (Ala-ins)
CYTC2_E8K_E10I_Rev (Ala-ins)
CYTC2_E8K_E10I_Fwd
CYT_C2_E8K_E10I_Rev
CYT_C2_E8K_Fwd (Ala-ins)
CYTC2_E8K_Rev (Ala-ins)
CYTC2_E10I_Fwd (Ala-ins)
CYTC2_E10I_Rev (Ala-ins)
pGEX_HCCS_MfeI_Fwd
pET-Blue2-Down_Rev
pBAD_CYCS_EcoRI_Fwd
pBAD_CYCS_PstI_Rev
pET-Blue-2_HCCS_NcoI_Fwd
pET-Blue-2_HCCS_HindIII_Rev

ATGGGTGATGTTGAGGCGGGCAAGAAGATTTTTATTATGAAGTG
CACTTCATAATAAAAATCTTCTTGCCCGCCTCAACATCACCCAT
ATGGGTGATGTTGAGCGCGGCAAGAAGATTTTTATTATGAAGTG
CACTTCATAATAAAAATCTTCTTGCCGCGCTCAACATCACCCAT
ATGGGTGATGTTGAGGACGGCAAGAAGATTTTTATTATGAAGTG
CACTTCATAATAAAAATCTTCTTGCCGTCCTCAACATCACCCAT
GAGAAAGGCAAGAAGATTGCGATTATGAAGTGTTCCCAGTGCC
GGCACTGGGAACACTTCATAATCGCAATCTTCTTGCCTTTCTC
GTTGAGAAAGGCAAGAAGATTTATATTATGAAGTGTTCCCAGTGC
GCACTGGGAACACTTCATAATATAAATCTTCTTGCCTTTCTCAAC
GATTTTTATTATGAAGAGCTCCCAGTGCCACACCGTTGAAAAGGG
CCCTTTTCAACGGTGTGGCACTGGGAGCTCTTCATAATAAAAATC
ATGAAGTGTTCCCAGGCGCACCGTTGAAAAGGGAGG
CCTCCCTTTTCAACGGTGCGCCTGGGAACACTTCAT
TATTATGAAGTGTTCCCAGTGCGCGACCGTTGAAAAGGG AGGCAA
TTGCCTCCCTTTTCAACGGTCGCGCACTGGGAACACTTCATAATA
GTATAATATCATTAGAATTGCCAATCAGAATAACGAGCAGGC
GCCTGCTCGTTATTCTGATTGGCAATTCTAATGATATTATAC
CATTAGAATTGGCAATCAGAATAACGAGCAGGCTTGGAAGG
CCTTCCAAGCCTGCTCGTTATTCTGATTGCCAATTCTAATG
CATTAGAATTTACAATCAGAATAACGAGCAGGC
GCCTGCTCGTTATTCTGATTGTAAATTCTAATG
GAGTTGCCTTTTGATAGGGCGGATTGGATCATAAACCGTTGC
GCAACGGTTTATGATCCAATCCGCCCTATCAAAAGGCAACTC
GAGTTGCCTTTTGATAGGGGCGATTGGATCATAAACCGTTGC
GCAACGGTTTATGATCCAATCGCCCCTATCAAAAGGCAACTC
GGTATGAGTTGCCTTTTGATAGGTATGATTGGATCATAAACCG
CGGTTTATGATCCAATCATACCTATCAAAAGGCAACTCATACC
GAGTTGCCTTTTGATAGGTGCGATTGGATCATAAACCGTTG
CAACGGTTTATGATCCAATCGCACCTATCAAAAGGCAACTC
GGTGGTCATATGGGTTTGTCTCCATCTGC
GGTGGTTGCTCTTCCGCATTTCGAGGTCCAACGCCACCAAGCAGC
GACTCCATGGGCGACGCCGCGAAGGGCG
CTTCTAGATTATTTCACGACCGAGGCCAG
GGGCGAAAAAGAATTCAACGCCAAGTGCAAGACCTGCCA
TGGCAGGTCTTGCACTTGGCGTTGAATTCTTTTTCGCCC
GCGACGCCGCGAAGGGCAAAAAAATATTCAACGCCAAGTGCA
TGCACTTGGCGTTGAATATTTTTTTGCCCTTCGCGGCGTCGC
GGCGACGCCGCGAAGGGCAAAAAAATATTCAACAAGTGCAAGAC
GTCTTGCACTTGTTGAATATTTTTTTGCCCTTCGCGGCGTCGCC
GACGCCGCGAAGGGCAAAAAAGAATTCAACGC
GCGTTGAATTCTTTTTTGCCCTTCGCGGCGTC
CGCCGCGAAGGGCGAAAAAATATTCAACGCCAAGTGC
GCACTTGGCGTTGAATATTTTTTCGCCCTTCGCGGCG
CTCAATTGATGGGTTTGTCTCCATCTGC
GTTAAATTGCTAACGCAGTCA
GCGGAATTCGCCATGGGTGATGTTGAG
GAGCTGCAGTTACTCATTAGTAGC
CCAGCCATGGGTCATCATCATCATCATCACGGTTTGTCTCCATCTGCTCC
CGAAGCTTGTGCATAGTTTTACGAGGTCCAAC

Plasmid

Description

pRGK330

pBAD24-based plasmid for arabinose inducible expression

pRGK389

Template for R. capsulatus cytochrome c2

pRGK402

Expression of N-terminal hexahistidine-tagged HCCS (pET Blue2)
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Plasmid
Constructed
pRGK412
pRGK412
pRGK413
pRGK413
pRGK414
pRGK414
pRGK415
pRGK415
pRGK416
pRGK416
pRGK417
pRGK417
pRGK418
pRGK418
pRGK419
pRGK419
pRGK420
pRGK420
pRGK421
pRGK421
pRGK422
pRGK422
pRGK423
pRGK423
pRGK424
pRGK424
pRGK425
pRGK425
pRGK426
pRGK426
pRGK404
pRGK404
pRGK406
pRGK406
pRGK407
pRGK407
pRGK408
pRGK408
pRGK409
pRGK409
pRGK410
pRGK410
pRGK411
pRGK411
pRGK403
pRGK403
pRGK405
pRGK405
pRGK402
pRGK402

Reference
Feissner et al.
2006
Richard-Fogal
et al. 2012
This work

pRGK403
pRGK404
pRGK405
pRGK406
pRGK407
pRGK408
pRGK409
pRGK410
pRGK411
pRGK412
pRGK413
pRGK414
pRGK415
pRGK416
pRGK417
pRGK418
pRGK419
pRGK420
pRGK421
pRGK422
pRGK423
pRGK424
pRGK425
pRGK426

Expression of N-terminal GST-tagged HCCS (pGEX 4T-1)
Expression of C-terminal Intein-tagged HCCS (pTXB1)
Expression of human cytochrome c (pBAD)
Expression of cytoplasmic R. capsulatus cytochrome c2 (pBAD)
pBAD cyt c2(Ala-ins)
pBAD cyt c2(E8K/E10I/Ala-ins)
pBAD cyt c2(E8K/E10I)
pBAD cyt c2(E8K/Ala-ins)
pBAD cyt c2(E10I/Ala-ins)
pBAD CYCS(K6A)
pBAD CYCS(K6R)
pBAD CYCS(K6D)
pBAD CYCS(F11A)
pBAD CYCS(F11Y)
pBAD CYCS(C15S)
pBAD CYCS(C18A)
pBAD CYCS(H19A)
pGEX HCCS(H154A)
pGEX HCCS(H154G)
pGEX HCCS(H154Y)
pGEX HCCS(H211A)
pGEX HCCS(H211G)
pGEX HCCS(H211Y)
pGEX HCCS(H211C)

This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work

Reference
Feissner et al.
2006
Richard-Fogal
et al. 2012

Strain

Description

RK103

∆ccm E. coli strain MG1655 deleted for all ccm genes

RK112

∆ccm E. coli strain BL21 (DE3) deleted for all ccm genes
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Supporting Information References
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Feissner, R. E., Richard-Fogal, C. L., Frawley, E. R., Loughman, J. A., Earley, K. W.,
and Kranz, R. G. (2006) Recombinant cytochromes c biogenesis systems I and II and analysis of
haem delivery pathways in Escherichia coli. Mol Microbiol 60, 563-77.
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Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V., and Mann, M. (2006) In-gel
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of a trypanosomatid mitochondrial cytochrome c with heme attached via only one thioether bond
and implications for the substrate recognition requirements of heme lyase. Febs J 276, 2822-32.
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Chapter 6: Summary and Future Investigations
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Summary
The studies in this dissertation explore the structure(s) and function(s) of the system I
cytochrome c synthetase, CcmF (Fig 1), and the cytochrome c synthase for system III, HCCS.
The transmembrane b-heme binding site within CcmF was defined and spectroscopically
characterized, the requirements for formation of the CcmF-holoCcmE complex were determined,
and CcmFH (along with CcmG) was shown to be a cytochrome c synthetase independent of
CcmABCDE. For system III, interactions between HCCS and heme, and HCCS and cytochrome
c, were characterized, allowing us to propose mechanisms for heme binding, interaction with
apocytochrome c, thioether formation, and release of mature holocytochrome c from HCCS (Fig
2).
Characterization of the b-heme binding site in CcmF
Purification of CcmF revealed a stoichiometric and stable heme b, present in the absence
of the other Ccm components, and heme-binding was shown to depend on a conserved
transmembrane histidine (TM-His1) [1]. In Chapter 2 [2], a second conserved transmembrane
histidine (TM-His2) is shown to be required for binding the heme b (Fig 1). Exogeneous
imidazole is used to correct the cytochrome c assembly defects of mutations at TM-His1 and
TM-His2, providing further support for a ligand-type function for these histidines. Resonance
Raman spectroscopy is used to confirm the presence of a 6-coordinate, low-spin heme species in
CcmF with bis-His coordination. It is shown that replacement of TM-His1 with cysteine (a
residue that can substitute as an axial ligand) supports holocytochrome c formation at 70 % WT
levels, and purified CcmF TM-His1Cys contains heme b with unique spectral characteristics.
The stable heme b is shown to be conserved in CcmF proteins from a diverse set of prokaryotes
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(including Thermophilus thermophilus and Desulfovibrio vulgaris). Finally, the midpoint
potential of the CcmF b-heme is determined. These results constitute a thorough characterization
of the transmembrane binding site for the CcmF heme b (coordinated by TM-His1 and TM-His2)
and suggest a possible mechanism by which heme (from holoCcmE) becomes reduced (to Fe2+),
which is required for covalent attachment to the apocytochrome (Fig 1).
Requirements for formation of the CcmF-holoCcmE complex
Despite the wide assumption in the field that formation of a CcmF-holoCcmE complex is
an intermediate during cytochrome c biogenesis, experimental evidence in support of this was
lacking. In chapter 3, it is shown that CcmF and holoCcmE form a complex in the absence of
CcmH. This complex requires conserved CcmF P-His1 and P-His2 (Fig 1). Exogeneous
imidazole is used to correct the cytochrome c assembly defects of substitutions at P-His1 and PHis2, suggesting that these WWD-flanking histidines are axial ligands to heme from holoCcmE
when it is bound in the CcmF WWD domain. For complex formation to occur, holoCcmE must
be released from CcmABCD, and it is shown that the apo-form of CcmE interacts with CcmF at
20-fold lower levels than holoCcmE. These results establish the requirements for formation of
the holoCcmE-CcmF complex, an interaction at the heart of heme trafficking in system I
cytochrome biogenesis, and suggest a role for CcmH in mediating interaction between CcmF and
holoCcmE.
CcmFH (with CcmG) is the system I cytochrome c synthetase
Unlike the synthases for systems II and III (which, when expressed heterologously in E.
coli ∆ccm, are sufficient for holocytochrome c formation [3,4]), the synthetase activity of
CcmFH had not been directly demonstrated. In chapter 4, it is shown that CcmFH (and the
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periplasmic thioredoxin CcmG) can attach heme covalently to cytochromes c2 and c4 in E. coli
∆ccm, independent of CcmABCDE. This activity, termed CcmFGH-ind, is sufficient for robust
production of holocytochrome c with spectral and biochemical characteristics indistinguishable
from those of the holocytochrome c produced by the full system I. It is shown that CcmFGH-ind
requires three conserved histidines in CcmF (TM-His1, TM-His2, and P-His2) as well as the
conserved cysteine pairs in the thioredoxins CcmG and CcmH. These findings establish that
CcmFH (together with CcmG) is the cytochrome c synthetase for system I, and provide unique
mechanistic and evolutionary insights into cytochrome c biogenesis, as discussed in chapter 4.
HCCS forms a complex with heme and cytochrome c
Despite the identification of the yeast HCCS over twenty-five years ago [5], progress in
understanding the mechanism(s) of HCCS function had been limited by difficulties in purifying
the protein [6]. In Chapter 5 [7], the first biochemical work on an HCCS protein (the HCCS
from humans) is described. HCCS, expressed in recombinant E. coli as an N-terminal fusion to
glutathione S-transferase, purifies with a heme b that is coordinated by a conserved histidine
(His154, see Fig 2). When co-expressed with its cognate human apocytochrome, HCCS is
shown to form a complex with heme and cytochrome c, with axial ligands supplied by conserved
His154 of HCCS and His19 (of Cys-Xxx-Xxx-Cys-His) of the cytochrome c. It is shown that
the minimal requirements for covalent heme attachment to the apocytochrome are present in the
apocytochrome N-terminus (and include, but are not limited to, Cys-Xxx-Xxx-Cys-His), and a
non-substrate cytochrome (bacterial cytochrome c2) is converted into a robust substrate for the
human HCCS by engineering three sequence alterations. Trapped, intermediate complexes
between HCCS and site-directed variants of cytochrome c are characterized. These data allow us
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to delineate four steps in the long-sought mechanism of mitochondrial cytochrome c assembly by
HCCS, and are diagrammed in Fig 2.
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Future studies on system I
The structure of the b-heme binding site in CcmF has been investigated, but the role of
the b-heme in cytochrome c biogenesis remains hypothetical. Many of the requirements for
formation of the holoCcmE-CcmF complex have been identified, but a direct role for the WWD
domain in this interaction has not been described. Only a limited spectral characterization of the
holoCcmE-CcmF complex has been undertaken, and knowledge of the role that CcmH plays in
mediating complex formation between holoCcmE and CcmF is based only on the inability to trap
holoCcmE when CcmH is present. Some of the molecular details of cytochrome c biogenesis by
CcmFGH-ind are still unknown; in particular, the origin of the heme that is attached to
cytochrome c and the role of the CcmF WWD domain in holoCcmE-independent assembly.
Determining the midpoint potentials of all heme-bound intermediates
Initial attempts at determining the redox potential of the CcmF b-heme by potentiometric
methods were severely constrained by the large yields of protein that were required. Critically,
the technique described in this thesis (an adaptation of the Massey method [8] that was refined in
the laboratory of Emma Raven [9]; see chapter 2) requires yields that we are routinely able to
achieve with our membrane proteins. Thus, determining the midpoint potentials for each of the
heme carriers in system I (as well as system II, for which yields of holo-protein are similar, and
the cytochrome c:heme:HCCS complexes of system III) is a feasible goal.
Heme trafficking during cytochrome c biogenesis (for systems I, II, and III) involves
multiple changes in coordination of the heme, and the midpoint potential is very sensitive to
changes in axial ligation [10]. Furthermore, it is likely that many of the heme-protein
intermediates (e.g., the holoCcmE-CcmF complex, or the complex of HCCS with cytochrome c)
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have defined redox requirements that must be satisfied for heme trafficking and/or covalent
attachment to proceed. Therefore, establishing the midpoint potentials of the heme-protein
complexes would inform our understanding of the mechanistic requirements for the heme
reactions in cytochrome c biogenesis.
The role of the CcmF WWD domain
The conserved WWD domain [11] is a hydrophobic, extra-cytoplasmic feature that is the
hallmark of the heme-handling protein (HHP) superfamily [12], which includes CcmC, CcmF,
and CcsBA. In CcmC, the Kranz lab has shown that the WWD domain is directly involved in
binding heme (in holoCcmE): mutation of conserved residues in the WWD domain caused
spectral perturbations (and, for some substitutions, heme loss) in the holoCcmCDE complex
[13]. Two conserved histidines in CcmC that flank the WWD domain (His60 and His184, here
called P-His1 and P-His2, respectively) were shown to be axial ligands to the heme in the WWD
domain. For CcmF, although a direct role for the WWD domain in heme binding has yet to be
demonstrated, there is strong circumstantial evidence to support its involvement in hemebinding: i) conserved, WWD domain-flanking histidines P-His1 and P-His2 in CcmF (analogous
to P-His1 and P-His2 in CcmC) are individually required for cytochrome c assembly by system I,
ii) the cytochrome c assembly defects of mutations at P-His1 and P-His2 in CcmF can be
corrected by exogeneous imidazole, suggesting that these residues likely have a ligand-type
function, and iii) in the absence of either P-His1 or P-His2, holoCcmE forms a complex with
CcmF at levels 5-fold lower than WT CcmF, and the double P-His1/P-His2 mutant complexes
with holoCcmE at 10-fold lower levels (see chapter 3). Because P-His1 and P-His2 are
positioned adjacent to the WWD domain (as they are in CcmC), the above results strongly
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suggest a role for the CcmF WWD domain in binding heme from holoCcmE. Nonetheless,
direct experimental evidence demonstrating this function is still needed. Most directly (and
quickly), the hypothesis that the CcmF WWD domain binds holoCcmE could be tested by
engineering substitutions of conserved residues in the WWD domain and assaying for interaction
with holoCcmE. Comparing levels of holoCcmE that co-purify with CcmF carrying WWD
substitutions with those of WT CcmF (by heme stain and anti-CcmE immunoblot, as described
in Chapter 3) would be informative.
The role of the b-heme in system I
The CcmF heme b is required for every activity of CcmF that we have investigated thus
far. Holocytochrome c formation in the context of the full system I and by CcmFGH-ind, as well
as complex formation with holoCcmE, all require the conserved transmembrane histidines (TMHis1 and TM-His2), for axial coordination of the heme b. However, the precise role(s) of the
heme b in each of these functions is largely speculative. For the interaction of CcmF with
holoCcmE, we suggest that the transmembrane b-heme establishes a structural feature that is
required for holoCcmE to bind in the CcmF WWD domain. This seems likely given that the
CcmF protein is significantly destabilized in the absence of the heme b, with the protein being
more susceptible to degradation (yields of full-length protein are typically only a quarter of those
of WT).
For the CcmFGH-ind pathway, the role of the heme b is particularly intriguing, since the
origin of the heme that is ultimately attached to the cytochrome c (in the absence of
CcmABCDE) is currently unknown. As discussed in chapter 4, it is possible that, in CcmFGHind, the heme b is channeled from the transmembrane binding site to the external WWD domain
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for covalent attachment, as in system II cytochrome c synthesis, by CcsBA [14,15]. The
evolutionary insights that could be gained from studies comparing cytochrome c assembly by
CcmFGH-ind to the full system I under low-iron conditions, for example, are fascinating.
For cytochrome c assembly via the full system I, we have hypothesized that the b-heme
may be involved in reducing the heme in holoCcmE, prior to covalent attachment to the
apocytochrome [1,2,16]. Recall that reduced heme (Fe2+) is required for thioether formation
between the heme vinyls and apocytochrome thiols [17,18]. Additionally, reduction of heme in
holoCcmE would favor discharge of the covalent bond to His130 [16]; thus, this role for the
heme b provides a mechanism for releasing (apo)CcmE as well as preparing heme for covalent
attachment to the apocytochrome. Clarifying the role(s) that the CcmF heme b plays in each of
these activities will be challenging, but the information gained would greatly advance our
understanding of CcmF function. These studies may require reconstitution, in vitro, using
purified holoCcmE, CcmFH and apocytochrome.
The role of CcmH in mediating complex formation between holoCcmE and CcmF
We discovered that in the absence of CcmH, holoCcmE was trapped in complex with
CcmF at levels 10-fold higher than when CcmH was present (chapter 3). This suggests that
CcmH may play a direct role in mediating complex formation between CcmF and holoCcmE. In
cytochrome c biogenesis by system I, it is proposed that holoCcmE delivers heme to the CcmF
WWD domain (where heme is coordinated by CcmF P-His1 and P-His2), and CcmH
“chaperones” the apocytochrome and orients the thiols (of Cys-Xxx-Xxx-Cys-His) to facilitate
covalent attachment to the heme bound in the WWD domain [16,19,20,21,22]. To date, there
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has been no evidence of a direct interaction between CcmH and holoCcmE (nor has a direct
interaction between CcmF and the apocytochrome been reported).
In chapter 3, we briefly discuss two possible mechanisms by which CcmH may modulate
the interaction between CcmF and holoCcmE: i) in the absence of apocytochrome, CcmH may
physically occlude the CcmF WWD domain (exerting a “lid-like” function), or ii) CcmH may
facilitate rapid binding and release of holoCcmE from the CcmF WWD domain, such that a
stable holoCcmE-CcmF complex is difficult to detect when CcmH is present. While
distinguishing between the above scenarios may be difficult, defining a domain within CcmH
responsible for this apparent activity (modulation of CcmF-holoCcmE complex formation)
would be valuable for the field. Candidate domains/residues could be tested directly by
engineering stable truncations or site-directed mutations in CcmH, and determining the levels of
holoCcmE that co-purify with CcmF (using the same methods described in chapter 3). This line
of investigation benefits from past work that has shown the CcmH protein to be quite amenable
to engineering approaches, since stable C- and N-terminal truncations, as well as substitutions of
conserved residues, have been reported [23,24,25,26,27,28]. Here, as above, in vitro
reconstitution studies would be useful; the Kranz lab has expertise purifying holoCcmE [29] and
CcmF (alone and in complex with CcmH) [1,2].
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Future studies on system III
Our study on the human HCCS [7] (chapter 5) was the first biochemical analysis of an
HCCS protein. This seminal study defined the requirements for covalent heme attachment to
cytochrome c, characterized complexes between HCCS and cytochrome c, and delineated
individual steps for cytochrome c maturation by HCCS. Several intriguing lines of inquiry have
arisen from these findings, including defining elements in HCCS and the cytochrome c that
mediate complex formation, and further refining our understanding of the process of
holocytochrome c release from HCCS.
Requirements for complex formation with cytochrome c versus heme attachment
In chapter 5, we report conversion of a non-substrate cytochrome, the cytochrome c2
from R. capsulatus, into a robust substrate for HCCS by introducing three alterations to the Nterminal sequence. This engineered cytochrome, termed here cytochrome c2(+), thus contains
the minimal requirements for covalent heme attachment by HCCS. In chapter 5, we also
describe purification of HCCS in complex with heme and the human cytochrome c, with heme
axial ligands supplied by conserved His154 of HCCS and His19 (of Cys-Xxx-Xxx-Cys-His) of
the apocytochrome. The cognate human cytochrome c, therefore, includes elements that mediate
complex formation with HCCS in addition to containing the determinants for covalent heme
attachment. Intriguingly, cytochrome c2(+) does not detectably co-purify with HCCS
(unpublished data), despite being a robust substrate for covalent heme attachment. This indicates
that cytochrome c2(+) lacks the elements required for complex formation with HCCS, and,
further, that these elements are not required for covalent heme attachment.
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We have speculated that the complex formed between the human HCCS and the human
cytochrome c in our recombinant E. coli may be related to interactions that occur during
mitochondrial import of cytochrome c by HCCS (recall that HCCS is required for import of the
apocytochrome from the cytosol into the mitochondrial intermembrane space
[18,30,31,32,33,34]). Determining the specific amino acids that mediate complex formation,
therefore, could inform our understanding of this process. To identify the elements in the human
cytochrome c that mediate complex formation with HCCS, a site-directed mutagenesis approach
could be taken, initially targeting residues in the human cytochrome c. The elements found to be
required for complex formation could subsequently be engineered into the cytochrome c2(+),
and we could assay for cytochrome c2(+) in purifications of HCCS. Even low levels of complex
would be detectable, owing to our high-titer cytochrome c2 antisera. These studies would
establish possible side chain interactions that mediate stable complex formation between
cytochrome c and HCCS.
Production of novel cytochromes c by HCCS
Recently, we have discovered that a variant of the human cytochrome c carrying a
methionine substitution at conserved His19 (of Cys-Xxx-Xxx-Cys-His) can be matured by
HCCS at a low level (unpublished data). To our knowledge, this could turn out to be the first
example of a cytochrome c with bis-Met coordination of heme (the 6th axial ligand in
cytochrome c is a methionine residue, Met81). Therefore, strategies to improve yields of this
novel cytochrome c, thereby facilitating a thorough analysis of its structural and spectroscopic
properties, are certainly of a high priority. A method for improving the cytochrome c yields
could also open the door for analysis of other novel cytochromes c that may yet be discovered.
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Mechanistically, maturation of the His19Met cytochrome c is intriguing because it demonstrates
that methionine can serve as a heme axial ligand in the complex with HCCS, promoting covalent
attachment and subsequent holocytochrome c release (albeit at a much lower level than the
native histidine). As discussed in chapter 5, in the complex of HCCS with the WT human
cytochrome c, His19 is required for covalent heme attachment to the cysteines [7]; i.e.,
holocytochrome c formation cannot proceed in the absence of a suitable axial ligand.
Characterization of the complex between HCCS, heme, and the His19Met cytochrome c could
further elucidate the requirements for holocytochrome c formation by HCCS.
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Figures
Fig 1. Topology of the CcmF and CcmH integral membrane proteins from E. coli.
Possible histidine axial ligands to heme are starred (His173=P-His1; His303=P-His2;
His261=TM-His1; His491=TM-His2). The highly conserved WWD domain is shaded as are the
hydrophobic patches. Completely conserved amino acids (red) were identified by individual
protein alignments using CcmF ORFs from selected organisms, as described in (Kranz, RichardFogal et al. 2009). Diagram is from (Kranz, Richard-Fogal et al. 2009).
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Fig 2. Steps in the maturation of cytochrome c by human HCCS.
(A) Diagram depicting the 4 steps in holocytochrome c maturation by HCCS (discussed in text).
(B) PEP-FOLD generated model of the N-terminal 20 amino acid helix in human cytochrome c
before interaction with HCCS. Amino acids important for maturation are indicated by arrows.
Selected oxygen atoms are shown in red, nitrogens in blue, sulfurs in yellow, the heme
macrocyle is in pink, and the Fe atom at the heme center is orange. (C) The
HCCS:heme:cytochrome c complex (modeled with heme, pink) before thioether formation.
Heme is coordinated by His19 of apocytochrome c (PEP-FOLD ribbon diagram, green, as in B)
and His154 of HCCS (overlaid cartoon, blue). Amino acids and heme vinyls important for
maturation are indicated by arrows. (D) The N-terminal 20 amino acids from the X-ray crystal
structure of mature, released E. caballus holocytochrome c (pdb HRC1). Amino acids important
for maturation are indicated by arrows. Heme is coordinated by His19, as in the complex with
HCCS, and cytochrome c Met81, which replaces HCCS His154 in the folded, released
holocytochrome c. PyMOL was used for displays in B, C, and D. Amino acid numbering refers
to the H. sapiens cytochrome c N-terminal Met, as shown in Fig 3A (because the initiation Met
is processed off, pdb HRC1 refers to Lys8 as Lys7, His19 as His18, Met81 as Met80, etc).
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